

**OPTIMIZATION OF PCR-MULTIPLEX SSCP TO IDENTIFY  
MUTATIONS AND POLYMORPHISMS  
AT THE LDL RECEPTOR LOCUS**



**A THESIS SUBMITTED IN PARTIAL FULFILLMENT  
OF THE REQUIREMENTS FOR  
THE DEGREE OF MASTER OF SCIENCE (BIOCHEMISTRY)  
FACULTY OF GRADUATE STUDIES  
MAHIDOL UNIVERSITY  
2005**

**ISBN 974-04-6661-3  
COPYRIGHT OF MAHIDOL UNIVERSITY**

Thesis  
Entitled

**OPTIMIZATION OF PCR-MULTIPLEX SSCP TO IDENTIFY  
MUTATIONS AND POLYMORPHISMS  
AT THE LDL RECEPTOR LOCUS**



*Patthamawadee Charoensuk*

Miss Patthamawadee Charoensuk  
Candidate

*Klai-upsorn S. Pongrapeeporn*

Assoc.Prof.Klai-upsorn Pongrapeeporn,  
Ph.D.  
Major-Advisor

*W. Nuchpramol*

Assist.Prof.Wilairat Nuchpramol,  
M.D.  
Co-Advisor

*M. R. Jisnuson Svasti*

Prof. Dr. M. R. Jisnuson Svasti,  
Ph.D.  
Dean  
Faculty of Graduate Studies

*Vorapan Sirivatanauksorn*

Dr. Vorapan Sirivatanauksorn,  
M.D., Ph.D.  
Chairman  
Master of Science (Biochemistry)  
Faculty of Medicine Siriraj Hospital

Thesis  
Entitled

**OPTIMIZATION OF PCR-MULTIPLEX SSCP TO IDENTIFY  
MUTATIONS AND POLYMORPHISMS  
AT THE LDL RECEPTOR LOCUS**

was submitted to the Faculty of Graduate Studies, Mahidol University  
For the degree of Master of Science (Biochemistry)

on  
20 October, 2005

*Patthamawadee Charoensuk*

Miss Patthamawadee Charoensuk  
Candidate

*Klai-upsorn S. Pongrapeeporn*

Assoc.Prof.Klai-upsorn Pongrapeeporn,  
Ph.D.  
Chairman

*W. Nuchpramol*

Assist.Prof.Wilairat Nuchpramol,  
M.D.  
Member

*Sureerut Porntadavity*

Miss Sureerut Porntadavity  
Ph.D.  
Member

*N. Tirawan*

Assoc.Prof. Nednapis Tirawanchai,  
Ph.D.  
Member

*M. R. Jisnuson Svasti*

Prof. Dr. M. R. Jisnuson Svasti,  
Ph.D.  
Dean  
Faculty of Graduate Studies  
Mahidol University

*P. Sakolsatayadorn*

Prof.Piyasakol Sakolsatayadorn,  
M.D.  
Dean  
Faculty of Medicine Siriraj Hospital  
Mahidol University

## ACKNOWLEDGEMENT

I would like to express my sincere gratitude to my major advisor, Assoc.Prof. Klai-upsorn Pongrapeeporn. I deeply thank for her perceptive scientific guidance, enduring encouragement and supervision in this research. Discussions with her have broadened my understanding of both science and life.

I am deeply indebted to my co-advisor, Assist.Prof. Wilairat Nuchpramool for her kind guidance and valuable suggestions.

I am sincerely appreciated to member of my thesis examination committee Assoc.Prof. Nednapis Tirawanchai and Dr. Sureerut Porntadavity for their kind examination, valuable comments and constructive criticism in improving this thesis.

I would like to thank department of Preventive Medicine, Siriraj Hospital and Navy Hospital, Royal Thai Navy for their facilitation of blood collection.

I would like to acknowledge the contribution of the Faculty of Medicine Siriraj Hospital for “Siriraj Graduate Thesis Scholarship”. It is a special gift for my life.

I own my sincere thanks to all the lecturers and staff of Biochemistry department and my heartfelt thanks belong to my elder students, friends and younger students especially the members of our laboratory for their cheerfulness, friendship and kind support.

My most heartfelt thanks belong to my beloved family for their gentle love, entire care, enduring encouragement and invaluable opportunity. The usefulness of this thesis, I dedicate to my parents, my brotherhood and all the teachers who have taught me since my childhood.

Patthamawadee Charoensuk

## OPTIMIZATION OF PCR-MULTIPLEX SSCP TO IDENTIFY MUTATIONS AND POLYMORPHISMS AT THE LDL RECEPTOR LOCUS

PATTHAMAWADEE CHAROENSUK 4536230 SIBC/M

M.Sc.(BIOCHEMISTRY)

THESIS ADVISOR: KLAI-UPSORN PONGRAPEEPORN, PH.D. (Biochemistry),  
WILAIRAT NUCHPRAMOO, M.D., M.Sc. (Biochemistry), Dip. In Family  
Medicine.

### ABSTRACT

Familial Hypercholesterolemia is caused by a mutation within the low density lipoprotein receptor (LDLR) gene. The mutation impairs proper function of LDLR and results in very high level of plasma cholesterol. Such levels result in early and severe atherosclerosis and hence substantial excess mortality from coronary heart disease. Diagnosing FH on clinical grounds is relatively difficult, and previous genetic methods are too cumbersome for routine use. Thus, there is a need to develop screening strategies to ensure that more patients are being correctly diagnosed and treated. In this study, restriction enzymes were used to digest hypermutable CG region of some PCR-amplified exons to increase the sensitivity of multiplex SSCP. These RE digested-PCR products were selectively combined and analyzed by multiplex SSCP. Moreover, the multiplex SSCP was analyzed in gradient polyacrylamide gel to increase the resolution. The conditions of these multiplex-SSCP analyses were optimized until individual exon of each multiplex set was separately apparent. Six combination sets of PCR-multiplex SSCP were set up and five of them were validated by known mutations (M412T, S554L and IVS3+1G>T) and known polymorphisms (G1414A). No validation in combination set 3 was made because no mutation or polymorphism was available in this combination set. The common *Ava*II (exon13 in combination set 4), *Hinc*II (exon12 in combination set 5) and a novel polymorphism in exon 8 (in combination set 5) were readily detected in these samples using the PCR-multiplex SSCP protocols developed in this study. These optimized PCR-multiplex SSCP protocols are expected to be useful for screening mutations and polymorphisms in the whole coding region (plus promoter) of LDL receptor gene. It was rapid, simple, sensitive and was expected to be a potential tool for mutation screening of large numbers of clinical samples.

KEY WORDS: Familial Hypercholesterolemia, LDLR, PCR-multiplex SSCP, gradient polyacrylamide gel, Novel polymorphism

99 P. ISBN 974-04-6661-3

การหาสถานะที่เหมาะสมที่สุดของเทคนิค PCR-multiplex SSCP เพื่อค้นหาการกลายพันธุ์และความหลากหลายในยีน LDL receptor (OPTIMIZATION OF PCR-MULTIPLEX SSCP TO IDENTIFY MUTATIONS AND POLYMORPHISMS AT THE LDL RECEPTOR LOCUS)

ปฐมาวดี เจริญสุข 4536230 SIBC/M

วท.ม. (ชีวเคมี)

คณะกรรมการควบคุมวิทยานิพนธ์ : กล้ายอัสพร พงศ์พีพร, ปร.ด. (ชีวเคมี), วิไลรัตน์ นุชประมุข, พ.บ., วท.ม. (ชีวเคมี), อว. (เวชศาสตร์ครอบครัว).

บทคัดย่อ

Familial hypercholesterolemia (FH) เป็นโรคทางพันธุกรรมที่เกิดจากการกลายพันธุ์ในยีน low density lipoprotein receptor (LDLR) ส่งผลให้การทำหน้าที่ของ LDLR ผิดปกติไป ทำให้เกิดการเพิ่มขึ้นของระดับโคเลสเตอรอลในกระแสเลือด ระดับโคเลสเตอรอลที่เพิ่มขึ้นนี้จะทำให้เกิดกระบวนการตีตันของหลอดเลือด (Atherosclerosis) และเสียชีวิตเพราะโรคหลอดเลือดหัวใจอุดตันในที่สุด การตรวจพบความผิดปกติของยีน LDLR ตั้งแต่เริ่มแรก (early diagnosis) จะทำให้สามารถป้องกันการเกิดโรคหลอดเลือดหัวใจได้ ปัจจุบันการวินิจฉัยโรคโดยอาศัยข้อมูลทางคลินิกเพียงอย่างเดียวนั้นยังไม่เพียงพอ จึงได้มีการวินิจฉัยยืนยัน FH ด้วยเทคนิคทาง Molecular Biology อีกด้วย อย่างไรก็ตามเทคนิคเหล่านี้ค่อนข้างยุ่งยากและใช้เวลามากสำหรับยีน LDLR ซึ่งเป็นยีนที่ค่อนข้างใหญ่ การศึกษาในครั้งนี้จึงได้พัฒนาเทคนิค PCR-multiplex SSCP ขึ้น โดยใช้เอ็นไซม์ตัดจำเพาะ ตัดตรงบริเวณที่เป็น CG (ซึ่งเกิดการกลายพันธุ์ได้ง่าย) ของชิ้นส่วนดีเอ็นเอ และ ทำ gradient polyacrylamide gel electrophoresis เพื่อเพิ่มความไวให้กับเทคนิค SSCP อีกด้วย จนกระทั่งได้สถานะที่เหมาะสมและแยกแยะความแตกต่างได้อย่างชัดเจน จากการศึกษา สามารถจัดจำแนก PCR-multiplex SSCP ได้ 6 กลุ่ม สำหรับการวิเคราะห์ promoter และ exons ทั้งหมดของยีน LDLR และพิสูจน์ว่าวิธีนี้ใช้ได้จริงด้วยการนำตัวอย่างของผู้ป่วยที่ทราบว่ามีความผิดปกติทางพันธุกรรมหรือมีการเปลี่ยนแปลงของลำดับเบสมาทดสอบ นอกจากนี้ยังใช้ screen ผู้ป่วยจำนวน 13 คน และสามารถตรวจพบการเปลี่ยนแปลงของความหลากหลายทางพันธุกรรมชนิด AvaII และ HincII และยังคงค้นพบการเปลี่ยนแปลงความหลากหลายทางพันธุกรรมชนิดใหม่ใน exon 8 อีกด้วย คาดว่าวิธี PCR-multiplex SSCP นี้จะเป็นประโยชน์ในการตรวจกรองความผิดปกติของยีนหรือการเปลี่ยนแปลงลำดับเบสทั้งหมดของยีน LDLR ซึ่งคิดว่าจะเป็นวิธีที่รวดเร็ว ง่ายและมีความไวสูงเหมาะสำหรับใช้ตรวจกรองตัวอย่างที่มีปริมาณมากๆ ได้

99 หน้า . ISBN 974-04-6661-3

# CONTENTS

	Page
ACKNOWLEDGEMENTS	iii
ABSTRACT	iv
LIST OF TABLES	viii
LIST OF FIGURES	ix
LISTS OF ABBREVIATIONS	xi
CHAPTER	
I    INTRODUCTION	1
OBJECTIVES	5
II   LITERATURE REVIEW	
1. Cholesterol Metabolism	
1.1 Lipoprotein	6
1.2 Lipoproteins Metabolism	7
1.3 Lipoprotein Disorder	9
1.4 LDL-cholesterol and atherosclerosis	10
2. Familial Hypercholesterolemia (FH)	
2.1 Clinical features	12
2.2 Prevalence of FH	12
2.3 Diagnostic of FH	12
2.3.1 Biochemical diagnostic	13
2.3.2 Clinical diagnostic	13
2.3.3 Genetic diagnostic	15
2.4 Current treatment method	16
2.4.1 Dietary intervention	16
2.4.2 Pharmacotherapy	16
2.4.3 Other treatment options	17
3. Low density lipoprotein receptor (LDLR)	18
3.1 LDLR protein and domain structure	18

## CONTENTS (Cont)

	Page
3.2 LDLR gene	20
3.3 Mutations of LDLR gene	21
4. Mutation detection methods	23
4.1 Single-Strand conformation polymorphism (SSCP)	24
III MATERIALS AND METHODS	28
IV RESULTS	50
V DISCUSSION	65
VI CONCLUSION	71
REFERENCES	73
APPENDIX	80
BIOGRAPHY	99

## LIST OF TABLES

Tables		Page
1	Composition of the major human plasma lipoproteins	7
2	Some genetic causes of dyslipidaemia	9
3	Simon Broome Familial hypercholesterolemia Register diagnostic criteria for familial hypercholesterolemia	14
4	Classification of LDL receptor gene mutations	23
5	Sequences of oligonucleotides used in PCR assay for amplifying all exons and the promoter region of the LDLR gene	29
6	List of chemical substances	30
7	List of instruments	32
8	List of miscellaneous	33
9	Combination of amplified exons or RE-digested amplified exons for multiplex SSCP analysis	53
10	The conditions for multiplex SSCP assays	54
11	Mutations and Polymorphisms in 13 unrelated patients with primary hypercholesterolemia using PCR-multiplex SSCP technique.	69
12	Comparison of original SSCP method (Orita <i>et. al.</i> ) and PCR-multiplex SSCP developed in this study.	71


## LIST OF FIGURES

Figures		Page
1	Low density lipoprotein structure	6
2	Lipoprotein metabolism	8
3	Fredrickson (WHO) classification of dyslipidaemia	10
4	Cellular pathway of the LDLR	18
5	LDLR domain	20
6	LDLR gene	21
7	Mutation detection with SSCP	26
8	The experimental design	34
9	Multiplex assay of LDLR gene in this study	50
10	The amplification fragment of multiplex PCR in exon 3, exon 4 and exon 13 of LDLR gene.	52
11	Multiplex PCR-SSCP pattern of exons 3, 4 and 13 at the LDLR gene locus of hypercholesterolemic patients and control subject.	52
12	Silver staining of 4-8% gradient polyacrylamide gel of PCR-multiplex SSCP combination set 1	55
13	Silver staining of 4-8% gradient polyacrylamide gel of PCR-multiplex SSCP combination set 2	56
14	Silver staining of 4-8% gradient polyacrylamide gel of PCR-multiplex SSCP combination set 6	57
15	Nucleotide sequences from amplified exon 10 of the LDLR gene	58
16	Silver staining of 6-10% gradient polyacrylamide gel of PCR-multiplex SSCP combination set 3	59


**LIST OF FIGURES (Cont)**

Figures	Page
17 Silver staining of 6-10% gradient polyacrylamide gel of PCR-multiplex SSCP combination set 4	60
18 Nucleotide sequences from amplified exon 13 of the LDLR gene.	61
19 (A) The schematic drawing of <i>Ava</i> II digestion site in the PCR product of exon 13 of LDLR gene (B) A graose gel electrophoresis of <i>Ava</i> II polymorphism in exon 13 of the LDLR gene	62
20 Silver staining of 4-8% gradient polyacrylamide gel of PCR-multiplex SSCP combination set 5	63
21 Nucleotide sequence from amplified exon 8 of the LDLR gene	64
22 Nucleotide sequence from amplified exon 12 of the LDLR gene.	64

## LISTS OF ABBREVIATIONS



ASO	= allele-specific oligonucleotide
bp	= base pairs
CAD	= coronary artery disease
CHD	= coronary heart disease
°C	= degree celcius
dATP	= deoxyadenosine 5'-triphosphate
dCTP	= deoxycytosine 5'-triphosphate
ddNTP	= dideoxynucleotide
dGTP	= deoxyguanosine 5'-triphosphate
DGGE	= denaturing gradient gel electrophoresis
dTTP	= deoxythymidine 5'-triphosphate
DNA	= deoxyribonulceic acid
dNTP	= deoxynucleotide 5'-triphosphate
EGF	= epidermal growth factor
ER	= endoplasmic reticulum
FFAs	= free fatty acids
FH	= familial hypercholesterolemia
Fig	= figure
g	= gramme
gDNA	= genomic deoxyribonulceic acid
hr	= hour
HDL	= high density lipoprotein
HL	= hepatic lipase
HMG-CoA	= 3-hydroxy-3-methlyglutaryl-CoA reductase
IDL	= intermediate density lipoprotein
LCAT	= lecithin cholesterol acyltransferase
LDL	= low density lipoprotein
LDL-C	= low density lipoprotein cholesterol

**LISTS OF ABBREVIATIONS (Cont)**

LDLR	= low density lipoprotein receptor
LPL	= lipoprotein lipase
LRP	= LDL receptor-related protein
mg	= milligramme
min	= minute
mRNA	= messenger ribonucleic acid
ml	= millilitre
mM	= millimolar
MW	= molecular weight
ng	= nanogramme
PCR-RFLP	= polymerase chain reaction- restriction fragment length polymorphisms
PCR-SSCP	= polymerase chain reaction- single strand conformation polymorphism
RE	= restriction endonuclease
pmole	= picomole
SR-BI	= scavenger receptor class BI
SREBP	= sterol-regulatory element-binding protein
SSCP	= single strand conformation polymorphism
VLDL	= very low density lipoprotein
WHO	= World Health Organization
μl	= microlitre

## CHAPTER I

### INTRODUCTION

Coronary artery disease (CAD) is a multifactorial disorder resulting from the interplay of genetic and environmental factors. It is a major cause of morbidity and mortality in most Western countries. In Thailand it is also a major cause of death in our population. This multifactorial disease presents a particular challenge to different medical disciplines and is frequently associated with acquired familial hypercholesterolemia. It is clearly that the increase in plasma LDL (Low density lipoprotein) cholesterol is due to genetic alterations of LDLR (Low density lipoprotein receptor) gene specifying the formation of the LDLR, leading to defective catabolism of LDL (1). The LDLR gene spans 45 Kb on the short arm of chromosome 19 and consists of 18 exons and 17 introns. RNA splicing results in an mRNA of 5.3 Kb, with a coding region of 2.5 Kb and a protein product of 860 amino acids (2). Mutations in two other genes also cause the clinical FH phenotype. One of these is the apolipoprotein B-100 gene (APOB), located on chromosome 2p23-24, that codes for the protein component of LDL particles. In contrast to LDLR, only a small number of functional mutations have been identified in APOB. The third gene, proprotein convertase subtilisin/kexin type 9 (PCSK9), was recently identified on chromosome 1p32. To date, no epidemiologic research has investigated mutations in PCSK9.

LDLR mutations can be classified according to the effect they have on LDL receptor protein function. The LDLR protein is a cell surface receptor that removes LDL particles from the plasma by way of receptor-mediated endocytosis. In class 1 mutations, the LDLR protein is not synthesized; in class 2 mutations, the LDLR is not transported to the Golgi; in class 3 mutations, the LDLR does not properly bind with the LDL particles; in class 4 mutations, bound surface receptors are not internalized; and in class 5 mutations, the internalized LDL particles are not released in the endosome (3). In most populations, the prevalence of heterozygous FH is 1 in 500; 1 in  $10^6$  is found to be homozygous. Heterozygous patients carry a high risk of coronary

artery disease or myocardial infarction in their fourth or fifth decade of life and homozygous or compound heterozygous patients in their first or second decade of life (4). Early diagnosis of at-risk individuals will allow early pharmacologic and dietary treatment with the potential of reducing the risk of CAD. Diagnosis of FH is currently based on clinical, biochemical, and genetic criteria rather than on the identification of disease-causing mutations. Molecular diagnosis of FH by the identification of disease-causing mutation is labor-intensive, time consuming, and expensive because of the large size of the LDLR gene (45kb encoding 18 exons for a 5.3 kb mRNA). In addition, there are many rare or “private” mutations, including deletions in approximately one third of patients that add to the complexity of the molecular genotype. Consequently, very few clinical laboratories offer general molecular testing for FH, and those that do limit the analysis to a subset of mutations that are prevalent in certain ethnic groups (6).


Different strategies for mutation screening in the LDLR gene have been described. Most defects have originally been detected by restriction fragment length polymorphism (RFLP) analysis, but the method limited in the detection of point mutations, small deletions or insertions. Therefore, other, more sensitive methodologies such as analysis by denaturing gradient gel electrophoresis (DGGE) or single strand conformational polymorphism (SSCP), followed by DNA sequence determination, are more appropriate (2, 5). SSCP analysis was originally described by Orita *et al.* (13). This technique is a method capable of identifying most sequence variations in a single strand of DNA, typically between 150 and 250 nucleotides in length. Under non-denaturing conditions a single strand of DNA will adopt a conformation (presumably dependent on internal base-pairing between short segments by fold back) that is uniquely dependent on its sequence composition. This conformation will usually be different if even a single base is changed. Most conformations seem to alter the physical configuration or size sufficiently that, even though the variant sequence has the same charge, the configuration-to-charge (size-to-charge) ratio is different enough to be detectable as a mobility difference upon electrophoresis through a retarding matrix such as acrylamide gel (8). The optimal length of DNA for SSCP analysis appears to be from 150 to 200 nucleotides with mutation detection sensitivity for fragments size ranging from 70-90%. Sensitivity of

this technique decreases with increasing size of the fragment (7). Many modifications to the original protocol were developed (9-12).

At present, blood cholesterol levels tend to increase in Thai populations leading to high risk of coronary artery disease (37). This incident may be due to life style and genetic factor such as LDLR gene mutations. In case of genetic abnormality at the LDLR locus, DNA-based tests can provide unequivocal diagnosis of FH (5, 19). These DNA-based tests require a database of mutations, which are mostly ethnic specific. However, in Thai ethnic populations, database for LDLR gene mutations is not available. To establish a database of LDLR gene mutations for Thai ethnic populations, molecular analysis of the LDLR gene in Thai people should be essentially undertaken. However, molecular analysis using previous genetic methods such as PCR, PCR-RFLP, and large gel SSCP analysis are too cumbersome for routine screening (14). To avoid these problems and to obtain efficient and rapid genetic testing for all mutations in the LDLR gene, method of high sensitivity and rapid screening is essentially required. This project is thus proposed to develop such a method for identification of polymorphisms and mutations of the LDL receptor gene in population of Thai ethnic background.


In this development, restriction enzymes were used to digest hypermutable CG regions of some PCR-amplified exons to increase the sensitivity of multiplex SSCP. These RE digested-PCR products were selectively combined and analyzed by multiplex SSCP. Moreover, the multiplex SSCP was analyzed in gradient polyacrylamide gel to increase the resolution. The conditions of these multiplex-SSCP analyses were optimized until individual exon of each multiplex set was separately apparent. Therefore, abnormal mobility shift in an exon could be specified in each multiplex set and then subsequent DNA sequencing analysis could be made for that specified exon. Six combination sets of PCR-multiplex SSCP were set up and five of them were validated by known mutations (M412T, S554L and IVS3+1G>T) and known polymorphisms (G1414A). No validation in combination set 3 was made because no mutation or polymorphism was available in this combination set. These optimized multiplex-SSCP protocols were subsequently used to screen for polymorphisms and mutations in the whole coding region (plus promoter) of LDL receptor gene in a number of hypercholesterolemic patients (n=13). The common

AvaII (exon13 in combination set 4), HincII (exon12 in combination set 5) and a novel polymorphism in exon 8 (in combination set 5) were readily detected in these samples using the PCR-multiplex SSCP protocols developed in this study. These optimized PCR-multiplex SSCP protocols are expected to be useful for screening mutations and polymorphisms in the whole coding region (plus promoter) of LDL receptor gene. It was a rapid, simple, sensitive and was expected to be a potential tool for mutation screening of large numbers of clinical samples.



## OBJECTIVES

1. To optimize multiplex SSCP method.
2. To investigate polymorphisms and mutations in whole coding region of the LDL receptor gene in Thai subjects with primary hypercholesterolemia, using the developed multiplex SSCP method.



## CHAPTER II


### LITERATURE REVIEW

#### 1. Cholesterol Metabolism

Cholesterol is an important structural component of cell membranes and a precursor molecule for the synthesis of steroid hormones, bile acids and vitamin D. The cellular requirement for cholesterol is satisfied either by *de novo* synthesis within the cell, or by being supplied from extra-cellular sources. Cholesterol accumulating within the cell above the amount capable of being utilized by the cell is esterified with a long-chain fatty acid and stored within the cytoplasm as cholesteryl ester droplets. Efflux of excess cholesterol from the peripheral tissues occurs via reverse cholesterol transport, a pathway necessary to maintain cellular cholesterol homeostasis (15).

#### 1.1 Lipoproteins

Both *de novo* synthesized cholesterol and cholesterol derived from the diet are transported in the plasma predominantly as cholesteryl esters associated with lipoprotein particles. Lipoprotein particles are spherical with a central core of nonpolar lipids (primarily triglycerides and cholesteryl esters) and a surface monolayer of polar lipid (primarily phospholipids) and noncovalently bound apoproteins (Fig.1).



**Figure 1** Low density lipoprotein structure

(<http://www.med.unibs.it/~marchesi/biotec/slides/lipoproteine/LDL.gif>)

Lipoproteins are classified by the type and ratio of protein and lipids that they contain, which determines their size and density (Table 1)

**Table 1** Composition of the major human plasma lipoproteins

Lipoprotein	Source	Apolipoproteins	% Protein	Core lipids %TG/%CE	Diameter (nm)	Density (g/ml)
Chilomicrons	Intestine	A(I, II, IV), B-48, C(I, II, III), E	2	86/3	75-100	<0.95
VLDL	Liver	B-100, C(I, II, III), E	8	55/12	30-80	0.93- 1.006
IDL	VLDL	B-100, C(I, II, III), E	19	23/29	25-35	1.006- 1.019
LDL	VLDL	B-100	22	6/42	18-25	1.019- 1.063
HDL <sub>2</sub> ,HDL <sub>3</sub>	Intestine,liver: Chylomicrons, VLDL	A(I, II, IV), C(I, II, III), D, E	40-55	3-5/13-17	5-12	1.063- 1.21

### 1.2 Lipoproteins Metabolism

Dietary lipids are packaged in intestinal mucosal cells and secreted into the lymph as large triglyceride-rich particles called chylomicrons. Cholesterol absorption is mediated in part by the ABCG5 and ABCG8 transporters. Upon entering the circulation, lipoprotein lipase (LPL) rapidly lipolyzes the chylomicrons, thereby delivering free fatty acids (FFAs) to tissues such as muscle and adipose. The LDL (apoB/E) receptor and the LDL receptor-related protein (LRP) mediate the rapid uptake of the resulting remnant particles by liver (Fig.2) (16).

The liver actively synthesizes triglycerides and cholesterol, which, along with intestinally derived lipids, are packaged and secreted as very low-density lipoproteins (VLDLs). Like chylomicrons, VLDL particles are large and triglyceride-rich, but they have a different metabolic fate. VLDLs undergo lipolysis in the circulation and give rise to intermediate-density lipoproteins (IDL). Hepatic receptors remove a significant fraction (about half) of IDLs from the circulation, and the remainder undergo further lipolysis by LPL and hepatic lipase (HL) to produce LDLs. LDLs have a long half-life in the circulation and, in most individuals, are the predominant cholesterol-carrying particles. The LDL (apoB/E) receptor, which is

present in both liver and peripheral tissues, largely mediates the removal of LDL from the circulation.

HDLs are formed in the circulation from precursors secreted by liver and intestine, and from chylomicron and VLDL surface remnants. HDLs facilitate the removal of cholesterol from cells, a process mediated in part by ABCA1. The cholesterol is then esterified by lecithin cholesterol acyl transferase (LCAT) and transported to the liver, the only tissue capable of metabolizing and excreting excess cholesterol. The liver's uptake of HDL cholesterol is mediated partially by the scavenger receptor class BI (SR-BI). Hepatocytes can oxidize cholesterol to bile acids by a pathway involving cholesterol 7 $\alpha$ -hydroxylase (7- $\alpha$ -hydroxylase) (16).




Figure 2 Lipoprotein metabolism (16)

### 1.3 Lipoprotein Disorder

Lipoprotein disorders are some of the commonest metabolic diseases seen in clinical practice. Currently there is no satisfactory comprehensive classification of lipoprotein disorders. Genetic classifications have been attempted but are becoming increasingly complex as different mutations are discovered.








**Table 2** Some genetic causes of dyslipidaemia (17)

Disease	Genetic defect	Fredrickson	Rick
Familial hypercholesterolaemia	Reduced numbers of functional LDL receptors	Ila or IIb	CHD
Familial hypertriglyceridaemia	Possibly single gene defect	IV or V	
Familial combined Hyperlipidaemia	Possibly single gene defect	Ila, IIb, IV or V	CHD
Lipoprotein lipase deficiency	Reduced levels of functional LPL	I	Pancreatitis
Apo C-II deficiency	Inability to synthesize apo C( cofactor for lipoprotein LPL)	I	Pancreatitis
Abetalipoproteinaemia	Inability to synthesize apo B	Normal	Fat soluble vitamin deficiencies, neurological deficit

In practice, lipoprotein disorders are simplistically classified as being:

**Primary**-when the disorder is not due to an identifiable underlying disease. The Fredrickson or World Health Organization classification is the most widely accepted for the primary hyperlipidaemias (Fig.3). It relies on the findings of plasma analysis, rather than genetics. As a result, patients with the same genetic defect may fall into different groups, or may change grouping as the disease progresses or is treated. The major advantage of this classification is that it is widely accepted and gives some guidance for treatment (Table 2). The six types of

hyperlipoproteinaemia defined in the Fredrickson Classification are not equally common. Types I and V are rare, while types IIa, IIb and IV are very common.

Type	Normal	Type I	Type IIa	Type IIb	Type III	Type IV	Type V
Sample							
Lipoprotein	N	↑ Chylomicrons	↑ LDL	↑ LDL ↑ VLDL	↑ IDL	↑ VLDL	↑ Chylomicrons ↑ VLDL
Total Cholesterol	N	N or ↑	↑	↑	↑	N or ↑	N or ↑
Triglycerides	N	↑↑	N	↑	↑	↑	↑↑
LDL-CHOL	N	N or ↓	↑	↑	N or ↓	N	N
HDL-CHOL	N	N or ↓	N or ↓	N or ↓	N or ↓	N or ↓	N or ↓

**Figure 3** Fredrickson (WHO) classification of dyslipidaemia (17)

This classification is based on the appearance of a fasting plasma sample after standing for 12 hours at 4°C and analysis of its cholesterol and triglyceride content

**Secondary-** when the disorder is a manifestation of some other disease. Secondary hyperlipoproteinaemia is a well-recognised feature of a number of diseases which can be divided broadly into two categories:

- Clinically obvious disease such as renal failure, nephritic syndrome and cirrhosis of the liver.
- Covert conditions which may present as hyperlipidaemia. There include hypothyroidism, diabetes mellitus and alcohol abuse (17).

**1.4 LDL-cholesterol and atherosclerosis**

The presence of LDLR and reverse (HDL) cholesterol transport pathways allows for a sensitive regulation of cellular cholesterol content throughout the body. Unfortunately, this regulation is not always flawless. Absorption of excess

cholesterol can potentially increase the amount of cholesterol stored in the liver. This, in turn, can result in increased VLDL secretion, and subsequent LDL formation, and also down regulation of hepatic LDLR activity. Such events will potentially increase plasma LDL-cholesterol levels. Defects in the cholesterol metabolism can further induce accumulation of cholesterol in the periphery causing cardiovascular disease.

Atherosclerosis is a life-long process that begins with innocuous fatty streaks in childhood and progresses through several stages of plaque formation and gradual narrowing of the large arteries to subsequent heart attacks, strokes and peripheral vascular disease. As a major cholesterol-carrying lipoprotein in human plasma, LDL plays a major role in the development of atherosclerosis. The central process in the development of atherosclerosis is the infiltration of atherogenic cholesterol-rich lipoproteins, including LDL and VLDL, into the artery wall where subendothelial macrophages are activated by oxidized LDL particles via the scavenger receptor pathway. Total cholesterol levels of  $>6$  mmol/l in the circulation are associated with substantially increased risk of CHD. According to the current hypotheses, a priming factor in the development of atherosclerotic plaques is endothelial dysfunction due to oxidative stress, inflammation, infectious microorganisms, or shear stress.

Generally atherogenesis is considered a polygenic disease and numerous candidate genes are proposed. In addition to environmental factors, gene mutations affecting any of the metabolic pathways involved in the development of atherosclerosis may contribute to the risk of CHD. Not all cardiovascular diseases are polygenic in nature, and among patients with CHD onset before the age of 55, about 5% of cases are attributable to heterozygous FH (15).

## **2. Familial Hypercholesterolemia**

### **2.1 Clinical features**

FH was the first genetic disease of lipid metabolism to be clinically and molecularly characterized. It is a dominantly inherited autosomal disease characterized by extremely high levels of plasma cholesterol and LDL, which contribute to the formation of cutaneous and tendon xanthomas, arcus corneae and premature cardiovascular disease. Clinically identified FH usually results from defects in the LDLR gene. Homozygous deficient patients with two abnormal LDLR genes, either identical or different mutant genes, typically exhibit life-threatening coronary atherosclerosis and subsequent myocardial infarction before age 30 (15).

### **2.2 Prevalence of FH**

FH is the most common and most severe form of monogenic hypercholesterolemia. In most countries the prevalence of the heterozygous form of FH, in which a defective gene for the LDLR is inherited from one parent and a normal gene from another, is 1:500 and that of the homozygous form of FH is 1: 1,000,000 individuals, which renders FH probably the most common disease caused by a single-gene mutation in humans. It has been estimated that worldwide there are 10,000,000 people with FH of whom less than 10% are diagnosed, and less than 25% treated with LDL-lowering drugs. In many cases the diagnosis is missed until a dramatic clinical event occurs. In small number of genetically relatively isolated communities the prevalence of heterozygous FH is much higher than in most populations. In these populations, few LDLR mutations predominate. Increased prevalence of FH due to the founder effect can be detected in such populations as Ashkenazi Jews, Afrikaans-speaking white South Africans, French Canadians, Lebanese Christian Arabs, Icelanders and Finns (15).

### **2.3 Diagnostic of FH**

Three groups have developed diagnostic tools for FH: The US MedPed Program, the Simon Broome Register Group in the United Kingdom, and the Dutch Lipid Clinic Network (18).

### **2.3.1 Biochemical diagnostic**

The MedPed criteria use cutpoints for total cholesterol levels specific to an individual's age and family history. Cholesterol levels vary with age, and in men and women, and they are population specific. The cut-off level for diagnosis of hypercholesterolaemia should thus ideally be gender, age and population specific. In FH patients HDL-levels are within the normal range (or low), and so it is more specific to make the diagnosis using LDLcholesterol levels. LDL-cholesterol is usually calculated using the Friedewald formula, and consequently a fasting lipid profile is required, which is less convenient and more costly, and so the diagnosis is usually made using total cholesterol levels in the first blood measurement (often non-fasting), and then LDL-cholesterol measurements for a second (fasting) test. However, cholesterol levels alone are not sufficient to confirm a diagnosis of FH because the range of blood cholesterol levels in FH overlaps with that of people with non-genetic polygenic hypercholesterolaemia, leading to a false positive and false negative rate of between 8 and 18% (19).

### **2.3.2 Clinical diagnostic**

A diagnostic definition of FH, which supplements cholesterol measurements with clinical signs and family history has become widely used (Table 3.). The Simon Broome Register criteria in the UK, take into account that total and LDL levels differ for adults and children.

**Table 3** Simon Broome Familial Hypercholesterolemia Register diagnostic criteria for familial hypercholesterolemia

Criteria	Description
A	Total cholesterol concentration above 7.5 mmol/liter (290 mg/dl) in adults or a total cholesterol concentration above 6.7 mmol/liter(260 mg/dl) in children aged less than 16 years, or
	Low density lipoprotein cholesterol concentration above 4.9 mmol/liter(190 mg/dl) in adults or above 4.0 mmol/liter(150 mg/dl) in children
B	Tendinous xanthomata in the patient or a first-degree relative
C	DNA-based evidence of mutation in the LDLR or APOB gene
D	Family history of myocardial infarction before age 50 years in a second-degree relative or before age 60 years in a first-degree relative
E	Family history of raised total cholesterol concentration above 7.5 mmol/liter(290 mg/dl) in a first- or second-degree relative
Diagnosis	
A "definite" FH† diagnosis requires either criteria a and b or criteria c	
A "probable" FH diagnosis requires either criteria a and d or criteria a and e	

The criteria also take account of evidence of dominant transmission and the age of onset of coronary disease in the kindred. Using this approach, cases are categorised as ‘definite’ and ‘probable’. The presence of tendon xanthomata is the key feature in the ‘definite’ diagnosis of FH according to the criteria of the Simon Broome Register. These are most commonly found in the knuckles and in the Achilles tendons, and they are a result of cholesterol accumulation. Tendon xanthoma are usually not present until the fourth decade of life, and are therefore not helpful in systematic case finding among younger relatives. A family history of hyperlipidaemia or of premature coronary heart disease does not confirm a genetic cause or a monogenic pattern of inheritance. The specificity of family history of CHD

as indicating a genetic risk depends strongly on the prevalence of coronary heart disease in the population being studied. A similar diagnostic tool has been developed by the Dutch Lipid Clinic Network. This includes similar features to the Simon Broome criteria, but adds the calculation of a numeric score (19).

### 2.3.3 Genetic diagnostic

A definitive diagnosis of FH may be made using DNA-based mutation screening methods. At present these methods are relatively expensive. However, once the causative mutation in the patient has been found, relatively cheap molecular testing in relatives is possible. Molecular testing is relatively easy in countries with only one or a few different mutations causing FH, but in the majority of countries with high genetic heterogeneity at the present time the mutation screening methods available fail to identify a mutation in all patients with a clinical diagnosis of FH, with detection rates in general being 30–50%. In the UK up to 5% of FH patients are reported to have large deletions of the LDLR gene, and deletions in the gene have been widely reported, and these are routinely detected with time-consuming Southern Blot methods, although PCR based methods have been reported for deletion screening. In a study using Single Strand Conformation Polymorphism (SSCP) screening, Southern blotting, DNA sequencing and RNA analysis, only 66% of patients had detected mutations. SSCP analysis is routinely reported to have a sensitivity of 75–85%, suggesting that a mutation may have been missed for technical reasons in possibly 15–25% of patients (15). Although the low detection rate in genetic testing may be due in part to the insensitivity of the methods or because not all of the LDLR and APOB genes are screened, it is probably also the result of misdiagnosis using the clinical and blood cholesterol criteria. Finally, in some patients mutations may not be present in the LDLR or APOB but occur in the unidentified FH3 gene on chromosome 1, and to date the relative contribution of mutations at this locus to FH is unknown (20,21).

## **2.4 Current treatment method**

### **2.4.1 Dietary intervention**

Diet alone is not sufficiently effective for the treatment of heterozygous or homozygous FH. However, it should be the starting point of any management program. Dietary intervention relies upon the reduction of LDL-C by changing the type of fatty acids, reducing dietary cholesterol, including foods rich in soluble fiber that bind bile acids, and weight loss when indicated. Reducing cholesterol absorption with foods containing plant stanol- and sterol-esters may also prove effective. Both LDL-C production and removal rates appear to be affected by these dietary changes. Estimates suggest that a diet consisting of whole grains, legumes, fruits, vegetables, nuts, fish, and fat-free dairy products, and no more than 100 mg/day of cholesterol, 20% of calories from fat and 6% from saturated fatty acids reduces plasma LDL-C levels by between 18 and 21% in heterozygous FH adults and children. LDL-C reductions of 30% from an initial mean of 260 mg/dl were seen in FH subjects changing from a diet rich in butter (34% fat calories) to diets rich in either salmon or safflower oil. Thus, FH patients, despite their genetically elevated LDL-C, are as responsive to diet as other hypercholesterolemic subjects (22).

### **2.4.2 Pharmacotherapy**

The primary aim of drug therapy is to decrease plasma LDL-C. This may be achieved by increasing LDL removal via an increase in LDL receptors on the surface of hepatocytes and/or a decrease in LDL production. Treatment strategies that deplete liver cholesterol stores will upregulate LDL receptor gene transcription via the sterol-regulatory element-binding protein (SREBP) pathway. The bile sequestrants were the first class of drugs to exploit this pathway by preventing the absorption of bile acids from the ileum. Increased excretion of bile acids produces an increase in the conversion of cholesterol into bile salts, a decrease in liver cholesterol and a compensatory rise in LDL receptor synthesis by the liver. Although bile acid sequestrants have been shown to reduce plasma LDL-C levels by between 15 and 30% in heterozygous FH individuals, their effectiveness is limited by a simultaneous increase in de novo cholesterol synthesis which is also mediated by SREBP. Statins provide the most dramatic reductions in plasma LDL-C levels in heterozygous FH

adults and children when compared with other lipid-reducing therapies. The statins act by blocking the HMG-CoA reductase enzyme, which catalyses the rate limiting step in de novo cholesterol synthesis. Competitive inhibition of this enzyme by the statins decreases hepatocyte cholesterol synthesis, which causes the hepatocytes to synthesize more HMG-CoA reductase and LDL receptors. Although the increase in HMG-CoA reductase ensuring a steady state is maintained between cholesterol synthesis and utilization, the level of plasma LDL-C is reduced due to the increase in LDL-C receptors. There is clear evidence that statins also reduce the production of very low-density lipoprotein (VLDL) in the liver, and this may add to their LDL-C and triglyceride lowering effects (22).


### **2.4.3 Other treatment options**

Patients with homozygous FH respond poorly to treatments known to be effective in heterozygotes because they produce few functional LDL receptors. Current treatment options for these individuals and nonresponsive heterozygous FH patients include LDL apheresis and liver transplantation. LDL apheresis uses a continuous-flow blood cell-separator to directly remove LDL from plasma. Data suggest that repeating this procedure every 1–2 weeks, in combination with nicotinic acid therapy, produces a reduction in the mean plasma cholesterol level of around 50%. Liver transplantation can successfully reduce plasma LDL-C levels by providing an external source of LDL receptors. However, this procedure is associated with substantial risks and recipients require life-long treatment with immunosuppressive drugs (22, 23).

### 3. Low density lipoprotein receptor (LDLR)

#### 3.1 LDLR protein and domain structure


The LDL receptor is a cell surface glycoprotein that contains approximately two asparagine-linked (N-linked) oligosaccharide chains of the complex type and approximately 18 serine/threonine-linked (O-linked) oligosaccharide chains. About two-thirds of the O-linked sugars are clustered in one region of the molecule (24). The receptor is first synthesized in the rough ER and then sent to the Golgi apparatus. The Golgi apparatus subsequently targets the LDLR to the cell surface, where they gather in clathrin-coated pits. Clathrin coated pits are specialized regions of the plasma membrane that are lined on the cytoplasmic surface by a protein called clathrin. After the LDLR binds to LDL, the coated pits internalize and the clathrin coat disintegrates. Multiple endocytic vesicles fuse to form endosomes where the pH begins to fall below 6.5. At this acidity, the LDL dissociates from the receptor while the LDLR returns to the cell surface. LDL that is dissociated from the receptor is delivered to the lysosome where hydrolytic enzymes degrade LDL for metabolic use (25).



**Figure 4** Cellular pathway of the LDLR

(<http://www.med.unibs.it/~marchesi/biotec/slides/lipoproteine/LDL-receptors.jpg>)

The LDLR protein consists of five distinguishable domains (Fig.5). The first domain of the LDL receptor consists of the NH<sub>2</sub>-terminal 292 amino acids, which is composed of a sequence of 40 amino acids that is repeated with some variation seven times. Each of the seven 40-amino acid repeats contains six cysteine residues. A striking feature of each cysteine-rich repeat sequence is a cluster of negatively-charged amino acids near the COOH-terminus of each repeat. The charges on these sequences are complementary to a cluster of positively-charged residues that are believed to occupy one face of a single  $\alpha$ -helix in apo E, the best studied ligand for the LDL receptor. The second domain of the LDL receptor, consisting of ~ 400 amino acids, is 35% homologous to a portion of the extracellular domain of the precursor for epidermal growth factor (EGF). The third domain of the LDL receptor lies immediately external to the membrane-spanning domain and consists of a stretch of 58 amino acids that contains 18 serine or threonine residues. This domain is encoded within a single exon. Proteolysis studies reveal that this region contains the clustered O-linked sugar chains. The fourth domain consists of a stretch of 22 hydrophobic amino acids that is believed to anchor the receptor in the cell surface by spanning the membrane. The fifth domain is the cytoplasmic tail. It contains a COOH-terminal segment of 50 amino acids that projects into the cytoplasm. The cytoplasmic domain of the LDL receptor plays an important role in clustering in coated pits, either through interaction with clathrin itself or with some protein that is associated with clathrin on the cytoplasmic side of the membrane (24, 26).




**Figure 5** LDLR domains

(<http://www.iemrams.spb.ru:8100/english/molgen/fh-en/domain-e.htm>)

### 3.2 LDLR gene

The LDL receptor gene is located on the short arm of chromosome 19. It consists of 18 exons and 17 introns that span 45 kilobases (kb) (Fig.6). The gene encodes a single-chain transmembrane polypeptide of 839 amino acids, which consists of five functional domains. The amino-terminus of the protein contains the LDL-binding elements that recognize apolipoprotein B (apo B), the major apolipoprotein in LDL. The correspondence between gene exons and functional domains of the mature protein is well established. Exon 1 encodes the 21 amino acids of the signal sequence which is cleaved from the protein during translocation into the endoplasmic reticulum (ER). Exons 2–6 encode the ligand-binding domain, which is made up of seven repeats of 40 amino acids each. Exons 7–14 encode a 400 amino acids sequence that is 33% identical to a portion of the human epidermal growth factor (EGF) precursor gene. Exon 15 encodes 58 amino acids that are enriched in serine and threonine

residues, which serve as attachment sites for O-linked sugar chains. The 3' end of exon 16 and the 5' end of exon 17 encode the 22 hydrophobic amino acids of the membrane-spanning domain. The remainder of exon 17 and the 5' end of exon 18 encode the 50 amino acids that make up the cytoplasmic domain. The remainder of exon 18 specifies the 2.6 kb 3' untranslated region of the mRNA (27).




**Figure 6** LDLR gene

(<http://www.people.virginia.edu/~rjh9u/ldlrecep.html>)

### 3.3 Mutations of LDLR gene

In general, mutations causing a premature stop codon, or a frame-shift mutation or a large deletion or re-arrangement of the gene, are all likely to result in the generation of a truncated protein which in almost all cases will be dysfunctional. If such a mutation is detected, it is almost undoubtedly the cause of FH in this patient. For missense mutations two types must be distinguished. The first are those that alter a critical amino acid, for example one that changes or adds a residue such as cysteine, or substitutes a large bulky amino acid such as Tryptophan for a small one such as Glycine (19). Mutations causing such substitutions are very likely to result in a defective LDL-receptor and therefore to be the cause of FH in the patient (19). The second group are those missense mutations that cause a conservative amino acid change, or that occur in a non-critical region of the protein, and these may not be FH-causing and their effect must be interpreted with caution (19). The analysis of the updated data gives the following informations: (i) 63% of the mutations are missense, and only 20% occur in CpG dinucleotides; (ii) although the mutations are widely distributed throughout the gene, there is an excess of mutations in exons 4 and 9, and a deficit in exons 13 and 15; (iii) the analysis of the distribution of mutations located

within the ligand-binding domain shows that 74% of the mutations in this domain affect a conserved amino-acid, and that they are mostly confined in the C-terminal region of the repeats. Conversely, the same analysis in the EGF-like domain shows that 64% of the mutations in this domain affect a non-conserved amino-acid, and, that they are mostly confined in the N-terminal half of the repeats. The database is now accessible on the World Wide Web at <http://www.umd.necker.fr> (28, 29).



Mutations in the LDLR gene have been classified into five functional groups based on the characteristics of the LDLR produced (Table 4.) (22,27).

**Table 4** Classification of LDL receptor gene mutations

Class of mutation	Nature of the mutation
1	Gene fails to produce immunoprecipitable protein (null alleles). Variety of mutations including promoter deletions, splice site mutations, frameshift mutations and other large deletions. Some nonsense mutations may cause accelerated receptor protein degradation.
2	Proteins are encoded that are blocked, either completely (2a) or partially (2b), in transport between the endoplasmic reticulum and Golgi complex (transportdefective alleles). Abnormal folding of the protein appears to be the basis of the blocked transport. Most defects are in the binding and EGF precursor homology domains.
3	Gene encodes proteins that are synthesized and transported to the cell surface normally, but fail to bind LDL (binding-defective alleles). Defects are in the binding and EGF precursor homology domains.
4	Proteins are encoded that move to the cell surface and bind LDL normally, but are unable to cluster in clathrin-coated pits and thus do not internalize LDL (internalization-defective alleles). Defects are in the Cytoplasmic domain.
5	Gene encodes receptors that bind and internalize ligand in coated pits, but fail to discharge the ligand in the endosome and do not recycle to the cell surface (recycling-defective alleles). Defects are in the EGF precursor homology domain.

#### 4. Mutation detection methods

Analysis of DNA variation (polymorphisms and mutations) is one of the most common challenges faced by molecular biologists. Studies of polymorphisms and mutations as molecular markers of or underlying causes of disease have confirmed the importance of mutations and polymorphisms detection. With mutation detection currently being so important for the study of genetic diseases, gene discovery, and

solving problems of basic biology, there is a large demand for quick and relatively cheap methods for mutation detection. Therefore, many different methods have been developed for detecting new mutations and screening populations for known mutations or polymorphisms (29). Mutation detection can be performed in two fundamental processes.


-To detect mutations for the first time in a piece of DNA: This is a search and is referred to as screening for, or discovery of, mutations.

- To detect on subsequent occasions mutations in DNA once they have been detected initially. This may be for diagnosis of disease in a family, when the methods are referred to as diagnostic methods, or in the case of population studies when assessing single nucleotide polymorphism for linkage or other studies, when the methods are called genotyping methods (30).

#### **4.1 Single-Strand conformation polymorphism (SSCP)**

Single-strand conformational polymorphism (SSCP) is one of the most widely used mutation scanning techniques because of its simplicity. The principle of this method is based on the fact that the electrophoretic mobility of nucleic acids in a non-denaturing gel is sensitive to both size and shape. Unlike double-stranded DNA, single-stranded DNA is flexible and will adopt a conformation determined by intramolecular interactions and base stacking that is uniquely dependent on sequence composition (Orita *et al.*, 1989). This conformation can be affected when even a single base is changed. Conformational changes can be detected as alterations in the electrophoretic mobility of the single-stranded DNA in non-denaturing polyacrylamide gels. SSCP is still largely empirical because of the absence of a robust theory for predicting the dependence of conformation on sequence, and of mobility on conformation. SSCP is, nonetheless, a convenient mutation screening method. Detection levels of 70% to greater than 95% in certain model systems have been achieved. Achieving such high detection rates by SSCP may require running gels under several conditions, because the conformation of single-stranded DNA is sensitive to a number of parameters, including ionic strength, the type of gel matrix,

fragment length, and temperature. Originally, SSCP was performed on large sequencing gels in a cold room to control temperature and using radioactive nucleotides. The procedure was cumbersome and not always reproducible. The developments of non-radioactive techniques and temperature-controlled electrophoretic units, and the modification of the technique for standard and mini-gels, have increased the simplicity and reproducibility of this method. Basic Protocol: The target sequence from genomic DNA or cDNA is amplified by PCR. The amplicon is denatured to single-stranded DNA and electrophoresed on a non-denaturing gel. Bands of the single-stranded DNA at positions in the gel different from the wild-type indicate the presence of a mutation. In general, a wild-type sample will generate two SSCP bands. Similarly, a homozygous mutant sample will also generate two SSCP bands, but these will migrate differently from the wild-type. If it is a heterozygous mutant, four bands will be generated: two with the same mobility as the wild-type and two with different mobility. There may be only three bands if the mutation changes the conformation of one strand but not the other. Generating the product DNA products used for SSCP is generally amplified by PCR. The sensitivity of PCR-SSCP tends to decrease as fragment length increases. For fragments of about 200 bp, greater than 90% of single-base changes can be detected; whereas for fragments of 400 bp, the detection rate is lowered to 80%. Although mutations have been detected in fragments as large as 800 bp, the sensitivity of the assay will probably not be as high. Sequences longer than 400 bp should be divided into shorter segments before analysis by SSCP. This can be done by generating over-lapping subfragments separately or by amplifying the intact fragment and then digesting it with restriction enzymes. It is important that PCR conditions be optimized for stringency, as artifacts will interfere with the assay. The PCR product should be checked prior to SSCP analysis (38).



**Figure 7** Mutation detection with SSCP (38)

Takao Maruyama *et al.* (1995) developed simple SSCP methods for detecting these mutations and investigated four Japanese FH homozygotes and identified five point mutations: a splice site mutation in intron 12 (the 1845+2 T→C mutation), a missense mutation in exon 7 (the C317S mutation), a nonsense mutation in exon 17 (the K790X mutation), a missense mutation in exon 14 (the P664L mutation), and a missense mutation in exon 4 (the E119K mutation)(32). Humphries *et al.* (1997) developed SSCP for high-throughput mutational analysis and applied screen for mutations in the LDL receptor gene in patients with familial hypercholesterolemia (33). Using SSCP, Lee *et al.* (1998) also detected mutations in exon 4 of the LDLR gene in 15 of 80 of these individuals; 7 of 15 had the same C163Y mutation (34). Jensen *et al.* (1996) performed the PCR-SSCP analysis. This method was as sensitive and efficient as DNA sequencing in the ability to identify the sequence variations in the LDLR gene of patients with heterozygous and in 2002, they have shown that the

PCR-SSCP analysis is a highly efficient and sensitive technique for detection of mutations in the 18 exons including intronic splice-site sequences and the promoter region of the LDL receptor gene in FH patient in Denmark (35, 36).



## CHAPTER III

### MATERIALS AND METHODS

#### MATERIALS

##### 1. Subjects

DNA samples from a group of unrelated patients with primary hypercholesterolemia from Department of Preventive Medicine, Siriraj Hospital (N=11) and Navy hospital (N=13) were invited to participate in this study. Diagnosis of primary hypercholesterolemia (hyperlipidemia type IIa) was based on the presence of increased plasma total cholesterol and LDL-cholesterol before lipid-lowering therapy: total cholesterol levels  $\geq 290$  mg/dl, LDL-cholesterol levels  $\geq 190$  mg/dl and triglyceride levels  $\leq 200$  mg/dl. Patients with secondary causes of hyperlipidemia such as diabetes, hypothyroidism or hyperthyroidism and nephrotic syndrome were excluded. The normalipidemic subjects (N=100) with total cholesterol levels  $\leq 200$  mg/dl, LDL-cholesterol levels  $\leq 130$  mg/dl and triglyceride levels  $\leq 200$  mg/dl were recruited as control. Informed, written consents were obtained from all participants.

The study was approved by the Committee on Human Rights Related to Human Experimentation Mahidol University and the Ethical Committee on Research Involving Human Subject, Faculty of Medicine Siriraj Hospital, Mahidol University.

##### 2. Oligonucleotide Primers

The whole coding region of the LDL receptor gene (promoter and 18 exons) were amplified by PCR. For the amplification reactions, we used oligonucleotide primers designed by Charlotte *et al.* (promoter), Pocsai *et al.* (exon 4), Leitersdorf *et al.* (exon 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17) and Hobbs *et al.* (exons 15 and 18). The primer sequences, size of amplicons, and respective annealing temperatures were listed in Table 5.

**Table 5** Sequences of oligonucleotides used in PCR assay for amplifying all exons and the promoter region of the LDLR gene.

Region/ Exon	Primer Name	Oligonucleotide sequence (Sense & antisense, 5' to 3')	Size (bp)	T <sub>a</sub> (°C)
Promoter	Forward	GAG GCA GAG AGG ACA ATG GC	380	62
	Reverse	CCA CGT CAT TTA CAG CAT TTC AAT G		
Exon 1	SP90	CAT TGA AAT GCT GTA AAT GAC GTG G	210	58
	SP91	TTC TGG CGC CTG GAG CAA GCC TTA C		
Exon 2	SP57	CCT TTC TCC TTT TCC TCT CTC TCA G	183	58
	SP58	AAA ATA AAT GCA TAT CAT GCC CAA A		
Exon 3	SP59A	TGA CAG TTC AAT CCT GTC TCT TCT G	178	58
	SP60B	AAT AGC AAA GGC AGG GCC ACA CT		
Exon 4	P4.1	TGC AGC CCC CAA GAC GTG CT	386	58
	P4.2	CGC AGT TTT CCT CGT CAG AT		
Exon 5	SP62	CAA CAC ACT CTG TCC TGT TTT CCA G	173	68
	SP63	GGA AAA CCA GAT GGC CAG CGC TCA C		
Exon 6	SP64	TCC TTC CTC TCT CTG GCT CTC ACA G	173	58
	SP65	GCA AGC CGC CTG CAC CGA GAC TCA C		
Exon 7	SP66	AGT CTG CAT CCC TGG CCC TGC GCA G	169	68
	SP67	AGG GCT CAG TCC ACC GGG GAA TCA C		
Exon 8	SP68	CCA AGC CTC TTT CTC TCT CTT CCA	176	62
	SP69	CCA CCC GCC GCC TTC CCG TGC		
Exon 9	SP70	CCT GAC CTC GCT CCC CGG ACC CCC A	223	70
	SP71	GGC TGC AGG CAG GGG CGA CGC TCA C		
Exon 10	SP72	ATG CCC TTC TCT CCT CCT GCC TCA G	278	68
	SP73	AGC CCT CAG CGT CGT GGA TAC GCA C		
Exon 11	SP74	CAG CTA TTC TCT GTC CTC CCA CCA G	173	68
	SP75	TGG CTG GGA CGG CTG TCC TGC GAA C		
Exon 12	SP76	TCT CCT TAT CCA CTT GTG TGT CTA G	188	58
	SP77	CTT CGA TCT CGT ACG TAA GCC ACA C		
Exon 13	SP78	GTC ATC TTC CTT GCT GCC TGT TTA G	219	54
	SP79	GTT TCC ACA AGG AGG TTT CAA GGT T		
Exon 14	SP80	CCT GAC TCC GCT TCT TCT GCC CCA G	204	60
	SP81	ACG CAG AAA CAA GGC GTG TGC CAC A		
Exon 15	FH16	GAA GGG CCT GCA GGC ACG TGG CAC T	246	68
	FH35	GTG TGG TGG CGG GCC CAG TCT TTA C		

**Table 5** Sequences of oligonucleotides used in PCR assay for amplifying all exons and the promoter region of the LDLR gene. (Continued)

Exon 16	SP84	CCT CAC TCT TGC TTC TCT CCT GCA G	128	62
	SP85	CGC TGG GGG ACC GGC CCG CGC TTA C		
Exon 17	SP86	TGA CAG AGC GTG CCT CTC CCT ACA G	207	58
	SP87	TGG CTT TCT AGA GAG GGT CAC ACT C		
Exon 18	FH19	TCC GCT GTT TAC CAT TTG TTG GCA G	135	68
	FH38	AAT AAA ACA AGG CCG GCG AGG TCT C		

### 3. Enzymes

All of the enzymes used in this study were molecular biology grade. HaeIII and HpaII restriction endonucleases were purchased from BioLabs, USA. *Taq* DNA polymerase used for PCR and PCR-multiplex SSCP was expressed from a recombinant plasmid according to the Protocol of Pluthero (39). Commercial *Taq* polymerase purchased from Fermentus (Germany) was used to confirm the results and to perform DNA sequencing.

### 4. Chemical substances

**Table 6** List of chemical substances

Chemical substances	Molecular Weight	Source
Acrylamide (C <sub>3</sub> H <sub>5</sub> NO)	71.08	BDH, England
Absolute ethanol (C <sub>2</sub> H <sub>2</sub> OH)	46.07	Merck, Germany
Agar-C	-	Bio Basic Inc., Canada
Agarose	-	SeaKem, USA
Ammonium acetate	-	Sigma, USA
Ammonium chloride	53.49	Sigma, USA
Ammonium Persulfate ((NH <sub>4</sub> ) <sub>2</sub> S <sub>2</sub> O <sub>8</sub> )	228.20	Sigma, USA
Ampicillin (C <sub>16</sub> H <sub>18</sub> N <sub>3</sub> ONaO <sub>4</sub> S)	371.4	Bio Basic Inc., Canada
Boric Acid (H <sub>3</sub> BO <sub>3</sub> )	61.83	Merck, Germany
Bromophenol Blue(C <sub>19</sub> H <sub>9</sub> Br <sub>4</sub> O <sub>5</sub> SNa)	691.9	USB, Austria
Bromophenol Blue-Xylene Cyanole Dye solution		Sigma, USA
Calcium Chloride	147	Sigma, USA
Deionized Formamide	-	Bio Basic Inc, Canada

**Table 6** List of chemical substances (Continued)

Chemical substances	Molecular Weight	Source
2'-Deoxynucleotide 5' triphosphate (dNTP) -		BioBasic Inc, Canada
DL-Dithiothreitol (DTT)(C <sub>4</sub> H <sub>10</sub> O <sub>2</sub> S <sub>2</sub> )	154.25	BioBasic Inc, Canada
DNA Ladder Marker	-	Fermentus, Germany
Dimethyl Sulfoxide (DMSO) (CH <sub>3</sub> ) <sub>2</sub> SO	78.13	Merck, Germany
Ethidium bromide (C <sub>21</sub> H <sub>20</sub> N <sub>3</sub> Br)	394.31	Sigma, USA
Ethylenediamine tetraacetic acid (EDTA) (disodium salt, dehydrate)	372.24	Bio Basic Inc., Canada
37% Formaldehyde (CH <sub>2</sub> O)	30.0	Merck, Germany
Formamide dye mix	-	Amresco, USA
Glacial Acetic Acid (CH <sub>3</sub> COOH)	60.05	Merck, Germany
Glycerol (HOCH <sub>2</sub> CH (OH) CH <sub>2</sub> OH)	92.09	Merck, Germany
Guanidine-HCl (NH <sub>2</sub> ) <sub>2</sub> -C=NH.HCl)	95.53	Sigma, USA
Hydrochloric	36.46	Merck, Germany
IGEPAL	-	Sigma, USA
Isopropyl-β-D-Thiogalactopyranoside (IPTG) - (C <sub>9</sub> H <sub>18</sub> O <sub>5</sub> S)	238.31	Sigma, USA Sigma, USA
Lysozyme	-	BioBasic,Inc, Canada
Magnesium Sulfate (MgSO <sub>4</sub> . 7H <sub>2</sub> O)	246.5	Sigma, USA
Magnesium Chloride (MgCl <sub>2</sub> . 6H <sub>2</sub> O)	203.30	Sigma, USA
N, N'-methylene-bis acrylamide (C <sub>7</sub> H <sub>10</sub> N <sub>2</sub> O <sub>2</sub> )	154.2	Sigma, USA
N, N,N' N'-Tetramethyl-ethylenediamine (TEMED)	116.2	Bio Basic Inc., Canada
PCR purification Kit	-	QIAGEN, Germany
Potassium chloride	74.5	Sigma, USA
Proteinase K	-	Invitrogen, Germany
Silver Nitrate (AgNO <sub>3</sub> )	169.87	Merck, Germany
Sodium carbonate (Na <sub>2</sub> CO <sub>3</sub> )	105.99	Merck, Germany
Sodium chloride	58.44	Bio Basic Inc., Canada
Sodium dodecyl sulphate (SDS, C <sub>12</sub> H <sub>25</sub> O <sub>4</sub> SNa)	288.4	Sigma, USA
Sodium hydroxide (NaOH)	40.0	Merck, Germany
Tris (hydroxymethyl)aminomethane, (C <sub>4</sub> H <sub>11</sub> NO <sub>3</sub> )	121.4	Research Organics,USA
Tryptone powder	-	Bio Basic Inc., Canada

**Table 6** List of chemical substances (Continued)

Chemical substances	Molecular Weight	Source
Tween 20	-	Research Organics, USA
Xylene cyanol FF	554.6	Research Organics, USA
Yeast Extract	-	BioBasic Inc., Canada

## 5. Instruments

**Table 7** List of instruments

Instruments	Source
Autoclave	Hirayana, Japan
Centrifuge	Heraeus Sepatech, USA
DNA Thermal cycler (Gene Amp PCR system 2400, 9700)	Perkin Elmer, USA
Horizontal agarose gel electrophoresis set	Mupid II, Japan
Hoefer SE260	Pharmacia Biotech, USA
Hotplate stirrer SM22	Stuart Scientific, UK
Hot air oven	Memmert, Germany
Incubator	Heraeus, Germany
Microcentrifuge	Hettich, Germany
pH meter	Orion Research, USA
Pipettman	Gilson, France
Poraloid Camera (Fotodyne)	-
Power supply	Pharmacia Biotech, USA
Refrigerator	Sharp, Japan
Spectrophotometer	Shimudzu, Japan
Spin down	-
UV-Transilluminator	Herolab, Germany
Vortex mixer	IKA Work Inc., USA
Vertical electrophoresis set	Thailand
Water bath	Precision Qualitron Inc., USA

## 6. Miscellaneous

**Table 8** List of miscellaneous


Miscellaneous	Source
Cellophan membrane	Thailand
Camera film (Polaroid)	USA
Glove	Thailand
Microcentrifuge tube (0.6, 1.5ml)	Scientific Plastic, USA
Parafilm	Chicaco,USA
Plastic centrifuge tube (15, 50 ml)	Elkay, UK
Plastic trays	Thailand
Thin wall PCR reaction tube (0.2 ml)	Scientific Plastic, USA
Micropipette tips (0.2, 200, 1000 $\mu$ l)	Sorenson, Promega, USA
Nalgene filter	Pall Corporation, USA
Whatman Filter paper	Whatman Ltd, England


## METHODS

### 1. Determination of lipid profiles

Lipid profiles were analyzed by Department of Clinical Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University. Venous blood (5-10 ml) was taken after 12-14 hours of fasting. Plasma cholesterol and triglyceride levels were determined with automation by Hitachi 917 Autoanalyzer. The concentration of plasma HDL was measured after precipitation of LDL and VLDL fractions with dextran sulfate and  $MgCl_2$  and plasma LDL level was calculated using the formula described by Friedewald *et al* (40).

The experimental design presented in Fig.8. The methods used in this study are described as followings.





## 2. Genomic DNA extraction

### 2.1 Reagent preparations

#### 2.1.1 10 N NaOH

The preparation of 10 N NaOH involved a highly exothermic reaction which can cause breakage of glass containers. This solution was prepared with extreme care in plastic breakers. To 200 ml of sterile water for injection slowly add 100 g of NaOH pellets was slowly added with continuous stirring in a breaker placed on ice. When the pellets have dissolved completely, the volume was adjusted to 250 ml with sterile deionized water. The solution was stored in a plastic container at room temperature. Sterilization was not necessary.

#### 2.1.2 5%EDTA, pH 7.4

25 g of EDTA disodium salt was weighed and dissolved in 400 ml of sterile deionized water. The pH of the solution was adjusted to 7.4 with 10 N NaOH. The volume of the solution was adjusted to 500 ml. The solution was sterilized by autoclaving.

#### 2.1.3 Solution A, pH 7.2

6.35 g of  $\text{NH}_4\text{Cl}$ , 1.33 g of EDTA and 0.92 g of Trizma base were weighed and dissolved with 800 ml of distilled water. The pH of the solution was adjusted to 7.2 with HCl and the volume was adjusted to 1 liter. The solution was autoclaved. Working solution A was prepared by diluting solution A with 2 volume of sterile deionized water before use.

#### 2.1.4 Proteinase K (10mg/ml)

A lyophilized powder of proteinase K was dissolved at a concentration of 10 mg/ml in sterile deionized water. The stock solution was into small aliquots and stored at  $-20^\circ\text{C}$  until use.

#### 2.1.5 10% SDS

10 g of SDS was weighed and dissolved with sterile deionized water. The solution was stirred until it was homogeneous and the volume was adjusted to 100 ml. The solution was incubated at  $56^\circ\text{C}$  for 1-2 hours until it was dissolved. This solution was used with no need to be autoclaved.

### 2.1.6 1 M Tris-HCl, pH 7.6

60.6 g of Tris-HCl was weighed and dissolved with sterile deionized water. Approximately 13 ml of 6 M HCl was added to the solution to adjust pH to 7.6. The volume of the solution was adjusted to 500 ml. The solution was sterilized by autoclaving.

### 2.1.7 7.5 M Guanidine-HCl, pH 7.6

72.0 g of Guanidine-HCl was weighed and approximately 10 ml of 1 M Tris-HCl was added to adjust the pH to 7.6. The volume of the solution was adjusted to 100 ml with autoclaved sterile deionized water. The solution was filtered by 0.2  $\mu$ m Nalgene filter.

### 2.1.8 0.5 M EDTA, pH 8.0

93.0 g of EDTA disodium salt was weighed and approximately 400 ml of sterile water for injection and 10.0 g of NaOH pellets were added. The pH of the solution was adjusted to 8.0 with 10 N NaOH. The solution was sterilized by autoclaving.

### 2.1.9 TE 10-1 buffer

10 ml of 1 M Tris-HCl, pH 7.6 and 2 ml of 0.5 M EDTA, pH 8.0 were diluted in sterile deionized water and the volume were adjusted to 1 Liter. The solution was sterilized by autoclaving.

## 2.2 Procedure

Genomic DNA was isolated from peripheral leukocytes in 10 ml EDTA blood samples by Guanidine-HCl method described previously (UCLA,1993). Ten millilitres of whole blood were collected into 50 ml capped tube which contained 400  $\mu$ l of 5%EDTA. Two volumes of working solution A was added to the whole blood, mixed by vortex the pellet to prevent clumping and left for 10 minutes at room temperature. The pellet was collected by centrifugation at 3,000 rpm for 10 minutes. The supernatant was discarded. Two volumes of working solution A was added to the pellet and the previous step was repeated until supernatant was clear. This step was not repeated more than three times. The supernatant was discarded and the packed WBC was added by the following reagents. First, 400  $\mu$ l of sterile water and 40  $\mu$ l of Proteinase K was added into the packed WBC and then mixed with 1ml pipette-tip in order to thoroughly mix the content. Second, 400  $\mu$ l of autoclaved sterile water was

added and resuspended further. Third, 300  $\mu$ l of 10% SDS was added, and the sample was mixed gently by rocking the tube back and forth, air-bubble was avoided. After mixing, the solution was incubated at 37  $^{\circ}$ C for overnight. Finally, 300  $\mu$ l of 7.5M Guanidine-HCl was added and gently mixed. The whole solution was mixed vigorously and incubated at 68-70  $^{\circ}$ C for 1 hour. The mixture was centrifuged at 3,000 rpm for 10 minutes at 4  $^{\circ}$ C. Only the above clear solution was gently mixed and reincubated at 68-70  $^{\circ}$ C for additional 30 minutes. The mixture was recentrifuged as above. The supernatant was transferred to the new labeled 50 ml cap tubes with 5 ml of cold absolute ethanol. The tube was gently rock back and forth until cotton-like strands of DNA was apparent and then the mixture was stored at -20  $^{\circ}$ C for 1 hour. The cotton-like strand of DNA was transferred with 800  $\mu$ l of cold absolute ethanol to a new 1.5 ml eppendorf tube. The mixture was centrifuged at 10,000 rpm for 5 minutes and the alcohol supernatant was discarded. 800  $\mu$ l of 70% ethanol was added to the sample. The sample was then inverted to loosen the pellet and the sample was let stand for 1 minute. The mixture was centrifuged at 10,000 rpm for 5 minutes and let stand the supernatant was discarded. The DNA sample was then subjected to air dry at 37  $^{\circ}$ C for 2 hours or at room temperature until the sample was dry with the cap open to evaporate the ethanol. 100-250  $\mu$ l of TE 10-1 buffer was added to the sample and the sample was incubated at 37  $^{\circ}$ C for overnight. The sample was stored at -20  $^{\circ}$ C until use. To determine the integrity of DNA, 3  $\mu$ l of DNA was mixed with 2  $\mu$ l loading dye and analyzed on 1% agarose gel electrophoresis in 1X TBE buffer comparing with  $\lambda$ DNA/HindIII fragment. The agarose gel was then stained with ethidium bromide and visualized by UV Transilluminator. The gDNA quality was verified by Polymerase Chain Reaction and agarose gel electrophoresis.

### **3. Polymerase Chain Reaction (PCR)**

#### **3.1 For multiplex PCR assay**

##### 3.1.1 Reagent preparation

###### 3.1.1.1 10XPCR buffer (20mM MgCl<sub>2</sub>)

80  $\mu$ l of 25 mM MgCl<sub>2</sub> stock and 20  $\mu$ l of 10X *Taq*

Bufere with KCl were mixed in 600ml eppendorf tube.

###### 3.1.1.2 10mM dNTPs

10  $\mu$ l of each 100 mM dNTPs (dATP, dGTP, dTTP, dCTP) were aliquoted and diluted to 100  $\mu$ l with autoclaved sterile deionized water.

#### 3.1.1.3 *Taq DNA polymerase*

As described in Appendix A.

#### 3.1.2 Procedure

Each 25  $\mu$ l reaction mixture consists of 0.1-0.3  $\mu$ g of genomic DNA, 1X PCR buffer (2 mM  $MgCl_2$ ), 2 mM each of dNTP, 1  $\mu$ M of each oligonucleotide primer and 1U *Taq* polymerase. After initial denaturation, 35 cycles were performed in a programmable DNA thermal cycler (ThermoHybaid PCR) using the temperature profile of 1 min at 94°C, 1 min at 49°C (annealing temperature) and 2 min at 72°C. The primer extension of the 35th cycle was extended to 12 min. The multiplex PCR products were electrophoresed on a 2% agarose gel in 1X TBE buffer for 30 min at a voltage of 100V. The fragments were dyed with ethidium bromide and were visualised by ultraviolet illumination. And the multiplex PCR products from DNA samples of primary hypercholesterolemia and control subject were subsequently used for SSCP analysis.

### 3.2 For multiplex SSCP assay

#### 3.2.1 Reagent preparation

##### 3.2.1.1 10XPCR buffer (15mM $MgCl_2$ )

60  $\mu$ l of 25 mM  $MgCl_2$  stock and 40  $\mu$ l of 10X *Taq* Buffer with  $(NH_4)_2SO_4$  were mixed in 600ml eppendorf tube.

##### 3.2.1.2 10XPCR buffer (20mM $MgCl_2$ )

80  $\mu$ l of 25 mM  $MgCl_2$  stock and 20  $\mu$ l of 10X *Taq* Buffer with  $(NH_4)_2SO_4$  were mixed in 600ml eppendorf tube.

##### 3.2.1.3 10mM dNTPs

10  $\mu$ l of each 100 mM dNTPs (dATP, dGTP, dTTP, dCTP) were aliquoted and diluted to 100  $\mu$ l with autoclaved sterile deionized water.

#### 3.2.1.4 *Taq DNA polymerase*

As described in Appendix A.

### 3.2.2 Procedure

Each 25 µl reaction mixture consists of 0.1-0.3 µg of gDNA, 1X PCR buffer (1.5-2mM MgCl<sub>2</sub>), 0.2 mM each of dNTP, 0.4µM each of oligonucleotide primer and 0.5U *Taq* polymerase. After initial denaturation at 95°C 5 min, 35 cycles was performed in a programmable DNA thermal cycler (GeneAmp® PCR System 2400 or 9700) using the temperature profile of 1 min at 95°C, 1 min at annealing temperature (Table. 5) and 1 min at 72°C. The primer extension of the 35th cycle was extended to 5 min. The PCR products will be electrophoresed on a 2% agarose gel in 1X TBE buffer for 30 min at a voltage of 100V. The fragments will be dyed with ethidium bromide and visualised by ultraviolet illumination. PCR products from DNA samples of primary hypercholesterolemic and control subjects were subsequently combined into a set of multiplex for SSCP analyses. Each set was composed of 3 or 4 exons in 1:1:1 or 1:1:1:1 ratio, respectively. (For RE-digested amplified exon, 2 volumes were applied in the relevant combination set.)

## 4. Restriction digestion

Restriction endonucleases are enzymes that cleave DNA at specific sequences, yielding defined fragments of DNA molecules. They can be used to cleave a DNA molecule at unique site. In this study, there were two reasons to use this technique; first to generate the optimal sensitivity for SSCP of LDLR gene. Second, LDLR gene is a large gene which contains many hypermutable CG regions. RE digestion of hypermutable CG regions in the LDLR gene is expected to find new mutations and polymorphisms in this gene.

### 4.1 Procedure

Ten µl of PCR reactions were digested with the relevant restriction enzymes in the buffer recommended by the manufacturer. The reaction mixture will be incubated at 37°C for over night.

## 5. Electrophoresis

### 5.1 Agarose gel electrophoresis

#### 5.1.1 Reagent preparation

##### 5.1.1.1 10XTBE

108 g of Trisma base, 55g of Boric acid and 9.3 g of EDTA disodium salt were weighed and dissolved with sterile deionized water. The volume of the solution was adjusted to 1 liter and mixed.

#### 5.1.1.2 1X TBE buffer

100 ml of 10x TBE buffer was diluted to 1 litre with distilled water.

#### 5.1.1.3 1X loading dye

0.125 g each of bromophenol blue and xylene cyanol FF were weighed and 15 ml of glycerol was added. The volume of the mixture was adjusted to 50 ml with autoclaved sterile water for injection.

#### 5.1.1.4 100 bp DNA Ladder marker

5  $\mu$ l (0.5 $\mu$ g) of stock Ladder Marker and 5  $\mu$ l of 6X loading dye solution were taken and then 20  $\mu$ l of steriled water was added.

#### 5.1.1.5 1% Agarose gel electrophoresis

1 g of agarose was weighed and dissolved in 100 ml of 1X TBE buffer. The mixture was heated. The melting gel was poured into an electrophoresis chamber set with a comb inserted. The agarose gel was left to polymerize at room temperature for 30 min.

#### 5.1.1.6 2% Agarose gel electrophoresis

2 g of agarose was weighed and dissolved in 100 ml of 1X TBE buffer. The mixture was heated. The melting gel was poured into an electrophoresis chamber set with a comb inserted. The agarose gel was left to polymerize at room temperature for 30 min.

#### 5.1.1.7 Ethidium bromide solution (10 mg/ml)

1 g of ethidium bromide was weighed and dissolved in 100 ml of reverse osmosis water. The container was wrapped in aluminum foil or the solution was transferred to a dark bottle and store at room temperature.

### 5.1.2 Procedure

#### 5.1.2.1 Analysis of PCR amplification

PCR products were checked for successful amplification on 2% (w/v) agarose gel in 1XTBE buffer. The gel was allowed to cool and solidify for 30 min. The gel was immersed in 1xTBE buffer at a depth of 1-2 mm. 5  $\mu$ l of PCR

amplified products were pipetted and mixed with 2  $\mu$ l of gel loading buffer. The mixtures were loaded in each well on 2% agarose gel and electrophoresed for 20-30 minutes at 100 volts. After electrophoresis, the PCR products were stained with ethidium bromide solution for 1-2 minutes and visualized under ultraviolet light. The size of fragment was estimated by comparison with 100 bp DNA ladder marker under the same condition.

#### **5.1.2.2 Analysis of PCR product purification**

PCR products were purified on 1% agarose gel in 1X TBE. The gel was allowed to cool and solidify for 30 min. The gel was immersed in 1xTBE buffer at a depth of 1-2 mm. 100  $\mu$ l of PCR amplified products were pipetted, mixed with 10  $\mu$ l of gel loading buffer and 10  $\mu$ l of ethidium bromide solution. The mixtures were loaded in each well on 1% agarose gel and electrophoresed for 20-30 minutes at 100 volts. After electrophoresis, the PCR products were visualized under ultraviolet light.

### **5.2 Acrylamide gel electrophoresis**

#### **5.2.1 Reagent preparation**

##### **5.2.1.1 50% (49:1) stock acrylamide solution**

49 g of acrylamide and 1 g of N, N'-methylene-bis-acrylamide were weighed and dissolved in 100 ml sterile water for injection. The solution was filtered through Whatman paper no.1, kept away from light and stored at 4<sup>0</sup> C.

##### **5.2.1.2 20% ammonium persulfate**

0.2 g of ammonium persulfate was weighed and dissolved in 1 ml of sterile water for injection. The solution was freshly prepared, kept away from light and stored at 4<sup>0</sup> C.

#### **5.2.2 Procedure**

Polyacrylamide gel for determination of PCR products was prepared by dilution of the stock 50% acrylamide solution (49:1(w/v) of acrylamide and N, N'-methylene-bis-acrylamide) to give 8% polyacrylamide solution. For Hoefer SE260 apparatus : 1.6 milliliters of the 50% acrylamide stock solution and 0.5 ml of 10xTBE buffer were pipetted and adjusted to a total volume of 10 ml with sterile water for injection. After mixing, the solution was added with 50  $\mu$ l of 20%

ammonium persulfate and 5  $\mu$ l of TEMED and mixed. The gel solution mixture was immediately poured between the minigel glass plates using 1000  $\mu$ l pipette until the glass plate sandwich was full. A comb was placed in the assembled gel sandwich. The gel was left to polymerize for at least 30 minutes at room temperature. 2  $\mu$ l of loading buffer and 5  $\mu$ l of digested PCR products were mixed, and then the mixtures were loaded in each well of 8 % polyacrylamide gel. An electric current was applied at 100 volts for 60 minutes to resolved DNA fragments. After electrophoresis, the gel was stained by ethidium bromide solution for 1-2 minutes and visualized under ultraviolet light. The size of PCR fragment was estimated by comparison with 100 bp DNA ladder marker under the same condition.

## **6. Single strand conformation polymorphism (SSCP)**

Single-strand conformational polymorphism (SSCP) is one of the most widely used mutation scanning techniques because of its simplicity. The principle of this method is based on the fact that the electrophoretic mobility of nucleic acids in a non-denaturing gel is sensitive to variation of both size and shape. Unlike double-stranded DNA, single-stranded DNA is flexible and will adopt a conformation determined by intramolecular interactions and base stacking that is uniquely dependent on sequence composition (Orita et al., 1989). This conformation can be affected when even a single base is changed. Conformational changes can be detected as alterations in the electrophoretic mobility of the single-stranded DNA in non-denaturing polyacrylamide gels.

### **6.1 Reagents preparation**

6.1.1 50% (49.25:0.75) acrylamide stock solution with 1.5% cross link  
49.25 g of acrylamide and 0.75 g of N, N'-methylene-bis-acrylamide were weighed and dissolved in 100 ml sterile water for injection. The solution was filtered through Whatman paper no.1, kept away from light and stored at 4<sup>0</sup> C.

6.1.2 50% (49:1) acrylamide stock solution with 2% cross link

As described in 4.2.1.1

6.1.3 4% acrylamide with 1.5% crosslink

4.54 ml of 50% (49.25:0.75) Acrylamide stock solution with 1.5% cross link and 0.5 ml of 10XTBE were mixed and adjusted to the total volume of 6 ml with sterile water.

#### 6.1.4 6% acrylamide with 1.5% crosslink

0.72 ml of 50% (49.25:0.75) Acrylamide stock solution with 1.5% cross link and 0.5 ml of 10XTBE were mixed and adjusted to the total volume of 6 ml with sterile water.

#### 6.1.5 8% acrylamide with 2% crosslink

5.02 ml of 50% (49:1) Acrylamide stock solution with 2% cross link and 0.5 ml of 10XTBE were mixed and adjusted to the total volume of 6 ml with sterile water.

#### 6.1.6 10% acrylamide with 2% crosslink

1.2 ml of 50% (49:1) Acrylamide stock solution with 1.5% cross link and 0.5 ml of 10XTBE were mixed and adjusted to the total volume of 6 ml with sterile water.

#### 6.1.7 20% ammonium persulfate

As described in 4.2.1.2

#### 6.1.8 1X Loading dye

As described in 4.2.1.3

6.1.9 Formamide dye (Bromophenol blue – Xylene cyanol stock solution)

200µl of Bromophenol blue-Xylene cyanol FF solution, 800µl deionized formamide, 200 µl of 0.5 M EDTA were aliquoted. The solution was homogeneously mixed and kept at -20°C in dark.

## 6.2 Glass plate preparation for mini gel

The plates were cleaned with tap water and detergent and then thoroughly rinsed with distilled water to remove residual detergent. The plates were then washed with 70% ethanol. For each sandwich, one notched glass plate one rectangular glass plate and two spacers were required. The notched plate was laid on the flat surface and each spacer was placed along each edge extending along the side

of notch. The glass plates were fit onto the spacers. The top of the T of spacers were rested along the sides of the gel sandwich. On a flat surface, the spacers were aligned with the sides and also bottom of the glass plates. The sandwich was hold into the clamp assembly, making sure the bottom edge of the sandwich was rested on the flat surface. While holding the sandwich in place, slide each clamp into position and gently tighten the screws. The bottom- edge alignment of the sandwich was checked and adjusted the glass and spacer to ensure that the bottom edges were completely flushed. The caster was standing upright or hung from the Hoefer chamber.

### **6.3 8% Non-denaturing polyarylamide gel preparation**

1.6 milliliters of 50% (49:1) acrylamide stock solution and 0.5 ml of 10X TBE was mixed and adjusted to the total volume of 10 ml with sterile water for injection. 50  $\mu$ l of 20% ammonium persulfate and 5  $\mu$ l of TEMED were added and mixed gently. The gel solution mixture was immediately poured between the minigel glass plates using 1000  $\mu$ l pipette until the glass plate sandwich was full. A comb was placed in the assembled gel sandwich. The gel was left to polymerize for at least 30 minutes at room temperature. The electrophoresis was pre-run for 10 min at 100 volts before samples were loading.

### **6.4 4%-8% gradient non-denaturing polyarylamide gel (1.5%-2%crosslink)**

The glass plate was set as previously described (6.2). The gradient maker was set up with a stirrer in the downstream chamber and tubing leading from the gradient maker to the top of the gel plates. The top middle of the glass plates was attached by a yellow tip. The valve separating the two sides of the gradient maker and the tubing valve were initially close. Before pouring the gel 40 $\mu$ l of 20 % ammonium persulfate and 4 $\mu$ l of TEMED were added to both 4%and 8% acrylamide solution and the gel solution were mixed gently. The high percent gel mix was poured into the down stream chamber and low percentage gel mix into the upstream chamber of the gradient maker. The stirrer was ensured to mixing well in the downstream side. The valve between the two site of the gradient maker was then opened and also the valve in the tubing that leads to the gel plates. In the gradient maker, the 4 % gel mix flowed into the 8% gel mix forming the linear gradient of decreasing percentage concentration (in order to decrease percentage of gel from bottom to top). After the sandwich plates

were full with gel, insert the comb without trapping small bubbles, under the wells. After pouring the gel, the gradient maker was immediately rinsed with distilled water. The comb was removed after the gel was polymerised. The electrophoresis was pre-run for 30 min at 100 volts before samples were loading.

### **6.5 6%-10% gradient non-denaturing polyarylamide gel (1.5%-2%crosslink)**

The glass plate was set as previously described (6.2). The gradient maker was set up with a stirrer in the downstream chamber and tubing leading from the gradient maker to the top of the gel plates. The top middle of the glass plates was attached by a yellow tip. The valve separating the two sides of the gradient maker and the tubing valve were initially close. Before pouring the gel 40 $\mu$ l of 20 % ammonium persulfate and 4 $\mu$ l of TEMED were added to both 6% and 10% acrylamide solution and the gel solution were mixed gently. The high percent gel mix was poured into the down stream chamber and low percentage gel mix into the upstream chamber of the gradient maker. The stirrer was ensured to mixing well in the downstream side. The valve between the two site of the gradient maker was then opened and also the valve in the tubing that leads to the gel plates. In the gradient maker, the 6 % gel mix flowed into the 10% gel mix forming the linear gradient of decreasing percentage concentration (in order to decrease percentage of gel from bottom to top). After the sandwich plates were full with gel, insert the comb without trapping small bubbles, under the wells. After pouring the gel, the gradient maker was immediately rinsed with distilled water. The comb was removed after the gel was polymerised. The electrophoresis was pre-run for 30 min at 100 volts before samples were loading.

### **6.6 Procedure**

SSCP was performed by the method as described by Orita et al. (13). One  $\mu$ l of each set of PCR products was mixed with 10  $\mu$ l of 5x formamide dye mix, incubated in a boiling water-bath for 10 min before loading. Electrophoresis was carried out in 8% non-denaturing polyarylamide gel or 4%-8%, 6%-10% gradient non-denaturing polyarylamide gel and 0.5XTBE buffer without glycerol at 100 volts for 2.30-4 hour at 4°C with Hoefer (MIGHTY SMALL II SE260, Amersham Biosciences, USA) electrophoresis unit. Then SSCP was visualized by silver staining (14).

## 7. Silver staining

Highly sensitive detection of nucleic acids in the nanogram range has been achieved by the specific chemical reduction of silver ions. The methods for silver-staining nucleic acids employ either a histologically derived procedure that uses ammoniacal solutions of silver, or a photochemically derived reaction in which silver binds to nucleic acid bases and is then selectively reduced by chemical agents or light. These silver staining protocols can be as sensitive as radioisotopic methods. However, they are complex and time consuming and require the preparation and handling of several solutions. In an attempt to simplify the routine use of silver stains to detect nucleic acids, Bassam *et. al.* (52) optimized the photochemically derived silver stain originally introduced by Merrill *et. al.* (53) for protein staining and later applied to nucleic acids which uses formaldehyde to selectively reduce silver ions to metallic silver under alkaline conditions (41).

### 7.1 Reagent preparation

Reagents for silver staining method comprise three solutions, fix and stop solution (10% glacial acetic acid), staining solution, and developing solution.

#### 7.1.1 Fix/stop solution (10% glacial acetic acid)

100 ml of glacial acetic acid was added to 900 ml of distilled water.

#### 7.1.2 Staining solution (0.2% AgNO<sub>3</sub>)

2 g of silver nitrate was weighed and homogeneously dissolved in 1 L of sterile deionized water.

7.1.3 Developing solution (3%NaCO<sub>3</sub> with 37% formaldehyde; 100ml: 150µl)

3 g of sodium carbonate was weighed and dissolved in 100 ml of sterile water for injection. The solution was chilled to 10<sup>0</sup> C in the refrigerator. Immediately before use, 150 µl of 37 % formaldehyde was added.

### 7.2 Procedure

The staining procedure consists of just a few steps. After electrophoresis, the gel frames were removed from the electrophoretic apparatus. The screws were loosening, and the plates were removed out of the frame. The glass plates were separated by spacer at a lower corner. The short glass plates adhered with the gel

was placed in a plastic tray, fixed with 100 ml of fix solution, the glass plate was taken out and the gel in the fix solution. The gel was agitated well for 30 minutes or until the tracking dyes were no longer visible. Fixative was saved for later use in terminating the development reaction. The gel was rinsed three times in sterile water for injection with two minutes of agitation each time. After the gel was completely rinsed, it was transferred to 100 ml of staining solution and was agitated for 30 minutes. The gel was removed from the staining solution and rinsed for no longer than 5-10 seconds to remove an excess of silver nitrate in sterile water for injection. The gel was then placed in a chilled tray containing cold developing solution and was agitated again. As soon as the bands were clearly resolved, the fixative solution from the first step was poured directly into the developer, and the mixture was agitated for 3 min. The gel was rinsed twice in distilled water. The gel was collected by wrapping with cellophane membrane, and then air dried for over night at room temperature.

## **8. DNA sequencing**

When SSCP variants were detected, the original genomic template was used for DNA sequencing analysis. The original DNA template was amplified and purified using QIAquick Gel Extraction Kit (QIAGEN, Germany), and automated DNA sequencing by automatic sequencer 3730x (DNA Sequencing Services of Macrogen Inc, Korea).

### **8.1 DNA template preparation**


The PCR products was used as sequencing templates have to be cleaned to remove primers, nucleotides, *Taq* polymerase and salts which affect the sequencing reactions. 100  $\mu$ l of PCR products were run on 1% gel electrophoresis (as described in 4.1.2.2). The DNA band was purified by using QIAquick Gel Extraction Kits. The QIAquick Gel Extraction protocol for DNA purification from agarose gels was described as followings. The DNA fragment was excised from the agarose gel with a clean, sharp scalpel. The excised DNA fragment in agarose gel was transferred to 1.5 ml microcentrifuge tube and weighed. Three volumes of Buffer QG were added to 1 volume of gel (100 mg ~ 100  $\mu$ l). An incubate was made at 50°C for 10 min or until the gel slice was dissolved completely. To assist dissolve gel, the gel mixture was mixed by vortexing the tube every 2-3 min during the incubation. One gel volume of isopropanol was then added to the sample and mixed. A QIAquick spin column was

placed in a provided 2 ml collection tube. The sample was applied to the QIAquick column and centrifuged for 1 min at 13,000 rpm. For the gel mixture volumes of more than 800µl, the excess volume of the gel mixture was simplyed load and spun again. Flow-through was discarded and QIAquick column was placed back in the same tube. A 0.5 ml of Buffer QG was added to QIAquick column and centrifuged for 1 min at 13,000 rpm. To wash the column, 0.75 ml of buffer PE (150µl of PE and 600µl of absolute ethanol) was added to QIAquick and centrifuged for 1 min at 13,000 rpm. The flow-through was discarded and the QIAquick column was centrifuged for an additional 1 min at 13,000 rpm. The Place QIAquick column was placed into a clean 1.5 ml microcentrifuge tube. To elute DNA, 30 µl of buffer EB or H<sub>2</sub>O was added to the center of the QIAquick membrane, let stand for 1 min and then the column centrifuged for 1 min.

## CHAPTER IV RESULTS

### Multiplex assay


Multiplex assay is the assay in which several parts of gene are co-analyzed in one assay. It can be performed by two ways. First, multiplex at the PCR step and second multiplex at the SSCP step. In this study, multiplex PCR-SSCP was initially proposed to develop. Only three DNA fragment (exon 3, exon 4 and exon 13) of LDLR were performed multiplex PCR prior SSCP analysis. This multiplex PCR-SSCP technique was applied in 11 unrelated patients with primary hypercholesterolemia from Department of preventive medicines. The others DNA fragment of LDLR were not performed multiplex PCR because there were not the optimal condition for multiplex PCR. Therefore, PCR-multiplex SSCP was thus subsequently developed. Multiplex assay in this study was shown in figure 9.




**Figure 9** Multiplex assay of LDLR gene in this study

### 1. Multiplex PCR assay

We have been attempting to develop a rapid, effective screening assay enabling the simultaneous analysis of DNA alteration in the LDL receptor gene. Reaction conditions, including both reagent components and cycle condition were set up to optimize the assay. For preliminary experiment, multiplex PCR-SSCP has been developed for simultaneous analysis of mutation in exons 3, 4 and 13 of LDLR gene in primary hypercholesterolemia patients. The temperature profile of 1 min at 94°C, 1 min at 49°C (annealing temperature) and 2 min at 72°C were found to be optimal to co-amplify DNA fragments of exon 3, exon 4 and exon 13 in one PCR reaction. The amplification fragment of multiplex PCR products was shown in Figure 10. One  $\mu$ l of multiplex PCR products was mixed with 10  $\mu$ l of 5x formamide loading dye, incubated in a boiling water-bath for 10 min before loading. Electrophoresis was carried out in 8% polyacrylamide gel with 1.3% crosslink and 0.5XTBE without glycerol at 100 volts for 2.5 hour at 4°C with the Mini PROTEAN II cell electrophoresis unit (BioRAD). And then SSCP gel was visualized by silver staining, wrapped by cellophane and air dried. Multiplex PCR-SSCP pattern of exons 3, 4 and 13 at the LDLR gene locus of hypercholesterolemic patients and control subject was shown in figure 11. Two identical mobility shift was observed in PH<sub>2</sub> and PH<sub>5</sub> samples. These differences were confirmed by SSCP analysis of individual exon (data not show) and further characterized by automated DNA sequencing. There were AvaII polymorphism in exon 13 of PH<sub>2</sub> and PH<sub>5</sub>.



**Figure 10** The amplification fragment of multiplex PCR of exons 3, 4 and 13 of LDLR gene. Lane 1 was 100 bp ladder markers. Lanes 2-7 were multiplex PCR fragments of N, PH<sub>1</sub>, PH<sub>2</sub>, PH<sub>3</sub>, PH<sub>4</sub> and PH<sub>5</sub>, respectively.



**Figure 11** Multiplex PCR-SSCP pattern of exons 3, 4 and 13 at the LDLR gene locus of hypercholesterolemic patients and control subject. Electrophoresis was carried out in 8% polyacrylamide gel with 1.3% crosslink at 100 volts for 2.5 hours at 4°C.

## 2. Multiplex SSCP assay

### 2.1 Optimum PCR-multiplex SSCP condition

PCR-multiplex SSCP was developed for diagnosis of FH. The specific PCR primers that amplified all 18 exons and the promoter region were listed in Table 5. During the design of the combination sets, we combined different migrating bands of each exon in the multiplex SSCP analysis. All PCR products of 18 exons and promoter of the LDLR gene were multiplexed into 6 combination sets. Some amplicons of the combination sets were digested with RE for two purposes. First, it was expected that exon with abnormal pattern would be specified right away from the multiplex SSCP pattern. Second, the RE digestion was expected to increase sensitivity of the multiplex SSCP. Webcutter or NEBcutter were used to identify site cut of some exons. Combination of amplified exons or RE-digested amplified exons for multiplex SSCP analysis was shown in Table 9.

**Table 9** Combination of amplified exons or RE-digested amplified exons for multiplex SSCP analysis

Set	Exons in combination	Restriction Modification	
		Exon(s)	Enzyme
1	9,11,14	11	<i>Hae III</i>
2	3,4,15	3,4,15	<i>HpaII</i>
3	Promoter,1,5	Promoter	<i>HpaII</i>
4	2,6,13,18	2	<i>HhaI</i>
5	7,8,12	7	<i>Hae III</i>
6	10,16,17	-	-

To determine the best resolution setting, we evaluated different gradient polyacrylamide gel and time. Optimal combination sets were achieved by testing under non-gradient (8%T) or gradient [4%T(1.5%C)-8%T(2%C) or 6%T(1.5%C)-10%T(1.5%C)] polyacrylamide gel electrophoresis. The gradient polyacrylamide gel was of better resolution than non-gradient polyacrylamide gel. The 4%T(1.5%C) to 8%T(2%C) gradient polyacrylamide gel electrophoresis was used in PCR-multiplex SSCP combination set 1, 2, 5, 6 and the 6%T(1.5%C) to 10%T(1.5%C) was used in PCR-multiplex combination set 2 and 4. The optimal running time was 2.30-4 hours depending on DNA fragment. The conditions for these multiplex SSCP assays were summarized in Table 10.

**Table 10** The conditions for multiplex SSCP assays

Combination Set	PCR product : formamide dye ( $\mu$ l)	% gradient polyacrylamide gel	Running Time (hrs.)	Voltage
1	1: 5	4-8	3	100
2	1.5: 3	4-8	3	100
3	1: 3	6-10	4	100
4	1: 3	6-10	4	100
5	1.5: 3	4-8	2.30	100
6	1.5: 3	4-8	3	100


## 2.2 Validation of PCR-multiplex SSCP setup in LDLR gene

There were 6 combination sets of PCR-multiplex SSCP. Only 5 combination sets can be validated. They were combination sets 1, 2, 4, 5 and 6. Previously reported known mutations M412T and S554L were used to validate combination set 1. IVS 3+1 G > T (313+1G>T) was used to validate combination set 2. G1414A common polymorphism was used to validate combination set 6. The common AvaII and HincII polymorphisms can detect in exon 13 and exon 12 by PCR-multiplex SSCP combination set 4 and 5, respectively. Twenty four unrelated patients with FH were screened for mutations and polymorphisms in all 18 exons and the promoter region of the LDLR gene. We did not observe any mutation or

polymorphism in promoter, exon 1 or exon 5 of these 13 unrelated patients with primary hypercholesterolemia from Navy Hospital. Therefore, we can not show the validation of combination set 3.

### 2.2.1 PCR-multiplex SSCP of the combination set 1

This combination set 1 was validated with M412T (exon 9) and S554L (exon11) mutations. The M412T mutation caused by a transition of T to C at nucleotide position 1235 in exon 9. This nucleotide change was predicted to cause the substitution of a threonine for methionine at codon 412. The amino acid at this position has been changed from an amino acid with nonpolar side chain (M) to uncharged polar side (T). The S554L mutation caused by a transition of C to T at nucleotide position 1666 in exon 11. This nucleotide change was predicted to cause the substitution of serine to leucine at codon 554. The amino acid at this position has been changed from an amino acid with uncharged polar side chain (S) to nonpolar aliphatic side chain (L). The abnormal SSCP patterns of M412T and S55L were shown below.




**Figure 12** Silver staining of 4-8% gradient polyacrylamide gel of PCR-multiplex SSCP combination set 1. DS in lane 1 was double stranded DNA. Lanes 2-4 were individually amplified PCR fragments of exon 9, *HaeIII* digested exon 11 and exon 14 of normal control. Lanes 5-9 were fragments of PCR-multiplex SSCP of normal

control, DN, PP, H001 and H002, respectively. DN, PP, H001 and H002 were patients with FH phenotype.

### 2.2.2 PCR-multiplex SSCP of the combination set 2


The combination set 2 was validated with IVS3+1G>T of exon 3. The IVS 3+1 G>T mutation caused by the G to T transversion at position 1 of intron 3. The GT dinucleotide at 5' end of an intron is highly conserved serving as part of the consensus recognition signal for mRNA splicing in vertebrate genes. The multiplex SSCP of the combination set 2 showing the abnormal SSCP pattern of IVS3+1 G>T. The data was shown in figure 13.




**Figure 13** Silver staining of 4-8% gradient polyacrylamide gel of PCR-multiplex SSCP combination set 2. DS in lane 1 was double stranded DNA. Lanes 2-4 were individually amplified PCR fragments of *HpaII* digested exon 3, *HpaII* digested exon 4 and *HpaII* digested exon 15 of normal control. Lanes 5-9 were fragments of PCR-multiplex SSCP of normal control, PS, H001, H002 and H003, respectively. PS, H001, H002 and H003 were patients with FH phenotype.

### 2.2.3 PCR-multiplex SSCP of the combination set 6

The common polymorphism G1414A in exon 10 was used for validation of this multiplex set. G225 was a 14 years old girl previously diagnosed as homozygous FH patient. This patient has homozygous A at this polymorphic site. This nucleotide alteration did not change amino acid ( arginine to arginine) at codon 471 of the LDLR gene. G1414A( R471) polymorphism has been reported in NCBI database.




**Figure 14** Silver staining of 4-8% gradient polyacrylamide gel of PCR-multiplex SSCP combination set 6. DS was double stranded DNA. Lanes 2-4 were individually amplified PCR fragments of exons 10, 16 and 17 of normal control. Lanes 5-7 were fragment of PCR-multiplex SSCP of normal control, G225 and H001. G225 and H001 were patients with FH phenotype.



**Figure 15** Nucleotide sequences from amplified exon 10 of the LDLR gene, after direct sequencing of PCR products. (A) Heterozygous for a G to A transition at nucleotide position 1414 (26463 including intron) of normal control. (B) Homozygous A at the same nucleotide position of G225 and H001.

### 2.2.4 PCR-multiplex SSCP combination set 3


No mutations or polymorphisms in Exon 1, Exon 5 or promoter in our FH patients. Furthermore, we did not find mutations or polymorphisms in promoter, exon 1 or exon 5 of 24 unrelated patients with FH. Therefore, we can not show the validation of the PCR-multiplex SSCP combination set 3. Although, there were not mobility shift in this combination set but SSCP patterns were clearly and should be useful for screen mutations and polymorphisms in E1, E5 and promoter of LDLR gene.



**Figure 16** Silver staining of 6-10% gradient polyacrylamide gel of PCR-multiplex SSCP combination set 3. Lanes 1-3 were individually amplified PCR fragments of exon 1, exon 5 and *HpaII* digested promoter of normal control. Lanes 4-8 were fragment of PCR-multiplex SSCP of normal control, H003, H005, H006 and H007, respectively. H003, H005, H006 and H007 were patients with FH phenotype.


### 2.2.5 PCR-multiplex SSCP combination set 4

The abnormal SSCP pattern was observed in exon 13 of H007. The data have been shown as below.




**Figure17** Silver staining of 6-10% gradient polyacrylamide gel of PCR-multiplex SSCP combination set 4. Lanes 1-4 were individually amplified PCR fragments of *HhaI* digested exon 2, exon 6, exon 13 and exon 18 of normal control. Lanes 5-9 were fragment of PCR-multiplex SSCP of normal control, H002, H003, H013 and H007, respectively.

Then sequence variations were confirmed by direct sequencing. There were heterozygous for a T to C transition of H007 at nucleotide position 33039. The nucleotide change did not disturb amino acid sequence (GTT/GTC→Val/Val). The other subjects i.e., H002, H004 and H013 were of homozygous T at this nucleotide. This nucleotide change was the common *Ava*II polymorphism (SNP) in exon 13 of LDLR gene. The representative sequence results have been shown as below.



**Figure 18** Nucleotide sequences from amplified exon 13 of the LDLR gene, after direct sequencing of PCR products (A) Heterozygous for a T to C transition at nucleotide position 1959 (33039 including intron) of H007. (B) Homozygous T at the same nucleotide position of H013.

The PCR products of E13 were digested with *AvaII* to confirm the presence of this common SNP in our subjects. The amplified product of this region was 219 bp. The digestion of the amplified product with the restriction enzyme *AvaII* reveal two fragments of 182 and 37 bp, indicating the presence of the restriction site. The *AvaII* restriction map and the RFLP result were shown in figure 19.



**Figure 19** (A) The schematic drawing of *AvaII* digestion site in the PCR product of exon 13 of LDLR gene. (B) Agarose gel electrophoresis of *AvaII* polymorphism in exon 13 of the LDLR gene.

From RFLP result, we conclude that H007 was heterozygous for T to C transition and the other subjects i.e., H002, H004 and H013 were homozygous T corresponding with the DNA sequence data. This *AvaII* polymorphism was recorded

in the LDLR database (Appendix B). The allele specific frequency of this polymorphism of C is 0.37.

#### 2.2.6 PCR-multiplex combination set 5


The PCR-multiplex SSCP gel of combination set 5 was shown in figure 16. We found that H004 had the same SSCP pattern as normal control, H001 was the same as H002 and H003 was different from the others. The mobility shifts were apparent in exons 8 and 12. Therefore, exons 8 and 12 of these DNA samples were subjected to DNA sequencing.




**Figure 20** Silver staining of 4-8% gradient polyacrylamide gel of PCR-multiplex SSCP combination set 5. DS in lane 1 was double stranded DNA. Lanes 2-4 were individually amplified PCR fragments of *HaeIII* digested exon 7, exon 8 and exon 12 of normal control. Lanes 5-9 were fragment of PCR-multiplex SSCP of normal control, H001, H002, H003 and H004 respectively. H001, H002, H003 and H004 were patients with FH phenotype.

From DNA sequencing results of E8, there were heterozygous for a G to A transition at nucleotide position 24494 in normal control, H001, H002, H003 and H004. The nucleotide change did not disturb amino acid sequence (GAA/AAA→Lys/Lys). It might be novel polymorphism. In exon 12, there were

heterozygous for a C to T transition at nucleotide position 29800 in H003 and homozygous C in normal control, H001, H002 and H004. The nucleotide change did not disturb amino acid sequence (AAC/AAT→Asn/Asn) as well. Previous study in our lab shows that this is HincII polymorphism.



**Figure 21** Nucleotide sequence from amplified exon 8 of the LDLR gene, after direct sequencing of PCR products. Heterozygous for a G to A transition at nucleotide position 1167 (24494 including intron).



**Figure 22** Nucleotide sequence from amplified exon 12 of the LDLR gene, after direct sequencing of PCR products. (A) Heterozygous for a C to T transition of H003 of nucleotide position 1773 (29800 including intron) (B) Homozygous C of normal control.

## CHAPTER V

### DISCUSSION

In most populations in the world, the frequency of heterozygous FH is estimated to be 0.2%. At the molecular level, FH is a heterogeneous disorder caused by more than 900 different mutations in the LDLR gene and the number of identified mutations is increasing steadily (4). Identification of a LDL receptor gene mutation in an FH individual is of value for several reasons. An unequivocal diagnosis can be made, and affected relatives can be identified at an early age, when a clear-cut diagnosis based on clinical criteria is not possible. Mutation detection can be divided into two categories: a scanning mode, where a stretch of DNA is searched for unknown mutations, and diagnostic mode, where specific tests are designed to detect known mutations (42). To answer the questions in a genetically heterogeneous population, new molecular genetic techniques had to be established that allow a rapid and sensitive screening for new mutations. SSCP analysis of PCR-amplified genomic DNA fragments (Orita *et al* 1989) has become a simple and sensitive standard method for the detection of small genetic alteration. We further modified this technique by performing PCR-multiplex SSCP. In this study, we devised a PCR-multiplex SSCP to reduce the workload involved in performing mutation analysis in large regions of LDLR gene. The protocols were validated via known mutations or polymorphisms. In the analysis of DNA segments of which no genetic variation existed, validation was made by performing DNA sequencing when abnormal SSCP pattern or mobility shift was apparent.

Multiplex assay is the assay in which several parts of gene are co-analyzed in one assay. It can be performed by two ways. First, multiplex at the PCR step: more than one primer pairs were simultaneously used in one PCR reaction mixture prior to SSCP analysis. Pocsai *et al* developed multiplex PCR assay for screening deletions in the LDLR in 2001 (1). In this study, multiplex PCR and subsequently followed by SSCP was initially tried. However, it did not work because in multiplex PCR

condition, primers of some exons co-amplified with other part of gene so non-specific PCR product was apparent. For successful multiplex PCR assay, the relative concentration of primers, PCR buffer, balance between  $MgCl_2$  and dNTP, cycling temperature, amount of DNA template and *Taq* DNA polymerase are important (43). Second, multiplex at the SSCP step: PCR for individual exons or for individual part of the gene were performed and then these PCR products were pooled in multiplex assay by SSCP. Previous study, the former students used both techniques in the EGF precursor homology domain (E7-E14) and the ligand binding domain (E2-E6) of the LDLR gene (48, 49). In this study, multiplex PCR-SSCP was initially proposed to develop. After several trials of multiplex PCR-SSCP upon various combinations of amplified exons, only the combination of exons 3, 4 and 13 of LDLR gene was successfully optimized (as presented in Fig. 10). Therefore, PCR-multiplex SSCP was thus subsequently developed. The development was fairly successful and the protocol was applicable to investigate the whole regions of LDLR gene (promoter plus 18 exons). PCR fragments of some amplified exons were digested with restriction enzymes to increase sensitivity of the multiplex assay. There were 6 combination sets of amplified exons or RE-digested amplified exons for multiplex SSCP analysis. Several factors such as temperature, pH, running time, gel composition and size of the DNA fragments can influence the sensitivity of SSCP analysis (35). Many modifications to the original protocol developed by Orita *et. al.* include variables that affect the gel matrix, e.g., percentage of acrylamide monomer, cross-linking ratio, buffer systems, addition of neutral compounds to the gel and electrophoresis temperature. The most preferred gel characteristics for successful differential separation of single strand conformers in the range of 200-300 bp, where the method should be most sensitive and reliable, are 12% acrylamide and cross-linking ratios (%C) between 1 and 3 (10). Several publications have detailed the different effects that different conditions can have on resolving a particular sequence variation. Reduced cross linker ratio (bis:acrylamide 1:49) and 50-100 ml/l glycerol are popular (44). The sensitivity of the multiplex SSCP was also increased by using gradient polyacrylamide gel electrophoresis. To determine the best resolution setting, different gradient polyacrylamide gel and running time were evaluated. For PCR-multiplex

SSCP, the gradient [4%T(1.5%C)-8%T(2%C) or 6%T(1.5%C)-10%T(1.5%C)] polyacrylamide gel revealed better resolution than non-gradient (8%T) polyacrylamide gel. The optimal running time of these multiplex SSCP in gradient gel was 3-4 hours depending on DNA fragments. So far no publication reported gradient acrylamide gel electrophoresis in SSCP analysis. This study in our laboratory is thus the first report on multiplex SSCP analysis for mutation screening at the LDLR gene locus.

The sensitivity of a mutation detection method has usually been evaluated by the rate of detection of already known mutation (35). We have demonstrated the use of PCR-multiplex SSCP method for detection of M412T (exon 9) and S554L (exon 11) in combination set 1, IVS 313+1 G > T (exon 3) in combination set 2 and G1414A (exon 10) common polymorphism in combination set 6. In the combination set 1 (figure 9), abnormal mobility shifts of DN and PP samples were observed. Mobility shifts in exon 9 of M412T mutation and in exon 11 of S554L mutation were observed in the corresponding exonic banding patterns of the multiplex SSCP set 1. In the combination set 2 (figure 10), abnormal mobility shift of PS sample was observed. This mobility shift was correspondingly apparent in the region of banding pattern of exon 3. In the combination set 6 (figure 11), the multiplex SSCP banding pattern of G1414A (exon 10) in normal lipidemic subject was apparently different from the banding pattern of homozygous A in FH patients (G225 and H001). For the multiplex SSCP in the combination set 3 (figure 13), there was no genetic variation for validation at present time. However, the profile of this combination set 3 was fairly clear. It should have revealed the mobility shift pattern for any genetic variation if it is existing in any DNA segment of this multiplex set and it should thus be applicable for screening mutations and polymorphisms in exon 1, exon 5 and promoter of the LDLR gene. On the other hand, the profiling of these DNA segments can be collected as genetic profile for each FH patient. The common *Ava*II (exon 13) and *Hinc*II (exon 12) polymorphisms could be detected by PCR-multiplex SSCP combination set 4 and 5, respectively. In combination set 4 (figure 14), the heterozygous T to C transition in exon 13 is the common *Ava*II single nucleotide polymorphism (SNP). It is the variation at nucleotide position 33039 with an allele frequency of C is 0.37 (Appendix B). Previous study, the genotype frequencies at *Ava*II sites of Thai population were

57.9%, 36.6% and 5.5% for the (-/-), (+/-), and (+/+) genotypes, respectively (50). In combination set 5 (figure 17), the heterozygous for C to T transition in exon 12 is the common HincII polymorphism (SNP). In addition, there was a heterozygous G to A transition at nucleotide position 24494 in exon 8. This polymorphism did not change amino acid (GAA/AAA→Lys/Lys) and it has not been reported elsewhere. From LDLR database (<http://www.ucl.ac.uk/fh/>), only StuI polymorphism in exon 8 has been reported. Therefore, this G→A transition is a novel polymorphism observed via PCR-multiplex SSCP analysis in this study.

In this study, we tried to optimize PCR multiplex-SSCP condition and used known mutation to validate this technique. The optimized PCR-multiplex SSCP were subsequently applied in 13 unrelated patients with primary hypercholesterolemia. The multiplex SSCP screening was performed for all 18 exons and promoter region in these patients. The mutations and polymorphisms used for validation of the PCR-multiplex SSCP assays and the genetic variations observed by the multiplex SSCP assays were summarized in Table 11.

**Table 11** Mutations and Polymorphisms in 13 unrelated patients with primary hypercholesterolemia using PCR-multiplex SSCP technique.

PCR-multiplex SSCP of the combination set	Exon	Change in nucleotide sequence	Nucleotide No.	Change in amino acid sequence	Mutation name
1	9	ATG>ACG	1235	Met/Thr	M412T
	11	TCG>TTG	1666	Ser/Leu	S554L
	14	-	-	-	-
2	3	IVS 3+1 G>T	313	-----	313+1 G>T
	4	-	-	-	-
	15	-	-	-	-
3	1	-	-	-	-
	5	-	-	-	-
	promoter	-	-	-	-
4	2	-	-	-	-
	6	-	-	-	-
	13	GTT/GTC	1959	Val/Val	AvaII polymorphism <sup>a</sup>
	18	-	-	-	-
5	7	-	-	-	-
	8	GAA/AAA	1167	Lys/Lys	Novel polymorphism <sup>b</sup>
	12	AAC/AAT	1773	Asn/Asn	HincII polymorphism <sup>c</sup>
6	10	AGG/AGA	1414	Arg/Arg	G1414A <sup>d</sup>
	16	-	-	-	-
	17	-	-	-	-

a= Heterozygous T/C in patient H007,

b= Heterozygous G/A in normal control and

c= Heterozygous C/T in patient H003,

d= Heterozygous G/A in normal control,

Homozygous TT in patients H002, H004, H013

patients H001, H002, H003, H004

Homozygous CC in normal control and patients H001, H002, H004

Homozygous AA in patients G225 and H001

The patients under this study were primarily tested for the ApoB common R3500Q mutation prior to the LDLR gene screening. These patients have not been screened for the mutations in the PCSK9 gene (45) which also causes FH-like phenotype. Although new and recurrent mutations were not found in these patients, the polymorphisms observed in this study should be useful. In the general population, LDL receptor gene polymorphisms have been shown to be associated with variations in cholesterol levels (46) as well as a wide variation in the age of onset and the expression of coronary heart disease in FH patients (47).

SSCP analysis is reported to have a sensitivity of 75-85%, suggesting that a mutation may have been missed for technical reasons in 15-25% patients. This technical problem should be partly solved by trying the other optimal conditions. In case that several optimal SSCP conditions fail to reveal any mobility shift or mutation, the patients may be deserved to search for large insertion, deletion or large rearrangement by other appropriate techniques. SSCP is suitable for screening only one base change or small deletion or insertion.

The multiplex SSCP method developed in this study can considerably reduce cost (such as chemical reagents for polyacrylamide gel preparation, staining solution, etc.) and time involved in mutation detection by more than 50%. The availability of new methods that speed up the process of finding genetic aberrations in genes should allow the identification of an ever-increasing number of LDLR gene variants that cause hypercholesterolemia.

## CHAPTER VI

### CONCLUSION

For establishing a molecular diagnosis, the whole LDL receptor gene of each individual patient has to be screened for new and recurrent mutations. The 6 combination sets of PCR-multiplex SSCP analysis developed in this study seem to be a suitable method. It is relatively rapid, simple, sensitive and has been successfully applied for known mutation detection. The comparison between original SSCP method (51) and PCR-multiplex SSCP in this study was summarized in Table 12.

**Table 12** Comparison of original SSCP method (Orita *et. al.*) and PCR-multiplex SSCP developed in this study.

Method Property	Original SSCP	PCR-multiplex SSCP
Rapid	- screening 1 DNA fragment/ lane/SSCP gel	- screening 3 or 4 DNA fragments/lane/SSCP gel ( 3-4 times more rapid)
Simple	- large gel (20×40×0.2 cm)  - hybridization detection ( using <sup>32</sup> P-labeled DNA probes→cumbersome, dangerous and expensive)	- minigel (10×10.5×0.075 cm) (easy to handle)  - detection by silver staining (avoid hazardous radioactive, inexpensive)
Sensitive	- restriction endonuclease	- restriction endonuclease in hypermutable CG region (increase sensitivity of multiplex SSCP gel, expect to find new mutation at CG region)  - gradient SSCP gel

**Table 12** (Cont.) Comparison of original SSCP method (Orita *et. al.*) and PCR-multiplex SSCP developed in this study.

Method Property	Original SSCP	PCR-multiplex SSCP
		(increase sensitivity and resolution)

The new technique has a great potential for mutation screening of large numbers of samples in clinical diagnosis. We can use this multiplex assay to screen mutation and polymorphism in DNA sample and can also create a DNA profile for an individual subject. At an individual level, when an individual tested positive for a mutation, we can use that mutation to screen his or her family members so that preventive treatment for the family members at risk can be made and/or therapeutic intervention for patient can be managed in the right direction. At population level, identification of mutations in our population will generate a database. Availability of such database for LDLR gene mutations can likely lead to an implementation for population-based genetic screening program such as those programs established in Scotland and Netherland (18). Now, CAD is the leading cause of death in many countries, including Thailand. In the future by the year 2020, CAD is predicted by WHO to be a major cause of death for global population, especially in developing countries. So if we have our own mutation database, we can use possibly this database for diagnosis and prevention in our population.

In conclusion, this knowledge will be integrated in our routine molecular diagnostic strategy for FH. This should simplify diagnostic testing, facilitate genetic counseling and make it possible to diagnose FH at the molecular level at a presymptomatic early age.

## REFERENCES

1. Pocsai Z, Paragh G and Adany R. Multiplex PCR assay for screening deletions in the low density lipoprotein receptor gene. *Clin Chim Acta*. 2001;309(1):7-12.
2. Liguori R, Argiriou A and Simone VD. A rapid method for detecting mutations of the human LDL receptor gene by complete cDNA sequencing. *Mol Cell Probes*. 2003;17(1):15-20.
3. Melissa A. Austin, Carolyn M. Hutter, Ron L. Zimmern and Steve E. Humphries. Familial Hypercholesterolemia and Coronary Heart Disease: A HuGE Association Review. *American Journal of Epidemiology*. 2004;160(5):421-429.
4. Weiss N, Binder G and Keller C. Mutations in the low-density-lipoprotein receptor gene in German patients with familial hypercholesterolaemia. *J Inherit Metab Dis*. 2000;23(8):778-90.
5. Khoo KL, van Acker P, Defesche JC, Tan H, van de Kerkhof L and Heijnen-van Eijk SJ *et al*. Low-density lipoprotein receptor gene mutations in a Southeast Asian population with familial hypercholesterolemia. *Clin Genet*. 2000;58(2):98-105.
6. Bodamer OA, Bercovich D, Schlabach M, Ballantyne C, Zoch D and Beaudet AL. Use of Denaturing HPLC to Provide Efficient Detection of Mutations Causing Familial Hypercholesterolemia. *Clinical Chemistry*. 2002;48(11):1913–1918.
7. Bunn CF, Lintott CJ, Scott RS and George PM. Comparison of SSCP and DHPLC for the Detection of LDLR Mutations in a New Zealand Cohort. *Hum Mutat*. 2002;19(3):311.
8. Steve E. Humphries, Vilmundur Gudnason, Ros Whittall and Ian N.M. Day. Single-strand conformation polymorphism analysis with high throughput modifications, and its use in mutation detection in familial hypercholesterolemia. *Clinical Chemistry*. 1997; 43(3):427–435.
9. Weiss N, Eggersdorfer I and Keller C. Multiplex-PCR-based single-strand conformation polymorphism protocol for simultaneous analysis of up to five


- fragments of the low-density-lipoprotein receptor gene. *Biotechniques*. 1996;20(3):421-4, 426, 428-9.
10. Arseni Markoff, Alex Savov, Vladimir Vladimirov, Nadia Bogdanova, Ivo Kremensky and Varban Ganev. Optimization of single-strand conformation polymorphism analysis in the presence of polyethylene glycol. *Clinical Chemistry*. 1997; 43(1):30–33.
  11. P. Sunnucks, A. C. C. Wilson, L. B. Beheregaray K. Zenger, J. French and A.C. Taylor. SSCP is not so difficult: the application and utility of single-stranded conformation polymorphism in evolutionary biology and molecular ecology. *Molecular Ecology*. 2000;9:1699–1710.
  12. Lachtermacher MB, Seuanez HN, Moser HW and Smith KD. One-step multiplex PCR strategy for identification of mutations by SSCP and DNA sequencing. *Biotechniques*. 2000; 29(2):234-6.
  13. Orita M, Suzuki Y, Sekiya T and Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. *Genomics*. 1989;5(4):874-9.
  14. Pongrapeeporn KS, Thepsuriyanon P, Leowattana W, Ong-ajyooth S, Kiartivich S and Yamwong P. Inexpensive, rapid and convenient PCR-minigel SSCP protocol for polymorphisms and mutations analyses of LDL receptor gene. *J Med Assoc Thai*. 2001;84(3):676-83.
  15. Hanna Kankkonen. Gene Therapy in The treatment of Familial Hypercholesterolemia [webpage on the internet]. Available from: <http://www.uku.fi/vaitokset/2004/isbn951-781-382-1.pdf>
  16. Aldons J. Lusi, Rebecca Mar and Paivi Pajukanta. Genetics of atherosclerosis. *Annu. Rev. Genomics Hum. Genet*. 2004;5:189–218.
  17. Specialized investigations: Clinical disorders of lipid metabolism. Robert Britton. An illustrated colour text clinical biochemistry. New York: Churchill Livingstone; 1995. p122-123.
  18. Melissa A. Austin, Carolyn M. Hutter, Ron L. Zimmern and Steve E. Humphries. Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review. *Am J Epidemiol*. 2004;160(5):408-420.

19. Dalya Marks, Margaret Thorogood, H. Andrew W. Neil and Steve E. Humphries. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. *Atherosclerosis*. 2003;168:1-14.
20. Varret M, Rabes JP, Saint-Jore B, Cenarro A, Marinoni JC and Civeira *et al.* A third major locus for autosomal dominant hypercholesterolaemia maps to 1p34.1-p32. *Am J Med Genet*. 1999;64:1378-87.
21. Hunt SC, Hopkins PN, Bulka K, McDermott MT, Thorne TL and Wardell BB *et al.* Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred. *Arterioscler Thromb Vasc Biol*. 2000;20:1089-93.
22. Paul N. Hopkins. Familial hypercholesterolemia—Improving treatment and meeting. *International Journal of Cardiology*. 2003;89:13–23.
23. Philip J. Lee. The management of familial hypercholesterolaemia in childhood. *Current Paediatrics*. 2002;12:104-109.
24. Michael s. Brown and Joseph L. Goldstein. A receptor-mediated pathway for cholesterol homeostasis [webpage on the Internet]. Available from: <http://nobelprize.org/medicine/laureates/1985/brown-goldstein-lecture.pdf>
25. Department of Biology, Lake Forest College, USA. Hypercholesterolemia: So much cholesterol, so many causes [webpage on the Internet]. Available from: <http://campus.lakeforest.edu/~debburman/BIO221S02/fiveprojects/diseasereviewarticle/abstracts/FH.pdf>
26. A K Soutar and BL Kniht. Structure and regulation of the LDL-receptor and its gene. *Lipids and cardiovascular disease. British Medical Bulletin*:1990;No.4,p.891-916.
27. Mathilde Varret, Jean-Pierre Rabès, Gwenaëlle Collod-Bérout, Claudine Junien and Catherine Boileau. Software and database for the analysis of mutations in the human LDL receptor gene. *Nucleic Acids Research*. 1997;25(1):172-180.
28. Mathilde Varret, Jean-Pierre Rabès, Rochelle Thiant, Maritha J. Kotze, Heike Baron and Ana Cenarro *et al.* LDLR Database (second edition): new additions to the database and the software, and results of the first molecular analysis. *Nucleic Acids Research*. 1998;26(1):248–252

29. S.E. Humphries, D. Galton and P. Nicholis. Genetic testing for familial hypercholesterolaemia: practical and ethical issues. *Q J Med.* 1997; 90:169–181 [review].
30. RGH Cotton. Mutation detection. In: David N Cooper, editors. *Nature encyclopedia of the human genome, Volume 4.* New York: Nature Publishing Group; 2003.p.204-210.
31. Gene structure and function [webpage on the Internet]. Available from: <http://www.oup.co.uk/pdf/0-19-856494-5.pdf>
32. Maruyama T, Miyake Y, Tajima S, Harada-Shiba M, Yamamura T and Tsushima M *et al.* Common Mutations in the Low-Density-Lipoprotein–Receptor Gene Causing Familial Hypercholesterolemia in the Japanese Population. *Arterioscler Thromb Vasc Biol.* 1995;15(10):1713-8.
33. S.E. Humphries, V. Gudnason, R. Whittall and I.N. Day. Single-strand conformation polymorphism analysis with high throughput modifications, and its use in mutation detection in familial hypercholesterolemia. *International Federation of Clinical Chemistry Scientific Division: Committee on Molecular Biology Techniques, Clin Chem.* 1997;43(3):427–435 [review].
34. Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.gov/OMIM> (for FH [143890], LDLR gene [606945]).
35. Jensen HK, Jensen LG, Hansen PS, Faergeman O and Gregersen N. High sensitivity of the single-strand conformation polymorphism method for detecting sequence variations in the low-density lipoprotein receptor gene validated by DNA sequencing. *Clin Chem.* 1996;42(8 Pt 1):1140-6.
36. Jensen HK. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark. *Dan Med Bull.* 2002;49(4):318-45.
37. Viroj Wiwanitkit, MD, Danai Wangsaturaka, MD and Oranee Tangphao, MD. LDL-cholesterol lowering effect of a generic product of simvastatin compared to simvastatin (Zocor™) in Thai hypercholesterolemic subjects – a randomized crossover study, the first report from Thailand. *BMC Clin Pharmacol.* 2002;2: 1-6.

38. Amersham Biosciences [homepage on the Internet]. Available from : [http://www.mdyn.com/aptrix/upp00919.nsf/Content/elpho\\_applications%5Celpho\\_applications\\_fragment\\_analysis%5Celpho\\_applications%5C2.+SSCP](http://www.mdyn.com/aptrix/upp00919.nsf/Content/elpho_applications%5Celpho_applications_fragment_analysis%5Celpho_applications%5C2.+SSCP)
39. Pluthero FG. Rapid purification of high-activity Taq DNA polymerase. *Nucleic Acids Research*. 1993;(21):4850-51.
40. Durrington PN. Lipids and their metabolism: In: hyperlipidaemia; diagnosis and management, 2<sup>th</sup> ed, UK: University of Manchester; 1995.p.4-71.
41. Uni-graz.at [homepage on the Internet]. Available from : <http://www.uni-graz.at/~binder/thesis/node73.html>
42. Jensen HK, Jensen LG, Meinertz H, Hansen PS, Gregersen N and Faergeman O. Spectrum of LDL receptor gene mutations in Denmark: implications for molecular diagnostic strategy in heterozygous familial hypercholesterolemia. *Atherosclerosis*. 1999;146(2):337-44.
43. Markoulatos P, Siafakas N and Moncany M. Multiplex polymerase chain reaction: a practical approach. *J Clin Lab Anal*. 2002;16(1):47-51.
44. Spinardi L, Mazars R and Theillet C. Protocols for an improved detection of point mutations by SSCP. *Nucleic Acids Res* 1991;19:4009.
45. Sozen MM, Whittall R, Oner C, Tokatli A, Kalkanoglu HS and Dursun A *et al*. The molecular basis of familial hypercholesterolaemia in Turkish patients. *Atherosclerosis*. 2005;180(1):63-71.
46. Ahn YI, Kamboh MI and Aston CE *et al*. Role of common genetic polymorphisms in the LDL receptor gene in affecting plasma cholesterol levels in the general population. *Arterioscler Thromb*. 1994;14: 663-670.
47. Hill JS, Hayden MR and Frohlich J *et al*. The incidence of coronary artery disease in heterozygous familial hypercholesterolemia. *Arterioscler Thromb*. (1991);11: 290-297.
48. Lampoon Kasemsuk. Multiplex SSCP analysis of EGF precursor homology domain of LDL receptor gene. [M.S. Thesis in Biochemistry]. Bangkok, Faculty of Graduates studies, Mahidol University; 2002.
49. Kwandao Kerdsaeng. PCR-minigel SSCP analysis of the exons encoding the ligand binding domain of LDLR gene. [M.S. Thesis in Biochemistry]. Bangkok, Faculty of Graduates studies, Mahidol University; 2003.

50. Theerasak Pimsawat. Polymorphisms at the 5' flanking region, exons 1,8,13 and 18 of low density lipoprotein receptor gene in Thai subjects. [M.S. Thesis in Biochemistry]. Bangkok, Faculty of Graduates studies, Mahidol University; 1999.
51. Orita M, Iwahana H and Kanazawa H. *et. al.* Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphism. *Proc. Natl. Acad. Sci. USA.* 1989;86:2766-2670.
52. Bassam, B. J., Caetano-Anolles, G., Gresshoff, P. M. Fast and sensitive silver staining of DNA in polyacrylamide gels. *Anal. Biochem.* 1991;195:80-83.
53. Merrill, C. R., Goldman, D., Sedman, S. A., Ebert, M. H. Ultrasensitive stain for proteins in polyacrylamide gels shows regional variation in cerebrospinal fluid proteins. *Science.* 1981;211:1437-1438.





## APPENDIX

### A. Taq DNA polymerase preparation

#### A.1 Reagents Preparation

##### A.1.1 LB broth

5 g of Bacto-tryptone, 2.5 g of yeast extract and 2.5 g of NaCl were weighed and the volume was adjusted to 500 ml with sterile deionized water. The solution was sterilized by autoclaving.

##### A.1.2 LB agar (LB broth +1.5% agar)

3 g of the agar was weighed and dissolve in 200 ml of the LB broth.

##### A.1.3 Ampicillin stock (10 mg/ml)

0.1 g of ampicillin was weighed and dissolved in 1ml of autoclaved sterile water.

##### A.1.4 50 mM CaCl<sub>2</sub> and 10 mM Tris-HCl, pH 8.0 solution

200 µl of 1 M CaCl<sub>2</sub> and 40 µl of 1M of Tris-HCl, pH 8.0 were aliquoted. The volume was adjusted to 4 ml of autoclaved sterile water.

##### A.1.5 SOB solution

2 g of Bacto-tryptone, 0.5 g of yeast extract and 0.005 g of NaCl were weighed and the volume was adjusted to 100 ml with sterile deionized water. The solution was sterilized by autoclaving. The solution was stored at 4 °C until used.

##### A.1.6 1 M glucose

1.8 g of glucose was weighed and dissolved in 10 ml of autoclaved sterile water. The solution was filtered by 0.2 µm Nalgene filter.

##### A.1.7 1M MgSO<sub>4</sub>

24.65 g of  $\text{MgSO}_4$  was weighed and dissolved in sterile deionized water and the volume was adjusted to 100 ml. The solution was filtered by 0.2  $\mu\text{M}$  Nalgene filter.

#### A.1.8 SOC solution

200  $\mu\text{l}$  of 1 M  $\text{MgSO}_4$  and 200  $\mu\text{l}$  of 1M glucose were aliquoted into 10 ml of SOB. The solution was mixed and stored at 4  $^{\circ}\text{C}$  until used.

#### A.1.9 Buffer A solution

1 ml of 1M Tris-HCl (pH8), 2 ml of 1 M glucose and 80  $\mu\text{l}$  of 0.5 M EDTA were aliquoted and diluted in sterile deionized water. The volume was adjusted to 40 ml of autoclaved sterile water.

#### A.1.10 Prelysis buffer

0.004 g of lysozyme was weighed and dissolved in 10 ml of buffer A.

#### A.1.11 1 M KCl

7.455 g of KCl was weighed and dissolved in sterile deionized water and the volume was adjusted to 100 ml. The solution was sterilized by autoclaving.

#### A.1.12 100 mM PMSF

0.0174 g of PMSF was weighed and dissolved in 1ml of absolute ethanol. The solution was stored at  $-20^{\circ}\text{C}$  until use.

#### A.1.13 Lysis buffer

100  $\mu\text{l}$  of 1 M Tris-HCl (pH 8.0), 500  $\mu\text{l}$  of 1 M KCl, 20  $\mu\text{l}$  of 0.5 M EDTA, 100  $\mu\text{l}$  of 10 mM PMSF, 50  $\mu\text{l}$  of autoclaved Tween 20 and 50  $\mu\text{l}$  of IGEPAL were aliquot and diluted in sterile deionized water. The volume was adjusted to 40ml of autoclaved sterile water.

#### A.1.14 1 M DTT

0.1543 g of DTT was weighed and dissolved in 1ml of autoclaved sterile water.

## A.2 Preparation of fresh competent *E.coli* cells

The following procedure was modified from that of Sambrook *et al.* Frozen stock of *E. coli* cells (DH5 $\alpha$ ) were inoculated in LB broth and then incubated overnight at 37 °C with shaking. The 500  $\mu$ l fresh overnight inoculum was subcultured into a further 50 ml LB broth and incubated with shaking for approximate 2.50-3 hrs at 37 °C until the cells reached logarithmic phase, optimal density at 550 nm was 0.5. Three milliliters of inoculum was aliquot into Focal tubes, chill on ice for 10 min and centrifuge at 2,000 rpm for 5 min at 4 °C in a pre cooled rotor. The *E.coli* cell pellet was resuspended in 1.5 ml ice-cold sterilized solution of 50 mM CaCl<sub>2</sub> and 10 mM Tris-HCl (pH 8.0) and stand on ice bath for 15 min. This suspension was centrifuged for 5 min at 2,000 rpm in a pre cooled rotor. The *E.coli* cell pellets were then resuspended in 200  $\mu$ l of ice-cold sterilized solution of 50 mM CaCl<sub>2</sub> and 10 mM Tris-HCl (pH 8.0), then the cells were transferred to 1.5 ml eppendorf tube.

## A.3 Transformation of competent *E.coli* cells

The recombinant molecules of pTaq plasmid (2  $\mu$ l) were mixed with 200  $\mu$ l of competent *E.coli* cells. The mixture was incubated on ice bath for 30 min, then heated at 42 °C for exactly 2 min and let stand on ice again for 1 min. One milliliter of SOC/LB medium (with 100 mg /ml Ampicilin) was added to the mixture and incubate for 1 hr at 37 °C. After incubation, the cells suspension was centrifuge at 5,000 rpm for 1 min. The supernatant was discard about 900  $\mu$ l and then vortex and gently resuspended with pipette tips to disperse cells. The cells then were spreaded on LB agar plate with ampicillin (100 mg/l) and incubated at 37 °C overnight.

## 3.3 Gene Expression

A single colony (or 3-5 colonies) is used to innoculate 2 ml LB broth, with ampicillin (100 mg/l) and then incubated overnight at 37 °C with shaking. The 100  $\mu$ l fresh overnight inoculum was subculture into a further 10 ml LB broth with ampicillin (100 mg/l) in a 125 or 250 ml flask. The incubation of the culture is made at 37 °C until the OD<sub>550</sub> is 0.2 (usually 2-3 hrs) with shaking. The culture is cooled in on ice bath to prevent overgrowth until use. 1.25 mg of IPTG was dissolve to 1 ml LB broth, and then take to 10ml of inoculum and incubate it at 37 °C for 12 hrs (should be

exactly). The inoculum was transferred to Folcol tube and chill on ice bath. This inoculum was centrifuged for 5 min at 2,000 rpm, 4 °C in a pre-cooled rotor. The *E.coli* cells pellet were resuspended and vortex gently in 5 ml buffer A. The cell suspension were centrifuged for 5 min at 2,000 rpm, 4 °C. The supernatant were discard and the pellet cells were resuspended in 0.5 ml of prelysis buffer (0.5ml buffer A + 2 mg lysozyme). The cell suspension was mixed gently and place at room temperature for 15 min. 5ml of lysis buffer were added and mixed gently. The mixture were transferred into glass tube and incubated at 75 °C for 1 hr. The mixture was transferred into 1.5 ml eppendorf tubes and place on ice bath for 5 min then centrifuge at 1,200 rpm at 4 °C for 10 min. The supernatant were transferred into new 1.5 ml eppendorf tubes. 100 µl of 10 mM DTT was added in a 1 ml of the lysate. The Taq DNA polymerase was assay activity by PCR.

## B. LDLR database

[Accession Number: AY 324609]

[Available from: <http://droog.gs.washington.edu/parc/data/ldlr/ldlr.ColorFasta.html> ]

```

GCTTTAAGTT  GAATCTTTAA  ACTTATCTTT  ATTTTTGAGA  CACAGTCTCA  50 | REPEAT
CTCTGTGCCT  CAGGCTGGAG  TGCAGTGGTA  CAACCACAGC  TCAGTGCAGC  100
GTTGACCTCC  TGGGCTCAA  CCATCCTCCC  GCCTCAGCCT  CCCCAGTAGC  150
TGGGACTACA  GCGCACACA  ACCATGTCCA  GCTTATTTT  GTATTTTTTG  200 | var (163) : [T:0.01] | var (172) : [A:0.01]
TAGAGACAGG  GTCCCACTGT  GTTGCCTGG  CTTGTTCTGA  ACTCCTAGGC  250
TCAAGTGATC  CCCCCGCTC  ACCCTCCCAA  AGTGCTGGGA  TTACAGGCAT  300
GAGCCACCC  ATCCAGACTT  CACTTTTTTG  TTTAATGTCG  CAAATGGCAT  350
AAGGAATGGG  ATTCAATGGG  GACACATTTA  TAAACGTTGC  AGCAGCTCCT  400 | var (385) : [T:0.18]
AGAACTTGCC  TATCCTGTGA  AACTTCTCTA  GGTGATTGCT  AATTACTTCT  450 | REPEAT
TTTTTTTTTT  TTTTTTTGA  GACGGAGTCT  CACTCTGTGC  CCCAGGCTGG  500
AGTACAGTGG  CGCAATCTCG  TCTCACTGCA  AACTCCACCT  CCCCAGTTCA  550
CGCCATCTCT  CTGCCCTCAG  CTCCCGAGTA  GCTGGGACTA  CAGGCACCCG  600
CCACCACGGC  CGGCTAATTT  TTTGTATTTT  TTTTGTAGTA  AGGTGGGGTT  650
TCACTGTGTT  ATCCAGGATG  GTCCTGATCT  CCTGACCTCG  TGATCCACCT  700 | var (689) : [T:0.01] | var (700) : [C:0.20]
GCCTCAGCCT  CCCAAAGTGC  TGGGATTACA  GCGGTGAGCC  ACCATGCCCA  750
GCCCGCTAAT  TATTTCAATT  TGACCTTGAC  ACTGAGCCTG  CCAAGTAGGT  800
TCAAGCATTT  TGATGGCCCC  TTTACAGGTT  GGGAAAGCTA  ATTTATCTGT  850
CCAAAGCCGA  ATTCTGAAAC  TGAGTCTTAA  CTGCCAAAAA  TTCTTATCAT  900 | var (881) : [A:0.07]
CAATTTCTTC  TTCTGGGTTG  GGCACAGTGG  CTCATGCCTG  TAAAGCCAGC  950 | REPEAT
AATTTGAGAG  GCATCATGAT  GCAAGAGGAA  GAGGATTGAG  TGAAGCTAGG  1000 | var (953) : [G:0.02] | var (978) : [A:0.07]
AGTTTGGGAC  CAGCCTGGGC  AACATAGTGA  GACCCCATCT  ATAAAAAATA  1050
ATTAATAATT  AGTTGGGCAT  GGTGGTGCAC  TCCTGTGGTC  CTAGCTATTC  1100
AGGAGGCTGA  GGTGGGAGGA  TTCTTGAGC  CCAGGGTTGA  CGCTGCAGAG  1150 | var (1141) : [T:0.01]
AGCTGTGATC  ACGCCACTGC  AGTCCAGCCT  GAGTGACAGC  TGGAAATAAT  1200
GATAAATAAA  TAATAATAAA  TTATTAATAA  AATTATAATA  AAAATAATTA  1250
AAAAATTAAT  TTCCCTGATT  AATCTTTTTT  TTTGTCTTTC  TGAGAGTTCA  1300
ATTTGTCCCT  TTTCTGCCCT  GTCTCCTAGG  TTTCCCTAAA  ATCCTGTCTGA  1350
GAGGTTAGCA  CTGCCCTGCC  AAGTCAGTTT  GCAAAATCCC  AGAGAAATCC  1400
AGCTTATTCC  TGGGGGAACC  GCCAAGACTG  CCCAGCCTG  TGTGGGGTTC  1450

AGGCAAGTTT  CTCACATGTG  CCTTTTTGGC  AAGAGGCCCT  TGGCAACCCC  1500 | var (1497) : [T:0.01]
ATGAGTCCCC  AAAGAGACTC  AATCTAATAA  GTTGTCTCTC  ACCAGCTCTC  1550
TGTGGCTTAG  GGGTTCAAGT  TCAACTGTGA  AAGCCCTGTT  TTGTTTTGAT  1600
TTTGTCTTGA  GGGAGAGGAA  ACCGCCCTTC  TGTTTTGTCA  ACTCCTTCTC  1650
CTAAGGGGAG  AAATCAATAT  TTACGTCCAG  ACTCCAGGTA  TCCGTACAAT  1700 | var (1694) : [A:0.01]
TGATTTTTCA  GATGTTTATA  CTCAGCCAAA  GCGGGGATCC  CACAAAAAAA  1750 | var (1733) : [T:0.01]
AAAATATTTT  TTTGGCTGTA  CTTTTGTGAA  GATTTTATTT  AAATCCCTGA  1800
TTGATCAGTG  TCTATTAGGT  GATTTGGAAT  AACAAATGTA  AAACAATATA  1850
CAACGAAAGG  AAGCTAAAAA  TCTATACACA  ATTCTAGAAA  AGGAAAAGGC  1900
AAATATAGAA  AGTGGCGGAA  GTTCCCAACA  TTTTATGTTT  TTTCTTTTTG  1950
AGGCAGAGAG  GACAATGGCA  TTAGGCTATT  GGAGGATCTT  GAAAGGCTGT  2000
TGTATTCTCT  CTGTGGACAA  CAACAGCAA  ATGTTAACAG  TTAACATCG  2050
AGAAATTTCA  GGAGGATCTT  TCAGAAGATG  CGTTTCCAA  TTTGAGGGGG  2100
CGTCAGCTCT  TCACCGGAGA  CCCAAATACA  ACAAATCAAG  TCGCTGCCC  2150
TGGCGACACT  TTCGAAGGAC  TGGAGTGGGA  ATCAGAGCTT  CACGGGTTAA  2200 | var (2155) : [T:0.01]
AAAGCCGATG  TCACATCGGC  CGTTCGAAAC  TCCTCCTCTT  GCAGTGAGGT  2250 | var (2206) : [T:0.01]
GAAGACATTT  GAAAAATCAC  CCACTGCAAA  CTCCCTCCCC  TGCTAGAAAC  2300
CTCACATTGA  AATGCTGTA  ATGACGTGGG  CCCCAGTGC  AATCGCGGGA  2350 | Exon 1 | UTR
AGCCAGGGTT  TCCAGCTAGG  ACACAGCAGG  TCGTGATCCG  GGTCCGGACA  2400
CTGCCTGGCA  GAGGCTGGCA  GCATGGGGCC  CTGGGGCTGG  AAATTGCCGT  2450
      M G P W G W K L R 9
GGACCGTCCG  CTTGCTCCTC  GCCCGGGCGG  GGACTGCAGG  TAAGGCTTGC  2500
W T V A L L L A A A G T A 22
TCCAGGCGCC  AGAATAGVTT  GAGAGGGAGC  CCCCAGGGGG  CCCTTGGGAA  2550 | var (2507) : [A:0.01]
TTTATTTTTT  TGGGTACAAA  TAATCACTCC  ATCCCTGGGA  GACTTGTGGG  2600
GTAATGGCAC  GGGTCCCTTC  CCAAACGGCT  GGAGGGGGCG  CTGGAGGGGG  2650
CGCTGAGGG  GAGCGCGAGG  GTCCGGAGGA  GTCTGAGGGA  TTTAAGGAA  2700 | var (2673) : [G:0.01]
ACGGGGCACC  GCTGTCCCCC  AAGTCTCCAC  AGGGTGAGGG  ACCGCATCTT  2750 | REPEAT
CTTTGAGAGC  GAGTCTAGCT  CTGTGCCCCA  GGATGGAGTG  CAGTGGCACG  2800 | var (2777) : [T:0.01]
ATCTCAGCTC  ACTGCAACCT  CCGCCTCCCG  GGTTTAAGCG  AGTCTCCTCT  2850
CTCAGCCTCC  CGAATAGCTG  GGATTACAGG  CGCCCAACCA  CCACGCCCCG  2900
CTAATTTTTG  TATTTTTAGT  AGAGACGGGT  TTTCAACCATT  TTGGCCAGGC  2950
TGGTCTCGAA  CCCCAGCCTC  AGGTGATCTG  CCAAAAAGTG  CTGGGATTAC  3000 | var (2951) : [C:0.01]
AGCGCTCAG  CACCCGGCCC  GGCCGGGACC  CTCTCTCTTA  ACTCGGAGCT  3050 | var (3004) : [T:0.06]
GGGTGTGGGG  ACCTCCAGTC  CTAACAACAAG  GGATCACTCC  CACCCCGGCC  3100

```

TTAAGTCCTT CTGGGGCGA GGGCGACTGG AGACCCGGAT GTCCAGCCTG 3150  
 GAGGTCACCG CGGGCTCAGG GGTCCCAGTC CGCTTTGCGC GACCCACAGG 3200  
 CGCCACTGCC ATCCTGAGTT GGGTGCAGTC CCGGGATTCC GCCCGGTGCT 3250  
 CCGGGACGGG GGGCACCACC TCCCGCCCTT GCCCCGCCCT CTTTGGCCCG 3300  
 CCCCCGAAT TCCATTGGGT GTAGTCCGAA CAGGCCACCC TCGAGCCACT 3350  
 CCCTTTGTCC AATGTGAGGC GGTGGAGGCG GAGGCGGGCG TCGGAGGAC 3400  
 GGGGCTTGTG TACGAGCGGG GCGGGGCTGG CGCGGAAGTC TGAGCCTCAC 3450  
 CTTGTCCGGG GCGAGGCGGA TGCAGGGGAG GCCTGGCGTT CCTCCGCGGT 3500 | NOT SCANNED  
 TCCTGTACA AAGGCGACA CAAGTCCCGG GTCGCCGGAG CCGCCTCCGC 3550  
 GACATACACG AGTCGCCCTC CGTTATCCTG GGCCTCCCTG GCGAAGTCCC 3600  
 CGGTTTCCCG TGTGCTCTGT GCGGACACCT CCGTCCCAC CTTGTCTTGG 3650  
 GGGGCGCCCT CGCCCCACCA GCCCCGATCA AGTTACACAGA GGGCCCCCGG 3700  
 CCACCCTCAA GGCCTCGGTT CTTACGAGG TTGAAACGTT GCCTCAGAAT 3750  
 CTCCCGCCCT CTTCTTGGTC TGCAGCCGAG ATCTTCAGCC ACGGTGGGGC 3800  
 AGCTATCCCT CGGGACCGAC CCCCTGGGTT GGCCTCGCTT GTTACAGGGC 3850  
 TGTGAATGGC TTCGGTTCAG CTGTCCAAGC GGCATTTTT CCTCTGGGTG 3900  
 AAATGGATTA GATTTTAGAT TTCCACAAGA GGCTGGTTAG TGCATGATCC 3950  
 TGAGTTAGAG CTTTTTAGGT GGCTTTTAAAT TAGTTGCAGA GAGACAGCCT 4000  
 CGCCCTAGAC AACAGCTACA TGGCCCTTTC CCTCCTGAGA ACCAGCCTAG 4050  
 CCTAGAAAAG GATTGGGATT GCCTGATGAA CACAAGGATT GCAGGAAACT 4100  
 TTTTTTTTTA TTGGCAAGGG GGTGGCTTTT GACTGGATGG AGAGCTTTGA 4150  
 ACTGCCTTGA AATTCACGCT GTAACATAA CACCAGTTTC CTCTGGGAGG 4200  
 CCAGAGAGGG AGGGAGGGTG TAATGAAATA CGGATGATTG TTCTTTTATT 4250  
 TTTATTTACT TATTTATTTT TAACTTTTT GTAGAGATGA GGTCTCGCTT 4300 | REPEAT  
 GGTGCTCAG TCTGGTCTG AACCTCTGGC CTCAGCGGAT CCTCTACCT 4350  
 CAGCCTCCCA AAGTGTGGG ATTACAGGAG TGAGCCACCG CGCCCCACCG 4400  
 GGGATGATGA TGATTGCAAA CATTCTGCCA CTCAGTTTA CAAAAGAAAG 4450  
 AGAGGCACTG GATTAATGTG TATCTCACTC ACCAATCAAC CTCCTCCCTA 4500  
 AGAGAAAATG TTAAGGAAGT CTTAGGCAAG GCCTTGTGTT TCACTCACTT 4550 | var (4504) : [T:0.13]  
 TAGTTTCTCT CTCGCCGGAT GGCCTGAGAA GTGATGTTT CTCCTGTTGC 4600  
 AAGGAGACTA CACCCCTGAT GTTTTCCTCC AGACTTCTGA GAGCTGGTGT 4650  
 GTGTTTCTAG CACTTTCTAG CTCGCCACCT TCACGCTGTA GCTGGCTTCA 4700 | var (4658) : [A:0.01]  
 AGGCATATCC AGGGGGGAGT TTCTGTCCA TTTCTTTTAC AAAGGGAAGT 4750 | var (4714) : [C:0.02]  
 TGTTTGAAAT TGTAACGCAA GCCTTCACTT AGACCAAAAT CAGGCAACAG 4800 | var (4767) : [A:0.02]  
 CGGTGAGCCG AGCTCCAAAC GTGTCAATGA CTCACCCAAA TTTGAGTBAAG 4850  
 GGAGTTGGCT GCTTTAACGA GCCCGAGGGT GATTCCTTGG TCATTTCGGG 4900

AAATACCTAT CTTCCAGGGA AACTGCGGAA AAAACAGGGA GACCTTTGTT 4950  
 GAGACAGAAA ACCGTGATGGG GAATFCTGTT CCTCATTCCT GCTCTTATCT 5000  
 GTAGACTTCC TCCCTGATAA GATCCAATTC TAGATGGGTC GGTTCCTCCT 5050  
 TGCCTTGTAT GGTGCTTTGA TGGGCTTTAT TATTATTATT ATTATTATTA 5100  
 TTATTATTTT GATGGGCTTT TTGATGTCCC TTTTCTTCC AACTCTGTTC 5150  
 CCAACTGTC AAGCAATAGC CTTTTGTTGC TAAGAGACTG CAGATGTAAC 5200  
 CGACCAGCAG CAAACAGTGA GTCAGGCTCT CTCTTCGGGA AGCAAAATCA 5250 | var (5237) : [T:0.01]  
 ATTGCTGAGA TCACCTGGG GAAAATAACC ACCTTATTG GAAAGAAAGCA 5300  
 CTGATCAATT GATGCTATT TTTTTTTTTT TTGAGTTGGA GTCTCGCCCT 5350 | REPEAT  
 GTCACCCAGG CTCGAGTGA ATGGCATAAT CTCGCCTCAC TGCAATCCCC 5400  
 GCCTCCGGG TTCCAGCAAT TCTCCTGCCT CAGCCTCCTG AGTAGCTGGA 5450  
 ATTATAGGCG CCTGCCCAA CACCCGGCTA ATTTTGTAT TTGTAGTAGA 5500  
 GATGGGGTTT CACCAGTTG GCCAGGCTGG TCTCGAATC CTGACCTCGT 5550  
 GATCCACCCG CCTCAGCCTC CAAAAGTCCA AGGATTGCAG GCGTGACCCA 5600  
 CTGTGCCAGC CAATCAATTG ATTTCTCATT CATTTTCAGC TGGCTCTGTT 5650 | var (5612) : [G:0.15]  
 CCCTTAAAGC AGGGGATTTT CGTTTGTGTT TTTCCCTTC AAGGAAATGA 5700  
 TTCTAGCTAC AGTTTTGATT TCCTGTACA ACTGTTTTCA GTAGCACAGG 5750  
 GAAAAGAAA AATCGAAAAGCA TTCACCACCT CATTGTGTG CTGGGGGAAA 5800  
 AAGCAGAAA ATGTATTCTC TTTTTTTGTT TCGATGACCT TGTTCCTGAC 5850  
 TTGTTACTCG TGACTTGA GATCAGAGGG CTAGAGGACT AGAATTTATA 5900  
 GAGGTGTTTT TTTTGTGTTG TTATTTTTGT TCGAGTTGCC CAGGCTGGAG 5950 | REPEAT  
 TGCAGTGGCG CAATCTCGGC TCACTGCAAC CTCTGCCTCC CAGGTTCAAG 6000 | var (5959) : [T:0.03]  
 CGATTCTTCG GCCTCAGCCT CCTGAGTAGC TGGAACTACA GGCGCCCGCC 6050  
 ACCACACCCA GCTAATTTTT GTATTTTTCA GTAGAGATGG GATTTACCA 6100  
 TATTGGTCAA GCTGGCCTCG AACTCCTGAC CTCGTGATCC ACCCGCCTCA 6150  
 GTTCCCAA GTGCTGGGAG TACAGGCGTG AGCCGCCGTG CCGGCCCTTT 6200  
 TTGTTTTTTT GTGTTTTTGA GAGGAGCTCA TTGCTTTTTT GGCTTCCCTA 6250  
 GCGTGAGAAA ATCTGGGGAT CCATGCTCTA GTTACTTCC TTTTTTTTTT 6300 | var (6252) : [T:0.01] | REPEAT  
 TTTTTTTGAG ATGGAGTCTC GCTTAGATTG CCTAATCTCA GCTCATTGCA 6350  
 ACTTCTGCCT CCGGGTTTCA AGGGATTCTC GTGTCTCAGC CTCCTGGGTA 6400  
 GCTAGGATAC GGGCACCCGC TACCATGCCT GGCTAATTTT GACTTTTTAG 6450 | var (6411) : [A:0.01]  
 TAGAGACAGG GTTTCGCCAC GTTGGCCAGG CTGGTCTCGA ACTCCTGACC 6500  
 TCAGGTGAGC CGCCTGCCTT GGCCTCCCAA AGTGTGAGA TTACAGGCGT 6550 | var (6548) : [T:0.06]  
 GAGCCACCCG GCTTGGCCTA ATTTGCTTTT CCTGAAAATC AAATGGTCTA 6600  
 ATATGAAAAA CGCCAACCTT GCTTGAAGA ATAAGAAAAG GGTGCGGTTT 6650

```

CGTTGGGCCG TTGATGTTTG GAACAGGACT GGTTTTGTCC CTTGCTCGG 6700
AAAGGGCAGC AACTGTGAGG ACAGCTCCCT GACGTGCTCT CACTCAGCAC 6750
TGTTCCCGTT CTGAGCACTG TCCCCTACTG CTAGGCCAAG GGAGCTCATT 6800
TGGCAGGCAA CTGCTGTCTG GCTGCGCCTG TGGCAGTAAA ATCTGCCGTT 6850 | var (6825) : [T:0.04] | REPEAT
ATTTTTTGGG GGCAGGGTCT TGCCCTGTGG CTCAGGCTGA AGTGTGCAAT 6900
TATAGCTCAC TGCAGCCTCC AGCTTCTGTA CTCAACTGAT CCTCCTCTCT 6950
CAGCCCTCTG AGTAGCTGGG ACTATAGCCA CGTGTACCA CTCCCACCTC 7000
AGTTTGTGTT TTTATTTATT TATTTATTTA TTTATTGAGA TGGAGTTTTG 7050 | REPEAT | var (7014) : [G:0.01]
CTCTTGCTGC CCAGGCTGGA GTGCAATGGC GCGATCTCGG CTCACCCGAA 7100
CCTCCACCTC CTGGTTCAAAG CGATTCTCCT GCCTCAGCCT CCTGAGTAGC 7150
TGGGATTACA GGCATGCACC ACCACGCCCG GCTAATTTTG TATTTTTCGT 7200 | var (7180) : [A:0.07] | var (7198) : [A:0.01]
AGAGATGGGG TTTCTCCACA TTGGTTCCAG CTGTTCTCGA ACTCCCAACC 7250
TCAGGTGATC CACCCGCCCT AGCCTCCCAA AGTGCTGGGA TTATAGGCGT 7300
GAGCCCCGGA ACCCGGCCAC TCCCAGCTAA GTTTAAATTT TTTGTTTGT 7350 | REPEAT
TGTTGCTTTG TTTTTATTTT TTGAGACAGA GTCTCCCGCC CAGGCTGGAG 7400 | var (7359) : [C:0.01] | var (7378) : [G:0.01]
CGCAGATCAC TGCATCCCTG ACCTCCGAGG CTTAAGCCAT CCTCCCACT 7450
CAGCCCTCCA AGTAGCTGGG ATTACAGGTG TGTGCCACTA TGCTTGCGTA 7500
AGTTGTGTAT TTTTGTAGA GATGGGGTTC AAGGGATTCT CGCTTTGTTG 7550
CCTCGGTTGG TCTCAAACCT CTGGGCTCAA GCAGTCTCC CTCCTCAGCC 7600 | var (7555) : [A:0.01]
TCCCAAGGTG CTGGGGAAT CCACCTTTGA AACATTGTCT GGAGAGTTGC 7650
CCAGGTGGGA GATCACAGAA ATAGGTCATC GTGGGGTCC TCCCATGGGT 7700
GCAGCTTGA GCCACCTGTG GCCAGCAAT ATTTGGAGAA TAATAGTCAG 7750
GGGAGAGCTT GAGGTCCAGG GAAAGTTTT GTTTTTCTTC AGGGAAAGGT 7800
TTTTATTGTT CTTTATCCCT CTTTAAAGGA CCTTCAGGTG TTACTGCAT 7850
TCCCGGTCTA CCCAGTGGCA CATTTAGTTT GTAAGCTGGG CCCTCGTACA 7900
GAGGTAGGGA GGTGAGACCA TTGGATTAGT GGTACCCAAA CCTCCGCTCA 7950
CCTAGTGGGG TGATCAGAGG CTCCTCCCTT AAGATCTTGA TTGCCAACCC 8000
CTCTGGCCCA ACTTTCCCTT TTATTTATCG CAAGCCCTCT GGAATCTCAA 8050
TTGCTTTTTG CCCACCCGGT GTGTCAGCAC AAGAAATGAG TCATTTCCTC 8100
CTTTAAGCAC AGTTGAAATT GAGCTGTGAG TCAGTGAGGT GTGTACGATA 8150
TTGTCAAAGC GGGGTGTGTA CAGTATTGAC AGATCTETAG TTGGGCAAGA 8200 | var (8173) : [A:0.45]
GAATTATCAG AGTTTGTGAC CACAGCAGAT TCCAAAGCTC GACTCATTTT 8250 | var (8238) : [T:0.02]
CTTCTCTCTT CCTTCCCTTT TTCTTTTTCT TTTTTTTTTT TTTTTTGACA 8300 | REPEAT
GAGTCTCGCT CTGTTGCCCA GGCTGGAAGT CAGTGGCACA ATCTGGGCTC 8350

ACTGCAGCCC CTGCCTCCTG GGTTCAAATG ATTCTCATGT TTCAGCCTCC 8400
CGAGTAGCTG CAATTACAGG CATTCCGGTT CAAGTGATT TCCTGCCTCA 8450 | REPEAT
GCCACCTGAG CAGCTGGGAT TACAGGGGCC CGCCACCACG CCCGGCTAAT 8500
TTTTGTATTT TTAGTAGAGA CGGGGTTTCA CCATGTTGGC CAGGCTGGTC 8550 | var (8522) : [A:0.01]
TCGAACTCCT GAACCTCAGG GATCCGCCCA CTTCCGGCCTC CCAAAGTGTCT 8600
GAGATTACAG ACGTGAGTCA CCGCGCCAGG CCTGTTCTGT TCTTTAATTC 8650 | var (8622) : [T:0.01] | REPEAT
TCAAAAACCC CTCTAGGAAG TAGAGACTGC CATTCTCCCC CATTTTACAG 8700
ATCAGGAAAC TGAGTCCAGG AAGGATTTAG TCAGTTACCC AAGTTGTCTT 8750 | var (8728) : [C:0.01]
AGTTAAATGG CCTGAAAGCC CAATGAAGCC CAGGATTGTC TATCTAACCC 8800 | var (8773) : [G:0.27]
CCTTACTACT CTAACCTTCA GGGAAATCCA ATGAATGTGC TGGGTCAAAC 8850
ATCAAAGTTG AAATGGATAA AGGGGGCTGG ATGGCGTGGC TGATGCCTGT 8900 | REPEAT
AATCCTAGCA CTTTGGGAGG CCGAGATGGG TGGGTGGATT GCTTGAGCCC 8950 | var (8927) : [C:0.10]
AAGAGTTTGA GACCAGCCTG GGC AACATAG TGAGACACCT GTCTCTGCAA 9000
AAAAATAATA AAAAGTTAGC TGAGTGTGAT GGTGCACCCC TCTAGTCACA 9050
GCTGTTGAGT TAGGCTTAGG CAGGAGGATC GCATGAACCT GGGAGGTGGA 9100 | var (9059) : [A:0.01]
GGCGGCCGTG AGCCTCAGTC ATGCCACTGC ACTCCAACCT GGGCAACAGA 9150
GTGAAAGCCG GTGTCCGAAA GAGAAAGAAA AAAAGACATA GATACATCTT 9200 | var (9167) : [A:0.10]
TTAAAGTTAG GTTGTATGTT AATTACCTAC AACTCAGTTT CAACTGTGCT 9250
TAAAGGAGGA AATGACTCAT TTCTTGCTAC ATATCAAATT AGCCCAAAAT 9300 | REPEAT
GTAGTGGCTT AAAACAACAC ATTTATGATT TCTCAGTTTT TGGGTGTCAG 9350
GAATTTGGAA GCAGCACAGC TAGACGGTTC CAGCTCAGGG TCTCTCATGA 9400
AGTTGCAATC AAAATATTGG CAGGAGAGAA AAACATATT TCAGAAGCTG 9450 | NOT SCANNED
CAGGCATAGG AAGACTTGGC TGGGGTTGAA GGATCCACTT CCAAGATGGC 9500
GCACCTCAGT GCTCTTGGCT GGAGGCCCTCA GTTCCCTGCT GCGTGGAGCT 9550
CTCCCTCCAG CTGCTTAGT GGACTCATGA CATGCAGCTG GCCTCCCTG 9600
GAGCAGTCGA TCCAAACAAT AGCATGGCCA TGAAC TAGGC TCAGAAGCCA 9650
CTCCCTGTGC TCTCTACATT TTCTATCAG AAGCAAAGTCA TTA AAAAGTCC 9700
AGTGCCACTC CAGGGGAGAC GAATTAGGCT CTGCCTTCTG AAAGGATTAT 9750
CACAGAAGAT GCGGTCCCTT ATTCTTTTTT TAAAATTATT CTTTTTTTTT 9800 | REPEAT
TTTTGTAGAG ATGGGGTCTT GGTATGTTGC CTAGGCCAGT CTGGAATTCC 9850
TGGGCTCAAA CAATCCTGTC TCTGCCTCCC AAAGTGTGG GATTACAGGC 9900
ATGAGCCACT GCACCTGGTC ATGTGGTCA ATTTCTTTTT TCTTTTTTTTT 9950 | REPEAT
TTTTTTTTGA GACAGAGTCT CTGTCCGCCA GGCTGGAGTA TGGTGGCGTG 10000
ATCTCAGTTC ACTGCAGCCT CCGCCTCCCG GGTTC AAGCG ATTCTCCTGC 10050
CTCAGCCTCC TGAGTAGCTG GGATTACAGG CGCCCGCAA CATGCCAGC 10100
TAATTTTTTT AGTAGAGATG GGGTTTACC ATGTTAGCCA GGATGGTCTC 10150

```

```

GATCTCCTGA TTTGGTGATC CGCCACCTT GGCCTCCAA AGTTTCAACC 10200
ATCGATCAGA ACTTATTGAT GTACTTATGT AGCTAGGCAC GGTGGCGCGT 10250 | REPEAT
GCCTGTAATC CCAGCTACTT GGAAGGGTTA AGGCAGGAGA ATCGCTTGAA 10300
CCTGGGAGGC AGAGGTTACA GTGAGTCAAG ATCATACCAT TGCCTCCAG 10350
TCTGGGCAAC AGAATGAGAC TCTGTCTCAA AAACAAAAAA CAAACCCTTG 10400
TATGTGATTT TCCTGGATAG CATCTGTTAC ATCTTCACAA AGATAAAAAAG 10450
TCAGACTTGG CTGGGCATGG TGGCTCACAC CTGTAATCCC AGCACTGAGA 10500 | REPEAT
GGCTGAGGCA GGCAGATCAC TTAGAGTCAG GAATTTGAGA CCAGGCTGGG 10550
CAGCATGGT AAACCCCGTC TCTACAAAA ATACAAAAAT TAGCCGGGTG 10600 | var (10595) : [T:0.02]
TGGTGTCAAG CACCTGTATT CCCAAGCTAC TCAGGAAGCT AAGGCAGGAG 10650
AATCACTTGA ACCCAGAGGT GGAGGTTTGC AGTGAGTTGA GATTGTGCCA 10700
TTGCCTCCA GCCTGGGCGA CAGAGTGAGA CTCTGTGTCA AAAATAAAAT 10750
AAAAATAAAT TTTAAAAAAG GCAGATTTTT TTTTCTTCTT GGTATTGTTA 10800
CCTTATTATA GTAATAATAA GTGCATAGTG CATGCTGAGA TAAGCAATCA 10850
TAATTTGTTA TTGCGGCCGG GCATGGTGGC TCCAGCCTAT AATCCCAGCA 10900 | REPEAT
CTTTGGTCAG GAGTTCAAGG CCAGCCTGGC CAATATAGTG AAATCCATCT 10950
CTACTAAAA ACAGAAATT ACCTGGGCAT GGTGGCAGTT GCTGGTGATC 11000
CCCAGCTACT TGGGAGGCTG AGGCAGGAGA ATCGCTTGAA CCTGGGAAGC 11050
AGAGGTTGCA GTGAGCCAAG ATTGCACCAC TGCCTCCAG CCTGGGTGAC 11100
AGAGTGAGAC TCTGTCTGAA AATAATAATA ATAATAATTT GTTATTGCTT 11150
TTATTGCCTT AGTTTACATA GGAATCAAAA GTTTATACTT TGATTTATAA 11200
AAGTTGCTTT GATTCTAGTT CACAGAACCA GAATCTTTCA TATAAAGGTA 11250 | NOT SCANNED
TTAGAGGGCC CAGTGTGGTG GCTCATGCCT GTAATCCCAG CATATTGGGA 11300 | REPEAT
GGCTGAGGAG GGAGGATCAC TTTAGGAGTT TGAGGCCAGC CTAGGCAACA 11350
TAGTGAGACC TTGTCTCTAC AAAAAATTCC AACATTAGCT GGGCATGGTG 11400
GCATGTGCCT GTAGTCCCAT TTATTGGGG GGCTGAGGCA GGAGGATCAC 11450
TTGAGCCCAC GAGGTTCAAT CCAGGTTGCA GTAAGCCATG ATCCTGCCAC 11500
TGCCTCCAG TTTGGGTAAC AGAGCGAAGC TATGTCTCAA AAAAAGAAAA 11550
AAAAAGTATT CTAATCCAAA ATTTAATATA TAAAACATAA TGCAGGCCAA 11600 | REPEAT
GTGTGGTGGC ATATACCTAT AATCACAACA CTTTGGGAGG CTGAGGTGGG 11650
AGGATTGCTT GAGCCCAAGA GTTCAAGACC AGCCTAGGTA ACACAGTAAG 11700
ACCCCATCTC TACAAAAAGT AGAAAAATTA GCCTGGCATG GTGGTGAGTG 11750
CTTTAATCC CAACTACTTA GGGGCTGAG ATGGGAAGAT TGCTTGAGCC 11800 | var (11773) : [A:0.06]
TCAGAGTTTG AGGCTGCAGT GGGCCGTGAT CGCTCCACTG ATCGCTCTAA 11850

TAATTTGTTA TTGCGGCCGG GCATGGTGGC TCCAGCCTAT AATCCCAGCA 10900 | REPEAT
CTTTGGTCAG GAGTTCAAGG CCAGCCTGGC CAATATAGTG AAATCCATCT 10950
CTACTAAAA ACAGAAATT ACCTGGGCAT GGTGGCAGTT GCTGGTGATC 11000
CCCAGCTACT TGGGAGGCTG AGGCAGGAGA ATCGCTTGAA CCTGGGAAGC 11050
AGAGGTTGCA GTGAGCCAAG ATTGCACCAC TGCCTCCAG CCTGGGTGAC 11100
AGAGTGAGAC TCTGTCTGAA AATAATAATA ATAATAATTT GTTATTGCTT 11150
TTATTGCCTT AGTTTACATA GGAATCAAAA GTTTATACTT TGATTTATAA 11200
AAGTTGCTTT GATTCTAGTT CACAGAACCA GAATCTTTCA TATAAAGGTA 11250 | NOT SCANNED
TTAGAGGGCC CAGTGTGGTG GCTCATGCCT GTAATCCCAG CATATTGGGA 11300 | REPEAT
GGCTGAGGAG GGAGGATCAC TTTAGGAGTT TGAGGCCAGC CTAGGCAACA 11350
TAGTGAGACC TTGTCTCTAC AAAAAATTCC AACATTAGCT GGGCATGGTG 11400
GCATGTGCCT GTAGTCCCAT TTATTGGGG GGCTGAGGCA GGAGGATCAC 11450
TTGAGCCCAC GAGGTTCAAT CCAGGTTGCA GTAAGCCATG ATCCTGCCAC 11500
TGCCTCCAG TTTGGGTAAC AGAGCGAAGC TATGTCTCAA AAAAAGAAAA 11550
AAAAAGTATT CTAATCCAAA ATTTAATATA TAAAACATAA TGCAGGCCAA 11600 | REPEAT
GTGTGGTGGC ATATACCTAT AATCACAACA CTTTGGGAGG CTGAGGTGGG 11650
AGGATTGCTT GAGCCCAAGA GTTCAAGACC AGCCTAGGTA ACACAGTAAG 11700
ACCCCATCTC TACAAAAAGT AGAAAAATTA GCCTGGCATG GTGGTGAGTG 11750
CTTTAATCC CAACTACTTA GGGGCTGAG ATGGGAAGAT TGCTTGAGCC 11800 | var (11773) : [A:0.06]
TCAGAGTTTG AGGCTGCAGT GGGCCGTGAT CGCTCCACTG ATCGCTCTAA 11850
AGTGAGACCC TGCTCAAAA AAAAAGAAAA TAGAAGAAAA CTAATACAT 11900
TCAATAAGAC TTTGATCTCT TTTCCAAGGT GTAATATAT TTTGGGAAAT 11950
TTTCCAGTTA CTTTGTCTC ATTTAATGT AATAATCTAA GTCTTGGTTT 12000
TCTAAGGAAA AGTTTTCTCT TATTATATCT TTTGTTAATG TTTCTCTCCC 12050
ATTTCTTTTG ATCTGATCTT CAGATACATG ATTATCTTCA CTGCTAAATT 12100
TGTGTTCTCT GGCCCTACA TTTATAAATT CTCATAATTC TTTATCTAAG 12150
TATTTCTTCC CTACCTACTG AAGAAAACTC AAGTTTTCTT CCACCTAAT 12200
GATTATGCTG TGCTGTGAG TTTTCTCAT GACTCTTAC AGTACAAGTT 12250
TTTTGTTTTT GTTTTTTTAA TGGTCAGATG GATAGAACA CACAGTTTTT 12300
GTTTGTTTTT TTTTAACTTT TAAAAAATT ATAATAGATA AAGGGTCTCA 12350 | REPEAT
CTACGTTGTC CAGGCTGATC TCATACTCCT GGGCTCAAGC AATCCACCCA 12400 | var (12354) : [T:0.01]
CCTCTGCCTC CAAAAGTCTT GGGATTACAG TCATGAGCCA ACATGCCTGG 12450
CCAGTACAGG TTTTTTTTGA GACGAGTTT TGTTCTTGT CCGGAGGCTG 12500 | var (12451) : [C:0.10] | REPEAT
GAGTGCAATG CCACAATCTT GGCTCACCC AACGTCTGCC TCCAGGTTTC 12550 | var (12511) : [A:0.11]
AAGTGATTCT CCTGCCTCAG CCTCCTGAGT AGCTGGGATT ACAGGCATGT 12600 | var (12583) : [T:0.01]
GCCACCACGC CCAGCTAATT TTGTATTTTT AGTAGAGACG GGGTTTCACC 12650

```

ATGTTGGCCA GGCTGGTTTC GAACTGCTGA CCTCAGGTGA TCTGCCACC 12700  
 TGGGCTCCC AAGTGTGTGG GATTACAGGC ATGAGCCACC ATGCCCAGCT 12750  
 GTAGTACAGG TTTTAAATATG CTAATACTC TTCCTTCTT TATTAATGTG 12800  
 CATGGAAGTT CTAATATTTT TTTCCCATAC CCCAGAGAGT CCATATTTTG 12850  
 GAATCAACAA CACTAGCCTT TGTGACAAAG TGTCTCTCT GGGTFCCTC 12900  
 TTTGTGTCT CCACTGAATT TTGGGGTTCA TAAAATTTCA TTTGTGTGC 12950  
 TTGCTTAATT CCCTGGGAAT CAGACTGTTC CTGATCGGAT GACATTTCTG 13000  
 GTTAATTCTT TAGTGGCAG GAAATAGACA CAGGAAACGT GGTCAGTTTC 13050  
 TGATTCTGGC GTTGAGAGAC CCTTCTCTCT TTTCTCTCT CTCAGTGGGC 13100 | Exon 2  
 V G 24  
 GACAGATGCG AAAGAAACGA GTTCCAGTGC CAAGACGGGA AATGCATCTC 13150 | var (13109) : [T:0.09]  
 D R C E R N E F Q C Q D G K C I S 41  
 CTACAAGTGG GTCTGCGATG GCAGGCGTGA GTGCCAGGAT GGCTCTGATG 13200  
 Y K W V C D G S A E C Q D G S D 57  
 AGTCCCAGGA GACGTGCTGT GAGTCCCCTT TGGGCATGAT ATGCATTTAT 13250 | REPEAT  
 E S Q E T C 63  
 TTTTGTAAAT GAGACAGGGT CTCGCCATGT TGGCCAGGCT GGTCTTGAAT 13300 | var (13274) : [A:0.12]  
 TTCTGGTCTC AAGTATCCG CTGGCCTCGG CCTCCCAAAG TGCTGGGATT 13350  
 ACAGGCACCA CGCCTGGCCT GTGACACGAT TCTTAACCCC TTTTGTATGA 13400 | var (13362) : [A:0.01] | var (13377) : [T:0.01]  
 TGGCGGCTGG AAAAGTGGCC AGTGGATTTT GATGTATTCA ATCATGAATT 13450  
 AGGAGGTGGG GAGAGAATGA ATTATTGGAG CTTTCCCTAA AGCCATTAAT 13500  
 TGCTCTATT CTTTTTCAA TTGATGTGAA TTTACATAA CATGAAATTA 13550 | REPEAT  
 ACCAGCTCAG TGGCATTAA ACATCTGCAA TGCTGTGTGG CCACCACCTC 13600  
 TATCTGTGTC CAAAACCTTG CATAACCTAA TGCTTTTTT TTTTTTTTT 13650 | REPEAT  
 TTTGAGACGG AGTCTCGTTC CATCACCCAG GCTGGAGTGC AGTGGGTGTA 13700  
 TCTCAGTCA CTGCAACCTC GCCTCCCGAG GTTCACGCCA TCCTCTGCCC 13750  
 TCAGCCTCCC GAGTAGCTGG GACTACAGGC ACCCTCCACC ACATCCGGCT 13800  
 AATTTTTTGT ATCTTTAGTA GAGATGGGTT TCACCATGTT AGCCGGGATG 13850  
 GTCTCGATCT CCTGACCTCG TGATCCACCT GCCTCCGCTC CCCAAAGTGC 13900  
 TGGCATTACA GCGGTGAGCC ACCATGCCCG GCCTATTTTT TTTTTAAGA 13950 | REPEAT  
 GATGGAGTCT AATTTCTGTT CCCAGGCTGG AGTCCAGTGG TACCATCATA 14000  
 CTTCAGTCA GCCTTGACCT CTTGGGCTCA AGTGATTCTG TGCTCTGAAA 14050  
 CTCCAAAAGT ATTGGGATTA CAGGTGTGAG CCACCCCACT CAGCCTAATG 14100 | var (14085) : [T:0.03]  
 TCCAGTTTTT AACAAAGTCC ATTTAAATGC CCTCCGTTTT CACCCATAAA 14150  
 GGGGTAGGCT TGGCCGGGCA CAATGGCTTG TGCTCTGAGT CCCAGCTACT 14200 | REPEAT  
 TGGGAGGCTG AGGCAGAAA G CAGAAAAGT TGCTTTATAA AOCACAGGAG 14250  
 TTTGAGGGCC ACCTGGGTGG CATAGCTAGA CCTCATCTCT AAAAAATAAG 14300  
  
 TAATAAATAA ATATTTGTTT TTGTTTTTTT CTTTTTCTT TCTTTTTTTT 14350 | REPEAT  
 TTTTTTTTGA GACGGAGTCT TGCTCTGTTG CCCAGGCTGG AGTGCAGTGG 14400  
 CGCGATCTCA GCTCACTGCA AGCTGTGCCT CCTGGGTTCA TGCCATTCTC 14450  
 CTGCTCAGC CTCCGAGTA GCTGGGACTA CAGGCGCCCA CTACCAGGCC 14500  
 CAGCTAATTT TTTGTATTTT TAGTAGAGAT GGGGTTTTCAC CACGTTAGCC 14550  
 AGGATGGTCT CAATCTCCTG ACCTCGTGAT CCGCCAGCTT TGGCCTCCCA 14600  
 AAGTGTGGG ATTACAGGGC TGAGCCACTG AGCCCGCCCC ATATGTATGT 14650  
 ATATATATAT TTTTTTAAAA TGGGAGACCA GGCATGGTGG CTCATGCGCTA 14700 | REPEAT  
 GAATCCACAG ACTTTGGGAA GCTGAGGTAG CGCGATCACT TGAGGCCATG 14750  
 AGTTTGAGAC CAGCCTGCTC AACATGATGA AACTTCTATC TCTACTAAAA 14800  
 AAAAAAGTGG GATTAGTCA GGCACGGTGG CTCACACCTG TAATCCACGC 14850 | REPEAT  
 ACTTTCAGAG GCCGAGGCAG GAGGATCATG AGGTACAGGAG ATCGAGACCA 14900  
 TCCTGGCTAA CACGGTGAAT CCCCCTCTCT ACTAAAAAAA TACAAAAAAT 14950  
 TAGCCAGGCG TGGTGGCGGG TGCCGTGAGT CCCAGCTACT CAGGAGGCTG 15000  
 AGGCAGGAGA ATGGCGTGA CCGGGGAGGC GGAGCTTGCA GTGAGCCAAAG 15050 | NOT SCANNED  
 ATCGTGCCAC TGTACTCCAG CCTGGGCGAC AGAGCAAGAC TCTGTCTCAA 15100  
 AAAAAAATAA AAAAGTGGGA TTGACATTCT CTTCAAAGTT CTGGGGTTTT 15150  
 CTTTGCAAAG ACAGGATTGG CAAGGCCAGT GGGTCTTTTT TGTGTGTGTG 15200 | REPEAT  
 TGTGTGACGG AGTCTCACTC TGCCACCCAG GCTGGAGTGC AATGGCAGGA 15250 | var (15234) : [A:0.01]  
 TCTCGGCTCA CCGCAACCTC CTCCCTCCAG GTTAAAGTGA TTCTCCTGCC 15300  
 TCAGCCTCCC GAGTAGCTGG GACTACAGGT GCCCGCCACC ACACCCAACT 15350  
 AATTTTTTGA TTTTTAGTAG AGACAGGTT TCACTATATT GGCCAGGCTG 15400 | var (15368) : [C:0.01]  
 GTCTTGAACC CCTGACCTCA CGTGATCCAC CCGCCTTGGC CTCCCAAAGT 15450  
 GCTGGGATTA CAGCCGTGAG CCACTGTGCT CGGCCTCAGT GGGCTTTTCC 15500  
 TTTGAGTGC AGTTCAATCC TGTCTCTTCT GTAGTGTCTG TCACCTGCAA 15550 | Exon 3  
 L S V T C K 69  
 ATCCGGGAC TTCAGCTGTG GGGGCGGTGT CAACCGCTGC ATTCCTCAGT 15600  
 S G D F S C G G R V N R C I P Q 85  
 TCTGGAGGTG CGATGGCCAA GTGGACTGCG ACAACGGCTC AGACGAGCAA 15650  
 F W R C D G Q V D C D N G S D E Q 102  
 GGCTGTCGTA AGTGTGGCCC TGCCCTTGCT ATTGAGCCTA TCTGAGTCTT 15700  
 G C 104  
 GGGGAGTGGT CTGACTTTGT CTCTACGGGG TCCTGCTCGA GCTGCAAGGC 15750  
 AGCTGCCCGC AACTGGGCTC CATCTCTTGG GGGCTCATAC CAAGCCTCTT 15800  
 CCGCCCTTCA AATCCCCCTT TGACCAGGAG GCATTACAAA GTGGGGATGG 15850

```

TGCTACCTCT TCGGGTTTGT CACGCACAGT CAGGGAGGCT GTCCTGCGG 15900 | var (15864) : [A:0.02]
AGGGCTAGCC ACGTGGGACA CACACTGGCA AGCCGCTGTG ATTCGCGCTG 15950
GTCGTGATCC CCGTGATCCT GTGATCCCGG CCCCCTGAGG CTGAACACAT 16000 | var (15954) : [A:0.01]
AGTGACGCTT GCTAGCCAAG CCTCAATGAC CCACGTAACA TGAAGGGGGA 16050
AAAAGCCAGAA AGTTCTGCCA AGGAGCAAGG CCAAGAATCC CGAAGGGAAA 16100
TGGACTTTGA AGCTGGGCGT CTTCTTGCT GTCTTAATAC AAGTGGCACA 16150 | REPEAT
TCCAAATCCA AAACCCCGAA ATTCAAAGTC TTGAGCACCC GAAATTCTGA 16200
AACGTCTTGA GCACTGACCT TTAGAAGGAA ATGCTTATTG GAGCATTTTG 16250
GATTTCCGAT TTTTACCCT GAGTGTGGAG TCCTAATTAG GAAAAAACC 16300 | REPEAT
AGGCTGACCG AACCAAAAGGA AAGCAATAAA AGAAGGCAGA TAGGGTCAGG 16350 | REPEAT
CAGGGTGGCT CACCCCTGTA ATCCCAGCCT TTTGAGAGGC TGAGGCGGGT 16400 | var (16375) : [T:0.01]
GGATCACTTG AGGTCAAGGAG TTCGAGAGCA GCCTGGCCAA CACGGTGA 16450
CCCCATCTCT ACTGAAAATA CAAAACTAG CCAGGTATGG TGGCGCTGCG 16500
CTGTAATCCC AGCTACTCGG GAGGCTGAGA CAGGAGAATC ACTTGAACCT 16550
GGGAGGCAGA GGTTCAGTG AGCCAATATC ACGCCATTGC ACTCCAGCCT 16600
GGGGGACAAG AGCGAAATTC TGTCTCAAAA AAAAAGAAGA AGAAGGCCGA 16650 | REPEAT
CAAACTATGT AACTCTGCTT TTCTCCATGG TCCAGAACAC ACAGCCCTCC 16700
TGGTAAATA ACTCCTTATC TTCTGCTCC CAGCTATCAT CAGACACCTC 16750 | var (16728) : [G:0.41]
GGCTGATAGA AAATTGCAAG TTAGCTCACT GCAACCTCGG CATTATAAGT 16800 | var (16780) : [C:0.01]
ACTGCACAAA GCCCTCTTCA GCGCACAGCA CAAGCCCAT TCTATAAAAT 16850 | var (16819) : [T:0.01]
CTCCAGCAAG CGGCCAGGTG CAGTGGCTCA TACCCTGTAAT CCCAGCATT 16900 | REPEAT
TGGGAGACTG AGCGGGCGG ATCACCTGAG GTCAGGAGTT TGAGACCAGC 16950
CTGGCCAACA GGTGAAAACC CCGTCTCTAT TAAAAATACA AAAAATTAG 17000
CCAGGCGTGG TGGCAGGTGC CTGTAATCCC AGCTACTTGG AAGGCTGAGG 17050
CAGGAGAAAT GCTTGAACCC GGGAGGTGGA AGTTGCAGTG AGCCGAGATC 17100 | var (17070) : [T:0.01]
TTGCCATCGC ACTCCAGCCT GGGGGACAAG AGTGAGACTT CGTCTCAAAA 17150
AAAAAAAATA AAATCCCCAG CAAGCCCTTG TCTTCTGGCA GTCAGCTCCT 17200 | NOT SCANNED | REPEAT
CTCTTGCTGA CCTGCTCATT GCTTTCTTGC AAGGTATTTT CCTACCTACT 17250
TTCTGGAAATA AATCTGTCTT TCTGTACTTA CAACTACCTT TTTTAAAAAT 17300 | REPEAT
TCTTTCTTTT TTGAGATGGA GTCTCACTCT GTTTGCCCGG GCTGGAGTTC 17350
AGTGGTGC AA TCTCAGTCA CTGCAACCTC TACCTACTGG GTTCAAGCGA 17400
TTCTCCTGCC TCAGCTTCCC GAGTAGCTGG GATTACAGGC GTGCACCAGC 17450
ACGCAGGCTA ATTTTTGTAT TTTTAGTAGA GAGGGGGTTT CACCATGTTG 17500
GCCAAGGTGG TCTTGAACCT CTGACCTCAA GTGATCCTCC CACCTCAGCC 17550 | var (17534) : [C:0.01]
TCCCAAAGCG CTAGGATTAC GGCATGAGC CACTGAGGCC GGCTGCACCT 17600 | var (17590) : [T:0.01] | REPEAT
ACAACCTGCT TGATAAATTC TTACCCCCAC ACCACTGGTC CAGATAGTCA 17650

GTGCTCACCC ACAACATTAA GGATATCCA AATTGAAAAC ATTCCAAAAT 17700 | REPEAT
CAGAAAAATA TTCCAACCTCT GAAAATATTC CAAAATCCAA AAAAATTCAA 17750
AATCCAAAAC ACTTCTGGTC CCAAGCATTT TAGAGAAGGG ATACTCAACC 17800
CAAAAATGAG ACAGCAATTC TATAAATGT GCTACCATCT TGCAGGTCTC 17850 | REPEAT
AGTTTAAACAG CTTTACACCT ATTAGCGCAC CAGTGCTCAT AGCAGTGCTG 17900
GGAATATGT ACAGATGAGG AAAGTGAAGC ACCGAGAGGG CAGTGGTTCA 17950
GAGTCCATGG CCCCTGACTG CTCCCCAGCC CGCCTTTCCA GGGGCTGGC 18000
CTCACTGCGG CAGCGTCCCC GGCTATAGAA TGGGCTGGTG TTGGGAGACT 18050 | var (18041) : [C:0.12]
TCACACGGTG ATGGTGTCT CCGCCCATCC ATCCCTGCAG CCCCCAAGAC 18100 | Exon 4
P P K T 108

GTGCTCCAG GACGAGTTTC GCTGCCAGG TGGGAAGTGC ATCTCTCGGC 18150
C S Q D E F R C H D G K C I S R 124
AGTTCGCTG TGA CT CAGAC CGGACTGCT TGGACGGCTC AGACGAGGCC 18200
Q F V C D S D R D C L D G S D E A 141
TCTGCGCCG TGCTCACCTG TGGTCCCGCC AGCTTCCAGT GCAACAGCTC 18250
S C P V L T C G P A S F Q C N S S 158
CACCTGCATC CCQCAGCTGT GGGCCTGCGA CAACGACCCC GACTGCGAAG 18300
T C I P Q L W A C D N D P D C E 174
ATGGCTCGGA TGAGTGGCGG CAGCGCTGTA GGGTCTTTA CGTGTTCCAA 18350
D G S D E W P Q R C R G L Y V F Q 191
GGGACAGTA GCCCTGCTC GGCCTTCGAG TTCCACTGCC TAAGTGGCGA 18400
G D S S P C S A F E F H C L S G E 208
GTGCATCCAC TCCAGCTGGC GCTGTGATGG TGGCCCCGAC TGCAAGGACA 18450
C I H S S W R C D G G P D C K D 224
AATCTGACGA GAAAACTGC GGTATGGGCG GGGCCAGGGT GGGGCGGGG 18500
K S D E E N C 231
CGTCTATCA CCTGTCCCTG GGCTCCCCCA GGTGTGGGAC ATGCAGTGAT 18550
TTAGGTGCCG AAGTGGATT CCAACAACAT GCCAAGAAAG TATTCCTATT 18600 | var (18560) : [A:0.01]
TCAATGTTGT TTCTTTTTTT TCTTTTCTTT CTTTATTTTT TTTTGGAGAT 18650
GGAGTCTCAC TCTGTGATTT TTTTCTCTC TAAATTTCTT ACATCCATAT 18700
GGCCACCATG AGGCCCCAGG CTGGCCGATG GTTGCTGTTA GCTTATTGGG 18750
AAATCACTGT TTGGAAGGTG CTGGTTGTTT TTTGTTGTTT GTTGTTTTTG 18800 | REPEAT
TTTTGTTTTT TATTTTGAGA CCGAGTCTCG TCTGTGCGCC AGGTGGAGT 18850 | var (18812) : [G:0.44]
GCAGTGGCGG GATCAGTCA CTGCAACCTC CGCTTCTGCG GTTCAAGCCA 18900 | var (18860) : [T:0.01] | var (18895) : [G:0.09]
TTCTCCTGCC TCAGCCCTCC AAGTAGCGCG GATTACAGGC ATGTGCCACC 18950

```

```

ACCTCCGGCT ATTTTTTTTT CTATTTAGTA GAGATGGGGT TTCACCATGT 19000 | var(18963) : [C:0.01]
TAGTCAAGCT GGTCATGAAC TCTTGACCTC AGGTGATCCA CCCGCCTCGG 19050
CCTCCCAAAG TGCTGGGATT ACAGGCCTGC ACTGCTGCAC CCAGCCTTTT 19100 | var(19077) : [A:0.02] | REPEAT
TTTGTTTTTT TGAGACAGGG TCTTGCTGTC ACCCAGGTTG AAGTAAAGTG 19150
GCACGATTAT GGCTCACTGC GGCCTTGATC TCCTTGGCTC AAGCGATCCT 19200
CTCACTTCAG CCTCTCAAGC AGTTGGAACC ACAGGCTGTA CCACCAAGCC 19250
TGGCCAAATTT TTTTGTACAG ACACAGGCTG GTCTTGAACCT CCTGGGCTCA 19300
AGCAATCCTC CTGCCTTGGC CTCCCAAAGT GCTGGGATTC CAGGCATGAG 19350
CCGGTGCACC CGGCAAAAAG CCTGCTTCTT TTTTCTCTGG TTGTCTCTTC 19400
TTGAGAAAAT CAACACACTC TGTCTGTGTT TCCAGCTGTG GCCACCTGTC 19450 | Exon 5
      A V A T C 236
GCCTGACGA ATTCCAGTGC TCTGATGGAA ACTGCATCCA TGGCAGCCGG 19500
R P D E F Q C S D G N C I H G S R 253
CAGTGTGACC GGGAAATATGA CTGCAAGGAC ATGAGCGATG AAGTTGGCTG 19550
Q C D R E Y D C K D M S D E V G C 270
CGTTAATGGT GAGCGCTGGC CATCTGGTTT TCCATCCCCC ATTCTCTGTG 19600
V N 272
CCTTGGCTGCT TGCAAAATGAT TTGTGAAGCC AGAGGGGGCT TCGCTGGTCA 19650 | REPEAT
GCTCTGCACC AGCTGTGCGT CTGTGGGCAA GTGACTTGAC TTCTCAGAGC 19700
CTCACTTCCT TTTGTTTTGA GACGGAGTCT CGCTCTGACA CCCAGGCTGG 19750 | REPEAT
AGTGCTGTGG CACAATCACA GCTCACGGCA GCCTCTGCCT CTGATGTCCA 19800
GTGATTCTCC TGCTCAGCC TCCCGAGTAG CTGAGATTA AAGCGTATAC 19850
CACCACGCCG GGCTAATTTT TTGTATTTT ATTAGAGACA GGGTTTCTCC 19900
ATGTTGGCCA GGCTGTCTTT GAACTCTGGT TCTCAGGTGA TCCACCCGCC 19950
TCGGCCTCCC AAAGTGTAG GATTACAGGT GTGAGCCACT GCGCCAGGCC 20000
TAATTTTTTT GTATTTTITAG TAGAGATGCG GTTTTGCCCT ATTGCCCAGG 20050 | REPEAT
CTGGTCTCGA ACTCCTGGGC TCAAGCGATC TCGCTGCCTT GCCTCCCAA 20100
AGTGCTGGGA TTACAGGCAC AAACCACCGT GCCCGAOGGG TTTTCTTAAT 20150
GAATCCATTT GCATGCGTTC TTATGTGAAT AAACCTATTAT ATGAATGAGT 20200
GCCAAGCAAA CTGAGGCTCA GACACACCTG ACCTTCCTEC TTCTCTCTC 20250
TGGCTCTCAC ACTGACACTC TCGGAGGGAC CCAACAAGTT CAAGTGTAC 20300 | Exon 6
      V T L C E G P N K F K C H 285
AGCGGCGAAT GCATCACCCCT GGACAAAATC TGCAACATGG CTAGAGACTG 20350
S G E C I T L D K V C N M A R D C 302
CCGGGACTGG TCAGATGAAC CCATCAAAGA GTGCGGTGAG TCTCGGTGCA 20400 | var(20394) : [T:0.01]
R D W S D E P I K E C 313

GGCGGCTTGC AGAGTTTGTG GGGAGCCAGG AAAAGGACTG AGACATGAGT 20450
GCTGTAGGGT TTTGGGAACT CCCTCTGCC CAGCCTGTGC AAAGGGCTCC 20500
TTTTTTCATT TTGAGACAGT CTGCGACGGT CGCCACGGCT GGAGCGCAAT 20550 | REPEAT
GGCGGATCT CGGCTCACTG CAACCTCTGC CTCCAGGTT CAAGTGATTC 20600
TCCTGCCCTA GCCTCTGAG TAGCTGGGAT TACAGGCGCC CACCACCAAG 20650
CCGGGGTAAT TTTTGTATG TTTAGTAGAG ATGGGGTTTC ACTATGTGG 20700
CCAGGCTGGT TTGGAACCTC TGACCTCATG ATCCGCCAC CTGGGCTCC 20750
CAAAGTGTG GGATTACAGG CGTGACCCAC CCCATGAAA AAAATTTAAA 20800
AATGAAGCGA TGCTGGGCGC GGTGGATCAC GCCTGTAATC CCAGCACTTT 20850 | REPEAT
GGGAAGCTGA GGCAGGCAGA TCAGGAGGGC AGGAGATTGA GACCATCTG 20900
GCTAATACGG TGAACCCCA TCTCTACTAA AACTACAAA AATTAGCCGG 20950 | var(20908) : [T:0.32]
GTGTGGTGGC AGGCACCTGT GATCCCAGCT ACTCAGGAGG CTGAGGCAGG 21000
AGAATCGCTT GAACCCAGGA GGTGGAGGTT GCAGTGAGCC GGGATCACAC 21050
CATTGCACTC CAGCCTGGGT GACAGAGTGA GACTCTGTCT CAAAAAATA 21100
AAAAAAAAAA AAAGCGAATT CTGAAATACA TGAATTTCTT TCCTTAGATG 21150
CCTGCTTCTG TCTTGAGGTT TGTGTTGTT GTTATTTTCA AACAGAGTCT 21200 | REPEAT | var(21181) : [-:0.25]
TGCTCTGTG CTCAGGCTGG AGTGCAGTGG CATGATCTTG GCTCACCACA 21250 | var(21246) : [T:0.05]
ACCTCCGGCT CCCAGGTTCA AGCGATTCTT CTGCCTCAGC CTCTGAGTA 21300
GCTGGGATTA CAGCTGAATG CCACCTTGTG GGGCTAATTT TTGTATTTT 21350
AGTAGAGATG GGGTTTCACC ATGTTGGCCA GGCTGGCCTC GAACTCTGTA 21400
CCTGAGTGA TCTGCCCGCC TCCTGAAATG CTGGGATTAC AGGCGTGAGC 21450
CACCTCGTCC TGGTGAGGGT TTTTTTTTTT CCCCAACCCT CTGTGGTGG 21500
TACTGAAAAG CCAATATTAG ATAACCTGTAC AGTATAGAGA AGGCAGTGGC 21550
AAGTTTTCTC TGTCATATAC CAGAGTGGGC TTGGGCATGG TGGCATACTC 21600 | REPEAT
CTGTAGTCTC AGCTAATCAG GAGGCTGAGG AAGGAGGATC GCTTGGGCCC 21650
AGGAGTTGGA CACTGTAGTG AGCTGTGATC ACACCAACCAC ACTTCAATCT 21700
GGCAACAGA GCAAGAGACC CTATCTCTAA AAAAAAGTAA GTATTTTGG 21750 | REPEAT
CACTGTGGGC CATAAGTCT CTGGTGCAGT TTCTCAACAT GGCTGTTGGG 21800 | var(21766) : [A:0.01]
TGAACACAAC CACGCACAGA ACGCAAAACA ATACACGTGG CTGTGGGCCC 21850
AGAAAATGTT ATTTATGGAC ACAAAAATTG GAATTTTATA TAACGTGTTT 21900
GTGTCAATGA AATGATTTCC CTTTTTATTT TTATTTTCT TCTCAAGTAT 21950
TTAAATATGT AAAAGCCATT TTTAGGCTG GCAGGATGGT TCACAGCTGT 22000 | REPEAT
AATCCCAGCA CTTTGGGAGG TCGAGGCGGG AGGATCACGA GGTGAGGAGA 22050
TCGAGACCAT CTTGGCCAAC ACAGTGAAC CCCGTCTCTA CTAATAATAC 22100
AAAAAATTA CCAGGCTTGG TGGCGCGCT CTGTAGTCCC AGCTGCTCAG 22150

```

GAGGCTGAGG CAGGAGAATC GCTTGAATGC AGGAGGCGGA GGTGTAGTG 22200  
 AGCCGAGGTT GCACCACTGC ACTCCAGCCT GAGCGACAGA GTGAGAGTCC 22250 | NOT SCANNED  
 GCCTCAAACA AAAAAATGTT TGCCCATGCT GGTCTTGAAC TCCTGGGCTC 22300 | REPEAT  
 AAGCTATCTG CCTGCCTTGG TCTCCCAAAG TTCTGGGATT ACAGGCATGA 22350  
 GCTACAGCGC CGGACTTTT GTTGTTTTAT ATCTATATAT CTATATATAA 22400  
 CTTGTTTTAT GTATATATAT AACTTGTTTT ATATATATAC ATAAACTGCA 22450 | REPEAT  
 GTAAAAAACA TGTAACATAA AATTTACCTT CTCAAAACCT ATTAAGTGCA 22500  
 CAGTTCGTG CCATTAGCAA ATTCACACTG TTGTACAACA TCACAACCAC 22550  
 CATCTCCAGA ACTTTTTTTT TTTTTTTTAT TCTTTTTGAG ACAGAGTCTC 22600 | REPEAT  
 ACTCGTCGCA CGGGCTGGAG TGCAGTGGTG CGATCTCGGT TCACTGCAAC 22650  
 CTCACCTTAC CAGGTTCAAG CAATTCCTCT GCCTCAGCCC CCTCAGTAGC 22700  
 TGGGATTACA GGTGCGCGTC CTACCACGCC CAGCTAATTT TTGTATTTTC 22750  
 AGTAGAGACT GACTGGGTTT CACCATGTTG GCCAGGCTGG TCTCGAACTC 22800  
 CTGACCTCAA GTGATCCTCC CACCTCAGCC TCCCAAAGTG CTGGGAATAC 22850  
 AGGCATGAGC CACTGCGCCC GGCCCCAGAA CTCTTTTATC TTCCCAAAC 22900 | REPEAT  
 GAAGCTCTGT CCCCATGAAA CACTCACTCT CCATCCCCTC CCCAACTCCT 22950  
 GGCACCCACC ATTCTACTTT CTGTCCCTAT GAATGTGATG GCTCTAGGGA 23000  
 CCTCCTCTGA GTGGAATCAG ACAGCATTTT CCTTTTTTGA CTGGCTTATT 23050  
 TCACTGAGCC AAGTGGCGTG GCACACGCCCT GTAATCCCAA AACTTTGGGA 23100 | REPEAT  
 GACCGAGGCG GCGCATCAC CTGAGGTCAG GAGTTCGAGA CCAGCCCGGC 23150  
 CAACATGGTG AAACCCCATC TCTAGTAAAA ATACAAAAAA TTAGCCTGTC 23200  
 ATGGTCGTGT GTGCCGTGTA TCCAGCTAA GTGGGAGGCT GAGGCAGGAG 23250  
 AATCGCTTGT ACCCAGGAGG CGGAGGTCGC AGTGAGCCGA GATCGTGCCA 23300  
 TTACACTCCA GCCTGGGCAA CAAGAGTGAA ACTCCGTCTC TCCTAAAAAT 23350  
 AAAAAAAAT TAGCTGGGCA TGGTGGCACA TGCCGTGAGT CCCAGCTACT 23400 | REPEAT  
 TGGGAGGCTG AGCGAGGAGA ATCACTTGAA CCCGGGAGGT GGAGGTTGTA 23450  
 ATGAGCCAAG GTTGGCGCGC AAGGGATGGG TAGGGGCCCG AGAGTGACCA 23500 | NOT SCANNED  
 GTCTGCATCC CCTGGCCCTG CGCAGGGACC AACGAATGCT TGGACAACAA 23550 | Exon 7  
 G T N E C L D N N 322  
 CGGCGGCTGT TCCACGCTCT GCAATGACCT TAAGATCGGC TACGAGTGCC 23600  
 G G C S H V C N D L K I G Y E C 338  
 TGTGCCCGCA CGGCTTCCAG CTGGTGGCCC AGCGAAGATG CGAAGGCTGAT 23650  
 L C P D G F Q L V A Q R R C E 353  
 TTCGGGTGG GACTGAGCCC TGGGCCCCCT CTGGCTTCC TGACATGGCA 23700  
 ACCAAACCCC TCATGCCTCA GTTTCCCATC CTGTTAAGTG TGCTTGAAG 23750 | REPEAT  
 CAGTTAGGAG GGTTCATGA GATTCCACCT GCATGAAAAA CTATCATTTG 23800 | var (23754) : [G:0.09]  
 CTGGCCAGAG TTCTTGCCT CTGGGGATTA GTAATTAAGA AATTTCAAGC 23850 | REPEAT  
 CGGGTGCCTA ATCCCTGTA TCCCAACACC TTGGGACCCC GAGGCGGGCA 23900  
 GATCACCTGA GGTCCGGAGT TCCAGACCAG CCTGACCAAC ATGGAGAAAC 23950  
 CCGTCTCTA CTAATAATAC AAAATTAGCC GGGCTTGGTG GTGCATGCCT 24000  
 ATAATCCAG CTACTCAGGA GGCTGAGGCA GGAGAATCAC TTGAACCTGG 24050  
 GAGGTGGAGG TTGTGGTGAG CCAAGATCGT GCCATTGCAC TCCAGCCTGG 24100  
 GCAACAAGAG TGAACCTCCA TCCAAAAAA AAAAAGAAAG AAAAAGAAAG 24150  
 AAGAAAAGAA ATTTACAGCT ACACAGCTTC ACACCTCTGG TTGGGTTGCC 24200  
 GTGGTGAATG ATGAGGTGAG GTGATGACTG GGGATGCAC CTGGCTGTTT 24250  
 CCTTGATTAC ATCTCCCGAG AGGCTGGGCT GTCTCCTGGC TGCCTTCGAA 24300  
 GGTGTGGGTT TTGGCCTGGG CCCCATCGCT CCGTCTCTAG CCATTGGGGA 24350  
 AGAGCCTCCC CACCAAGCCT CTTTCTCTCT CTTCCAGATA TCGATGAGTG 24400 | Exon 8  
 D I D E C 358  
 TCAGGATCCC GACACCTGCA GCCAGCTCTG CGTGAACCTG GAGGGTGGCT 24450  
 Q D P D T C S Q L C V N L E G G 374  
 ACAAGTGCCA GTGTGAGGAA GGCTTCCAGC TGGACCCCCA CACGAAGGCC 24500 | NOT SCANNED  
 Y K C Q C E E G F Q L D P H T K A 391  
 TGC AAGGCTG TGGGTGAGCA CGGGAAGGCC GCGGGTGGGG GCGGCCTCAC 24550  
 C K A V 395  
 CCCTTGCAGG CAGCAGTGGT GGGGGAGTTT CATCCTCTGA ACTTTGCACA 24600  
 GACTCATATC CCTGACCCG GAGGCTGTTT GCTCCTGAGG GCTCTGGCAG 24650  
 GGGAGTCTGC CGCCCTGTTA GGACTTGGGC TTGCCAGGGG GATGCCTGCA 24700  
 TATGTCTAG TTTTTGGGAA TATCCAGTTA ACGGAACCCCT CAGCCCTACT 24750  
 GGTGGAACAG GAACCGGCTT TCCTTTCAGG GACAACCTGG GGAGTGACTT 24800  
 CAAGGGGTTA AAGAAAAAAA ATTAGCTGGG CATGGTGCCA CACACCTGTG 24850 | REPEAT  
 GTCCCAAGTA CTCAGAAGGC TGAGGCGGGA GGATTGCTTG AGGCAGGAG 24900 | var (24879) : [A:0.08]  
 GATTGGTTGA TCCTCCACC TCAGCCTCCG GAGTAGCTGG GACCTCAGGT 24950 | REPEAT  
 GCATGCCACT ATGCCTGGCT AATTTCTTTT TTTCTTTTTT TTTTTTTTTC 25000 | REPEAT  
 GAGACGGAGT CTGCCTGTGT TGCCAGGCT GGAGTGCACT GGCAGGATCT 25050  
 CGGCTCACTG CAAGCTCCGC CTCCCGGTT CACGCCATTC TCCTGCCTCA 25100  
 GCCTCCCCAG TAGCTGGGAC TACAGGAGCC CGCCACTGCA CCAGGCCAAT 25150  
 TTTTTGTAT TTTTGTAGA GACGGGTTT CACTGTGTTA CCCAGGATGG 25200 | var (25184) : [C:0.04] | var (25185) : [A:0.04]  
 TCTCGATCTC CTGACTTCGT GATCCGCCCA CCTCGGCCCT CCAAAAGTGC 25250  
 CGGATTACAG CCGTGAGCCA CTGGCCCCAG CCGCTAATTT TCATATTTTT 25300 | REPEAT  
 AGTAAAAACA GGGTTTCACC ATGTGGCCA GGCTAGTCTT GAACTCCTGA 25350

```

ACCACACCTG GCTATTATTA TTTTITAGAG ACAGGGTGCT GCTCTATCTT 25450 | REPEAT
CCAGCCTGTA GTGCAGTGA GCCTCCATCA TAGCTCGCTG CAGCCTTGAC 25500
CTCCTGGGTT CACGTGATCG TCCCGCCTAA GCCTCTGGAG GAGCTGGGAG 25550
TACTGGCATG TGCCACCATG CCTGGTTAAT TTTTTTTTTT TTTTTTTTGA 25600 | REPEAT
GACAGAGTCT CATTCTGTCA CCCAGGCTGG AGTGCGGTGG TGCGATCTTG 25650 | NOT SCANNED
GCTTACTGAA ACCTCCACCT CCCAGGTTCC AGCAATTCTC CTGGCTCACC 25700
CTTCTGAGTA GCTGGGATTA CAGGTTCCGG CTACCAAACC TGGCTAGTTT 25750
TTGTATGTTT AGTAGAGACA GGGTTTCACC ATGTTGGTGA GGCTGGTCTC 25800
GATTCCTCCG CCTCAGCCTC CCAAAGTGCT GGGATTACAG GCTTGAGCCA 25850
CCGTGGCTGG CTTTTTTTTT TTTTTTTTTT TTTGTGGCAA TAAGGTCTCA 25900 | REPEAT
TTGTCTTGCC CAGGCTAGCC TTATGCTCCT AGCCTCAAAT GATCCTCTC 25950
CCTCAGCCTC CCAAAGTGCT GGGATTACAG GTGGGGCCCA CTGTGCCTGT 26000
TCCGTTGGG AGGTCITTTT CACCCTCTTT TTCTGGGTGC CTCCTCTGGC 26050
TCAGCCGGCC CCTGCAGGAT GACACAAGGG GATGGGGAGG CACTCTTGGT 26100
TCCATCGACG GGTCCCTCTT GACCCCTCTG CCTCGCTCCG CCGACCCCCA 26150
GGCTCCATCG CCTACCTCTT CTTACCAAAC CGGCACGAGG TCAGGAAGAT 26200 | Exon 9
  G S I A Y L F F T N R H E V R K M 412
GAGGCTGGAC CGGAGCGAGT ACACCAGCCT CATCCCCAAC CTGAGGAACG 26250
  T L D R S E Y T S L I P N L R N 428
TTGTCTGCTT GGACACGGAG GTGGCCAGCA ATAGAATCTA CTGGTCTGAC 26300
V V A L D T E V A S N R I Y W S D 445
CTGTCCAGA GAATGATCTG CAGGTGAGCG TCGCCCTGCG CTGCAAGCCTT 26350
  L S Q R M I C S 453
GGCCCGCAGG TGAGATGAGG GCTCCTGGCG CTGATGCCCT TCTCTCCTCC 26400 | var (26355) : [T:0.09] | var (26379) : [T:0.32]
TGCCTCAGCA CCGAGTTGA CAGAGCCAC GCGGTCTCTT CCTATGACAC 26450 | Exon 10
  T Q L D R A H G V S S Y D T 467
CGTCATCAGC AGGACATCC AGGCCCCCGA CGGGCTGGCT GTGACTGGA 26500 | var (26463) : [A:0.29]
  V I S R D I Q A P D G L A V D W 483
TCCACAGCAA CATCTACTGG ACCGACTCTG TCCTGGGCAC TGTCTCTGTT 26550
  I H S N I Y W T D S V L G T V S V 500
GGGATACCA AGGGCGTAA GAGGAAAACG TTATTCAGGG AGAACGGCTC 26600
  A D T K G V K R K T L F R E N G S 517
CAAGCCAAGG GCCATCGTGG TGGATCCTGT TCATGGGTGC GTATCCACGA 26650
  K P R A I V V D P V H G 529
CGCTGAGGGC TGCCAGGGA ATGGAGGGAG CAGGAAGGAG CTTACGGAAC 26700 | var (26689) : [G:0.41]

TGTTTAGTGG GCTGGGCATG GTGGCTAAA GCACCTGTA TCCCGACT 26750 | REPEAT
TTGGAGGGCC AAGTGGGTG GATCATCAAG ACCAGCCTGA CCAACATGGT 26800 | var (26790) : [G:0.04]
GAAACCTCGT CCTACTAAA AATACAAAA TTAGCCGGGT GTGGTGGTGG 26850
GCACCTGTA TCCAGCTGC TCGGGAGGCT GAGGCAGGAG AATCACTTGA 26900 | var (26870) : [T:0.03]
ACCTGGGAGA TGGAGTTGC AGTGAGCCAA CAGACCCCA CTGCACTCCA 26950
GCCTGGGTGA CAGAGTGAGA CTCCTGCTCA AAAAAAAA AAAAATAA 27000
ACAAAAAAT GGTACTGGC TAGACAACAG GATGGTATCT TCCAAAGCCA 27050
TTGGTGAATC AGCAGCTCCT GGTCAAGAC ACTGTCACT GTGTCCCTGG 27100
GCAGGAAGCA TCGCCCTGCG CACCTGCCCG GTGTACTCTG TAGCTGTCA 27150 | var (27130) : [A:0.09]
GTGACATCTG CTACCTAAGC ACGTAGAGAG TGGCATTTCA CAGTTTCACT 27200
GTGGTGGTGA CAACCCGGGA CGCACACTGT CCTTGCAGCT ACAATCAGGA 27250
GGTGAATGTT GGGTTTCCAG CAGAGAACC TGGAGAAGCC ACCTTGGTGG 27300
TCTGGAAGGG AAAAGCAGGG AAGAGAGCAT CATCAGATGC CTGGGGTGA 27350
AGGTGGGCC CACTATGGCCA GCGTCCCTTT TTATTTTAT TTATTTATTT 27400 | var (27352) : [A:0.10] | REPEAT
ATTTGAGATG GAATCTCGCT CTGTGCCCCA GACTGTAGTG CAGTGGTGGC 27450
ATCACGGCTC ACTGCAAGCT CCGCCTCACA GGTTCAGGCC ATTCTCCTGC 27500
CTCAGCCTCC CGAGTAGCTG GGACTACAG CACCCGCCAC CAGCCCGGT 27550 | var (27543) : [G:0.07]
TAATTTTTTG CATTTTTATT AGAGACGGGG TTTGACCCGG TTAGCCAGGA 27600 | var (27590) : [A:0.10]
TTGTCTAAAT CTCTGACCC TGTGATCCAC CCGCTCGGC CTCCTAAGT 27650
GCTTGGATTA CAAGCGTGAG CCACCAGGCC CGGCCCTTT TTTATTTTTT 27700 | REPEAT
ATTTTTTGG ACGGAGTCTC GCTCTGTGCG CCAGGCTAGA TTGCAGTGGC 27750 | var (27713) : [T:0.30] | var (27729) : [A:0.01] | var (27750) : [T:0.02]
GTGATCTCGG CTCACTGCA GCTCCGCTCC CAGGTTCAA GTGATCTCC 27800
TGCCCTAAC TCCCAACTAA TTAGGATTAC AAGCATGTAC CACCATGCCT 27850
GACTAATTTT TTGTATTTT AGTAGAGACT GGGTTTCACC ATGTTGGCTA 27900
GGCTGGTCTC GAACCCCTAG CCTCAAGTAA TCTGCCTGCC TCAGCCTCCC 27950
AAACAGGGGG GATTACAGGC ATGAGCCACT GTGCCCAACC CAACCTGGA 28000
TCTCTTTTAA ACAAGACAAT GCTCGCTGTT GCCACAGAAC AATGGGTGG 28050
GTACATGTGG CCGAGTGTGT TTGGCCACAT AACTGCCAGG CCAGAGGGAA 28100
AGAGACTCTC AGACTGTCTC CACTCAGATA CAAATGTGTG TGTGTGTGTC 28150
GTGTGTTCTG GTCTCATATT TGTGTTTTT GAGACAGGTT GTCGCTCTGT 28200 | REPEAT
CACTGAGTCT GGAGTGCAGT GCGCAATCA GAGTTCACCT CAGCCTCAA 28250
CTCTGGGCTC CAGTTGATTC TCCCACTTCA GCCTCCCAAG TAGCTGGAAC 28300
TACAGGTGAA CACCCTGTG CCCAGCTAAT TTATTTTATT TTTAGTAGAG 28350
ATGAGGTCTC ACTATGTTGC CCAGGCTGGT CTTGACCTCC TAGCCTCAAG 28400
CAATCCTCCT GCCTGGTCTC CCCAAAGTGC TGGGATTACA CGTGGCAGCC 28450 | var (28442) : [A:0.02]
ATTGGCATG GCTTGTGTTT TGTGTTTCT TCCTTTTTCT TCGAGATGG 28500 | var (28455) : [T:0.01] | REPEAT
CGTCTCAGTC TGCCACCCAG GCTGGAGTGC AGTGGTGTGA TCATAGCTCA 28550 | var (28520) : [C:0.02]

```

CTGTAGCCTC AACTTCTCTG GCTCAAGCAA TCCTCTTGAT TTCAGCCTCC 28600  
 CGGGCCTGGC CAGCATGGTG AAACCCCGTC TCTACTAAAA ATACAAAAAT 28650 | REPEAT  
 GTAGCCAGGC GTGGTGGTGG GCGCCTGTAA TCCCAGCTAC ACCAGAGGCT 28700  
 GAGGCAGGAG AATCGCTTGA GCCTGGAAAG TGGAGGTTGC AGCAAGCCAA 28750 | var (28730) : [T:0.05] | var (28741) : [G:0.27] | var (28748) : [A:0.01]  
 GATCGTGCCA CTGCCTCCA GCCTGGGCAA CAGAGACAGA CTCTGTCTCA 28800 | var (28766) : [T:0.07]  
 AAAAAAAAAA AAAAAACC AAACAAGCCA CATTGGGAGT TTGGGGTTCC 28850 | var (28817) : [C:0.01]  
 CAGCAGGACT ATTTCCCAAG CCTGAGCCTG GCTGTCTTCT CCAGAATTCC 28900  
 TTGCACGCAT TGGCTGGGAT CCTCCCCCGC CCTCCAGCCT CACAGCTATT 28950  
 CTCTGTCTCC CCACAGCTT CATGTACTGG ACTGACTGGG GAACTCCCGC 29000 | Exon 11 | var (28998) : [T:0.08]  
 F M Y W T D W G T P A 540  
 CAAGATCAAG AAAGGGGGCC TGAATGGTGT GGACATCTAC TCGTGGTGA 29050  
 K I K K G G L N G V D I Y S L V 556  
 CTGAAAAATC TCAGTGGCCC AATGGCATCA CCCTAGGTAT GTTCGCAGGA 29100  
 T E N I Q W P N G I T L 568  
 CAGCCGTCCC AGCCAGGGCC GGGCACAGGC TGGAGGACAG ACGGGGGTTG 29150 | var (29142) : [T:0.26]  
 CCAGGTGGCT CTGGGACAAG CCCAAGCTGC TCCCTGAAGG TTTCCCTCTT 29200 | REPEAT  
 TCTTTTCTTT GTTTTTCTTT TTTTGTAGAT GAGGTCTTGG TCTGTCACCC 29250  
 AGGCTGGAGT GCACTGGTGC AATCGTAGCT CACTGCAGCC TCCACCTCCC 29300 | var (29268) : [C:0.43] | var (29295) : [T:0.24]  
 AGGCTCAAGT GATCCTCCTG CCTCACCCCT CTGAGTAGCT GAGATTACAG 29350  
 ACACGTGGCA CCACGGCAGA CTAATTTTAT TTTATTTTGG GGAAGAGACA 29400  
 AAGTCTTTGT ATGTGGCCCT GGCTGGTCTC AAACCTCAGG TGCAAGCGAT 29450  
 CCTCCCCGCT CAGCCTTCCA AACTGTGGG ATTACAGGCG TGGGCCACCG 29500 | var (29490) : [A:0.08]  
 TAGCCAGCCT CCTTGAAGTT TTTCTGACCT GCAACTCCCC TACCTGCCCA 29550 | var (29524) : [G:0.29]  
 TTGGAGAGGG CGTCAACAGG GAGGGTTTCA GGCTCACATG TGGTTGGAGC 29600  
 TGCCTCTCCA GGTGCTTTTC TGCTAGGTCC CTGGCAGGGG GTCCTTCCTG 29650  
 CCGGAGCAGC GTGGCCAGGC CCTCAGGCCC CTCTGGGACT GGCATCAGCA 29700 | var (29664) : [T:0.25] | var (29678) : [A:0.28]  
 CGTGACCTCT CCTTATCCAC TTGTGTGTCT AGATCTCCTC AGTGGCCGCC 29750 | var (29723) : [A:0.01] | Exon 12  
 D L L S G R 574  
 TCTACTGGGT TGACTCCAAA CTTCACTCCA TCTCAAGCAT CGATGTCAAC 29800  
 L Y W V D S K L H S I S S I D V N 591  
 GGGGGCAACC GGAAGACCAT CTTGGAGGAT GAAAAGAGGC TGGCCACCC 29850  
 G G N R K T I L E D E K R L A H P 608  
 CTTCTCCTTG GCCGTCTTTG AGGTGTGGCT TACGTACGAG ATGCAAGCAC 29900  
 F S L A V F E 615  
 TTAGGTGGGC GATAGACACA GACTATAGAT CACTCAAGCC AAGATGAAGC 29950  
 CAGAAAACTG GTTGTGACTA GGAGGAGGTC TTAGACTCA GTTATTTCTA 30000  
  
 TTTTCTCTT TCTTTTTTTT TTTTTTTTTT AGACAGAGTT TTGCTCTCGT 30050 | REPEAT  
 TTCCAGGCT GGAGGCAAT GGCATGATCT CGGCTCACGG CAACCTCCAC 30100  
 CTCCCAGGTT CAAGTGATTC TCCTGTCTCA GGCTCCCCAG TAGCTGGGAT 30150  
 TACAGGCATG CACCACCACC ATGCCCGGCT AATTTTGTAT TTTTAGTAGA 30200  
 GACGGAGTTT CTCCATGTTG GTCAGGCTGG TCTGGAACCT CCGACCTCAG 30250  
 GTGATCTGCC TGCCCTGGCC TCCCAAAGTG CTGGGATTAC AGACTTGAGC 30300  
 CACCCGGCCC AGCTATTTCT GTTTCTTTTC TTTCTCTCTC TTCTTTTTTT 30350 | REPEAT | var (30337) : [A:0.22]  
 TTTTCTAAGA GACAGGATCT CACTCTGTCC CCAGGCAGGA GTGCAGTGCT 30400  
 GTGATCATAG CTCACCTGAG CCTTAACCTC CTGGGCTCAA GTGATCTTCC 30450  
 CACCTCAGCC TCCCAAGTAG CTGGAACCTC AGGTGCACAC CACCATGCC 30500  
 AGCTCATTTT TGTATTTTTT TTTTTTTTGA GACAGCTCAG TTCTGTCAAC 30550 | REPEAT | NOT SCANNED  
 CCGGCTGGAG TGCAGTGGTA CAATCTTGGC TCACTGCAAC CTCTGCCTCC 30600  
 CAGGTTCAAG CGATTCTCCT GCCTCAGCCT CCTGAGTAGT TGAGATTACA 30650  
 GGCATGTGTG CCATCATACC TGCTGATTTC TTGTATTTTT TTTTAGAGAT 30700  
 GGGGTCTCAG TATGTTGACC AGGCTTGTCT TAAACTCCCG GCCTCAAGTG 30750  
 ATCCTCCACC TTCAGTCTCC CAAAGTGCTG GGATTACAGG CATGAGCCAC 30800  
 TGGCCCGGTT TGTTTTCTT TTTTTTTTTG TTTTTTGGAG ACGGAATTT 30850 | REPEAT  
 ACCTTTGTTG CCCAGGATGG AGTGCAATGG CACGATATCG CCTCACCACA 30900  
 ACCTGTGCTC CTGGGTTTCA AACCATTTTC CTGCCTCAGC CTTCTTAGTA 30950  
 GCTGGGATTA CAAGCATGTG CCACCACGGC CGGCTGATTT TGTATTTTTA 31000 | var (30981) : [T:0.35]  
 GTAGAGATGG GGTTTCTCCA TGTGGCCAG GCTGGTCTCG AACTCCTGAC 31050  
 CTCAGGTCAT TGCCCCACCT CTGCCTCCCA AAGTGTGGG ATTACAGGCG 31100 | var (31063) : [A:0.22]  
 TGAGCCACCG TGCCCGGTTG TTTGTATTCT TTTTACTGAG AGTCTGAAA 31150 | var (31110) : [A:0.03] | REPEAT  
 GGCAGTGATC CTCTGTCAAG TGTGATCTTG GCTCTCAGGG GACATTTGGC 31200 | var (31151) : [A:0.01] | REPEAT | var (31163) : [A:0.36]  
 AATTTCTAGA GATTTTTTGG TTGTCAACA TCAATGGGGA AGACTGTTGG 31250  
 CATTTAGTGG GTAGAGGCTG GTGACGCTGC TGAACACCCA GAAACAGGAA 31300  
 GTAGCAGGCC CTAGATAGAG CCATCGTGGG GAAACCCCTG TCTAAGGAAA 31350  
 TGCCGCTATT TTATAACCCC ACGTCTCTGG CATGATTACC AACAGCCAAA 31400  
 AGTGGAGTCC CCCCAGTGT GTTCGTCCAT TTGCATTGCA GTAAAGGAAT 31450 | var (31416) : [G:0.29] | REPEAT | var (31425) : [A:0.03]  
 AGCTGAGGCC GGGTAATTTA TAAAGAAAAG AGATTTAAAC TGGGTATGGC 31500 | REPEAT  
 AGTTTTATGCC TATAATCCCA GAACCTTTGGG AGGCTGAGGC AGGAGGATCG 31550  
 CTTGAGTCCA GGAGTGTGAG ACCGAGACCA GCCTGGCCAA CATGACGAAA 31600  
 CTCTGTCTCT AAAAAAATA CAAAAAGTAG GCCAGGCAGC GTGGTTCAAC 31650 | REPEAT  
 CCTGTAATCC CAGCACTTTG GGAGGCCGAG GCGGGCGGAT CACGAGGTCA 31700  
 GGAGATCGAG ACCATCCTGG CTAACACGGT GAAACCCCGT CTCTACTAAA 31750 | var (31722) : [C:0.09]  
 AATACAAAAA CAAAATTAGC CGGGTGTGGT GGCAGGCCCC TGTAGTCCCA 31800 | var (31775) : [C:0.36]  
 GCTACTCGGG AGGCTGAGGC GGGAGAATGG CGTGAACCCG GGAGGCCGAG 31850

CTTGCAGTGA GCCAAGATCG CGCCACTGCA CTCCAGCCTG GGTGACCGAG 31900  
 TTGAGACTCC GTCTCAAAAA AAAAAAAAAA AAAAAATA CAAAAAGTAG 31950 | NOT SCANNED | REPEAT  
 CCAGGTGTGG TGGCAGGCAC CTGTAATCCT GGGTTCTCGA GACCGAGGCA 32000  
 TGAGAATTGC CTGACCCAG GAGGTGGAGG CTGCAGTGAG CCAAGATCAT 32050  
 GCCACTGCAC TCCAGCCTGG GCGACAGAGT GGGACTCTGT CTCAAAAAAC 32100  
 AACAAAAAAA AAGTTCTGGA AATGGATGGT GGTGATGGTG ATACTTCCAC 32150 | REPEAT  
 AACAGCGTGA ATCTGCTTAA GGCCACCGAA CTGTGCACTC ACAAATAGTC 32200  
 GAGATGGTAC ATTTTATGTT ATGTGTATTT CACCACAATT AAAAAGTAGT 32250  
 TGTGGGCCAG GTGTGGTGGT TCATGCCTGT AATCCCAGCA CTTTGGGAGG 32300 | REPEAT  
 TCAGAGGGAG GTGGATCATG AGGTCAGCAG TTCGAGACCA GCCAGGCCAA 32350  
 CATGGTGAAG CCCCATCTCT ACTAAAAATA CAAAAATTAG CCAGGCGTGG 32400  
 TGGCACATGC CTGTAGTCCC AGCTACTTGA GAGGCTGAAG CAGGAGAAATC 32450  
 GCTTGAACCT GGGAGGCTAA GATTGCAGTG AGCCGAGATC GGTCCACTGC 32500  
 ACTCCAGCCT GGACGACAGA GTGAGACTTC GTCTCAAAAA AAAAACCAAA 32550  
 AAAAAATTA GCTGTGGGTC AGGCACTGTG GCTCAGCCT GTAAATCCAG 32600 | REPEAT  
 CACTTTGGGA GACCGAGGTA GGTGGATGGC CTGAGGTCAG GAGTTCGAAT 32650  
 CCAGCCTGGC CAACATGGTG AAAGCCCGTC TCTACTAAA ATACAAAAAA 32700  
 TTAGTCAAGT ATGTTGGCAC ACCTGTAAAT CCAGCTACTC GGGAGGCTGA 32750  
 AGCAAGAGAA TCGTTTGAAC CCAGGAGGTG GACGTTGCAG TGAGCCGAGA 32800  
 TTGGGCCACT GTACTCCAGC CTGGGCAACA AAAGTGAATC TCTGTCTGAA 32850  
 ACAAAACAAA AAAACAACAA ACAGACAAAC AAAAAACTA GTTGTGGAGA 32900  
 GAGGGTGGCC TGTGTCTCAT CCCAGTGTTC AACGGGATTT GTCATCTTCC 32950  
 TTGCTGCCTG TTTAGGACAA AGTATTTTGG ACAGATATCA TCAACGAAGC 33000 | Exon 13  
 CATTTTCAGT GCCAACCGCC TCACAGGTTT CGATGTCAAC TTGTTGGCTG 33050  
 I F S A N R L T G S D V N L L A 643  
 AAAACCTACT GTCCCCAGG GATATGGTTC TCTTCCACAA CCTCACCAG 33100 | var (33079) : [C:0.37]  
 E N L L S P E D M V L F H N L T Q 660  
 CCAAGAGGTA AGGGTGGGTC AGCCCCACCC CCCCACCTT GAAACCTCCT 33150  
 P R 662  
 TGTGGAACCT CTGGAATGTT CTGGAATTTT CTGGAATCTT CTGGTATAGC 33200  
 TGATGATCTC GTTCTCGCCC TGACTCCGCT TCTTCTGCCC CAGGAGTGAA 33250 | Exon 14  
 G V N 665  
 CTGGTGTGAG AGGACCACCC TGAGCAATGG CGGCTGCCAG TATCTGTGCC 33300  
 W C E R T T L S N G G C Q Y L C 681  
 TCCTTGCCCC GCATGCAAC CCCCACTCGC CCAAGTTTAC CTGCGCCTGC 33350  
 L P A P Q I N P H S P K F T C A C 698  
 CCGGACGGCA TGCTGCTGGC CAGGACATG AGGAGCTGCC TCACAGGTTT 33400  
 P D G M L L A R D M R S C L T 713  
 GGCACACGCC TTGTTTCTGC GTCCCTGTGC CTCCAACATG CCCCCTCTGA 33450 | NOT SCANNED | REPEAT  
 GCCTCTCTCT GCTCATCTGT CAAATGGGTA CCTCAAGGTC GTTGTAAAGGA 33500  
 CTCATGAGTC GGGATAACCA TACTTTTCTT GGATGGACAC ATCAGCACCG 33550  
 GGCTTGACAT TTACCCAGTT CCCCTTTGAT GCCTGGTTTC CTCTTTCCCG 33600  
 GCCCCTGAA GAGGTGATCT GATTCTGAC AGGAGCCCTG AGGGAGGAAA 33650  
 TGGTCCCTTT TGTTGACTTT TCTTTTCTT TATTTTTTTC TTTTGAGATT 33700 | REPEAT  
 TGCCTGTACC CAGCCTGGAA TGCACTGGTG CCATCTTGGC TCCTGCTAC 33750  
 CTCTCCCACT GGGTTCAGC AATTCTCCTG CCTCAGCCTC CCAAGTAGCT 33800  
 GGGATTACAA GCATGCGCCA CCATGCCTGG CTAAGTTTTG TATTTTTAGT 33850  
 ACAGACAGGG TTTCTCCATG GTGGCCAGGC TGGTCTTGAA CTCCTGACCT 33900  
 CAGGTGATCC TCCCACCTCT GCCTCCGAA GTGCTACGAT TACAGGCATG 33950  
 AGCCACCGCG CCAATCCCC TTTGTTGACT TTTCTCATCC TCTGAGAAAG 34000  
 TCTCAGTTGA GGCCAGCACC TCCCTCAAGT GAATTGAATC TCCCTTTTGA 34050  
 ACAACAACAA ATAACAATAT GACCCAGACG TGGTGGCTCA CACCTGTGGT 34100 | REPEAT  
 CCCAGCTACT CGGGAGGCTG AGGTGTGAGG ATTGCTTGAG CCCAGGAGGT 34150  
 CAAGGCTACA GAGAGCTATA ATCACACCAC TTCCTCCAG CCTGGGGGAC 34200  
 AAAGTGAATC CACTGTCTGAA AAAAAACAAA AAAGAAAAAG GAAAAAGAAA 34250  
 CAATACGATC ACAAAAGTAGA TATTCATAGT GTTTATTTTC AGTACTCTTT 34300 | REPEAT  
 TTTTTTTTTT TTTTTTTTTT TGAGACGGAG TCTTGCTCTG TTGCCAGGC 34350 | NOT SCANNED  
 TGGAGTGACG TGGCAGGATC TTGGCTCACT GCAGCCTCTG CCTCCCAGGT 34400  
 TCAAGCGCTT GGCTCACTGC AACCTCCGCC TCCTGGGTTT AAGCGCTTCT 34450  
 TCTGCCTCAG CCTCCCCAGT AGCTGGGACT ATAGGCACGT CCCACTACGC 34500  
 CCAGCTAATT TTTTGTATTT TTTAGTAGAG ATGGGGTTTC ACTATGTTAG 34550  
 CCAGGATGGT CTCGATCTCC TGACCTCGTG ATCTGCCTGC CTTGGGCTCC 34600  
 CAAAGTGTG GGAATTATGG CATGAGCCAC TGCACCTGGC CTTTTTTTTT 34650 | REPEAT  
 TTTTTTTTTT AGATGGAGTT TCGCTCTTGT TGCCAGGCT GGAGTGCAAT 34700  
 GGTGTGATCT CGGCTCACTG CAACCTCTGC CTCCTGGGTT CAAGCAATTC 34750  
 TCCTGCCTCA GCCTCCCGAG TAGCTGGGAT TACAGGCACC TGCCACCACG 34800  
 CCTGGCTAAT TTTTGTACTT TTAGTAGAGA CGGGGTTTCT CCATGTTGGT 34850  
 CAGGCTGGTC TCAAACCTCT GACCTCAGGT GATCCACCCA CCTCGGCCTC 34900  
 CCAAAGTTCT GGAATTACAG ACATGAGCCA CCGCGCCTGG CCGTGTCTGG 34950  
 CCTTTTTTAG TTAITTTCTT TTTTTTTTTT TTTTTTTTTT AGACAGAGTC 35000 | REPEAT  
 TTACTCCGTC GCCCAGGCTG GAGTGCAGCG GTGCGATGTC TGCCCACTGC 35050  
 AAGCTCCGCC CCCTGGGTTT ATGCCATTCT CCTGCCTCAG CCTTCTGAGT 35100

```

AGCTGGGACT GCAGGCGCCT GCCACTACGC CCGGCTACTT TTTTGTATAT 35150
TTAGTAGAGA TGGAGTTTCA CTGTGTTAGC CAGGATGGTC TCGATCTCCT 35200
GACTTTGTGA TCCGCCCGCC TCGGCCTCCC AAAGTGCTGG GATTACAGGC 35250
GTGAGCCACC ATGCCAGGCT TTTTTTTTTT TTTTTTTTTT TGAGACGGAG 35300 | REPEAT
TCTTGGCTCG TCGCCCAGGC TGGAGTGCAG TGCCATGATC TCAGCTCACT 35350
GCAAGCTCCA CTTCCCAGGC TCACGCCATT CTCACGCCCT AGCCTCCCAA 35400
GTAGCTGAGA CTACAGGGGC CCGCCACCAC ACTCGGCTAA TTTTTTTGTA 35450
TTTTTAGTAG AGACGGGGTT TCACCATGTT AGCCAGGCTG GTCTTGAACT 35500
CCTAACCTCA GGGGATTACG CTGCCTCGGC CTCCTAAAAGT GCTGGGATTA 35550 | NOT SCANNED
AAGGTATGAG CCACCTCGCC TGGTGTGAGC CACCTCGCCC AGCCTGAGCC 35600
ACCTCACCCA GCCTAAGCCA CTGTGCCTGG CCTGATTTTG GACTTTTTAA 35650
AAATTTTATT AATAATTATT TTTGGGTTTC TTTTTTTTGA GACAGGGTCT 35700 | REPEAT
TACTCTGTCA TCCAGGGCAT CCTGTCTGTC TGTCATCCCA GTGATGGGAT 35750
CATACCTGTG TGCAGCCTCT ACCTCCTGGG CTCAAAGCGAT CCTCCCCCT 35800
CAGCCTCCTG AGTAGCTGGG AGTACAGGTG TGCACCACCA CACCTGGCTA 35850
ATTTTTTTTT TTTTTTTTGT ATATAGAGAT GGTATTTTGC CATGTTGACC 35900 | var (35876) : [C:0.19]
AGGCTAGTCT TAAACTCCTG GACTCACTCA AGAGATCCTC CTGCCTTGGC 35950
CTCCCAAGGT CATTTGAGAC TTTCGTCAAT AGGCGCACAC CTATGAGAAG 36000
GGCCTCGAGG CACGTGGCAC TCAGAAAGCG TTTATTTATT CTTTCAGAGG 36050 | Exon 15
                                     E 714
CTGAGGCTGC AGTGGCCACC CAGGAGACAT CCACCGTCAG GCTAAAGGTC 36100
A E A A V A T Q E T S T V R L K V 731
AGTCCACAGC CCGTAAAGGAC ACAGCACACA ACCACCCGGC CTGTTCCCGA 36150 | var (36139) : [A:0.18]
S S T A V R T Q H T T T R P V P D 748
CACCTCCCGG CTGCCTGGGG CCACCCCTGG GCTCACCACG GTGGAGATAG 36200
T S R L P G A T P G L T T V E I 764
TGACAATGTC TCACCAAGGT AAAGACTGGG CCCTCCCTAG GCGCTCTTC 36250
V T M S H Q 770
ACCCAGAGAC GGGTCCCTTC AGTGGCCACG AACATTTTGG TCACGAGATG 36300
GAGTCCAGST GTCGTCTCA CTCCCTTGTG GACCTTCTCT CACTTGGGCC 36350 | var (36308) : [C:0.01] | var (36314) : [A:0.02]
GTGTGCTCTG GGGCCCTCAG TTTCCTATC TGTAAAGTGG GTCTAATAAC 36400 | REPEAT
AGTTCITGGC CTCITTTGCAA GGATTAATG GGCCAAATCA TATGAGGGGC 36450
CAGGTCTTTC AGGCTCCTGG TTCCAAAAGT CAGCCACCCA CCGTGTGGGT 36500
CCCAAAATTT TATCAAGGCA CATTGCTTGC CTCAGCTTCA GGCATCTGCC 36550 | var (36525) : [T:0.03]
CAAAAAGGCC AGGACTAAGG CAAGGAGAGG GAGGGATTCC TCAGTACTCA 36600

GCTTTTCACA GAGGCTCCAA AAGGCTAAGG AATCCAGTAA CGTTTTAACA 36650
CAATTTTACA ATTTTTTTTT TTGAGACGGA GTTTTGTCTT TGTTCGCCAG 36700 | REPEAT
GCTGGAGTGC AGTGGCACGA TCTCGGCTCA CTGCAACCTC TGGCTCCCGG 36750
GTTCAAGCGA TTCTCCTGCC TCAGTCTCCC GAGTAGCTGG GATTACAGGC 36800 | var (36789) : [A:0.43]
ATGCGCCACC ACGCTCGGCT AATTTGTAT TTTTAGTACA GAAAGGGGTT 36850
CTCTGTTGGT CAGGCTGGTC GTGAACCTC AACCTCAGGT GAGCCACCGC 36900
CCTGAGCCTC CCAAAGTGC GGGATACAG GTGTGAGCCA CCACGCCTGG 36950
CCTTTTTTTT GAGACAGAT CTCGCTCTCG CCCATGCTGT ACTGCAGTGA 37000 | REPEAT
CGCAGTCTGG GCTCACTGTA ACCTCCGCTT CCCAGTTCA AGTGATTCTT 37050
CTGCGCGAGC CTCGCATGTA GAGTAGCTGG GATTACAGGC AGCCGCCACC 37100
ATGCTGGGCT AATCTTGCA TTTTAGTAG AGATGGGGTT TCACAGTGT 37150
GGCCAGGCTG GTCTAAAAT TCTGACCTCA AGTCATCTGC CTGCCTTGGC 37200
CCTGCCAAAG TGCTGGGATT ATAGATGTGA GCCACCGCGC CTGGCTTACA 37250
GTTTTATTCT TGGTGGCTCA CACCTGTAAT CTCAGCACTT TGGGAGGCCA 37300 | REPEAT | var (37288) : [T:0.21]
AGGTGGGAGA ATGGCTTGAG CCCAGGAGTT CAAGTCCAGC CTGGGCAACA 37350
TAGCAAGACC CTATCTCTAC TACAAAATAA ATAATAATAA AACTAATTTT 37400
TTTTCTTTTA AAACCCAACT ATTCAAATG GCAATGCAAT ATATTAAAAA 37450
AATTTTTTTT TTCTTTGAAA CGGAGTCTCT CACTGTCACC CGGGCTGGAG 37500 | REPEAT | var (37453) : [A:0.04]
TGCAGTGTGC CCATCTTGGC TCACTGCAAC CTCGCCCTCC CAGGTCCAAG 37550 | var (37535) : [A:0.07]
TGATTTCTGT GCTTCAGCCT CCCAGTAGC TGGGATTACA GGCACCCACC 37600
ACCATACCCA GCTAATATTT TTGTATTTT AGTAGAGATG GGGTTTCACT 37650
ATGTTGGGCA GGCTGGTCTG GAACTCCTGA CCTCGTGATC TGCCCGAGGA 37700
TCGGCGGCCCT CCCAAAGTGC TGGGATTGC AGGCATGAGC CACCGTGCCC 37750 | var (37702) : [T:0.20] | var (37703) : [A:0.10]
AGCCAAAATC TTTTATTTT TATTTTTTTT GGACACGGTC TCACGTGTGA 37800 | REPEAT
CCCCAGACTG GAGTGATAGA GTGCTGTCA TGGCTCACTGC AGCCTCAAC 37850 | var (37828) : [A:0.01]
TCCTGGGGCT CAGGTGATCT TCCTGCTTCA GTCTCCAGG TAGCTGGGAC 37900
TACAGGCATG AGCCACCACA CCCAGCTAAT TTTTGAATTT TTTTGTAGAG 37950
ACAGGGTTTC ACCTTGTGGC CCAGACTTGT CTCTAACTCC AGGGCTCAAAG 38000
CGATCTGCCC ACCTTGGCCT CCCAAAGTGC TGAGATTAAT GCAATTTAAA 38050
AAATTTTTTT GCCAGGCCTG GTGGCTCATG CCTGTATTCA CAACACCTTG 38100 | REPEAT
GGAGGCAAAAG GTGGGCAGAT CACTTGAGGT CAGGAGTTCG AGACTAGCCT 38150
GGCCAACATG GTGAACCCCT CTGTCTACTA AAAAAATACA AAAATTACCT 38200
GGGCACAGTG GTGGGTGCCT GTAATCCCAG CTACTTGGGA TGCTGAGGGT 38250
GGAGAAATGG TTGAACCTGG GAGGCAGAAAG TTGCAGTAAG CCAAGATCAT 38300
GCCACTGGAC TCCAGCCTCA GTGACAGAGC AAAACTCTGT CTCCAAAAAA 38350
ATTGTTTTTT TTTTTTTTTT TTCAAATCAT CACACTACAG CCAAGGCCTG 38400 | var (38378) : [A:0.29] | REPEAT
    
```

```

GCCACTTACT TTTGTAATA AAGTTTTATT GGAGCCAGTG GACCAGTGAG 38450
GCCGAATCTT GCAGGTGTAA GATCACAGTC TATCCTTGAA AATTTTGATA 38500
TTTTGTTCAT TGGGTGGTTT TTCATTAATT TAAATTTTAA AAAATAACAT 38550
ATTAAGGGCT GGTGTGGAGG TGCACGCCCTG CAGTCCTAGC TACTCCCAGA 38600 | REPEAT | var(38576):[A:0.45]
GGCTGAGGCG GGAGACTTGC TTGAGCCCAA GAGTTGAAGT CCAGCCTGGG 38650 | var(38609):[T:0.02]
CAACATAGCG AGACCCCATC CTCTAAAAAT AAAAATAATG CATTAGAATA 38700
TTATTGGATT CCTGGGCAGG GCACAGTGGC TCACACCTGT AATCCCAGCA 38750 | REPEAT
CTTTGGGAGG CTGAGGTGGG TGGATCACCT GAGGTCAGGA GTTTGAGACC 38800
AGCCTGGCCA ACATGGTGAA ACCCCGTCTC TACTAAAAAT ACAAAAAATTA 38850
GCCAGGCGTG GTGGCAGGTG CCTGTAATCC CAGCTACTCG GGAGGCTGAA 38900 | var(38879):[T:0.01]
GCACGAGAAT CGCTTGAATC CAGGAGGCGG AGGTTGCAGT GAGCTGAGAT 38950 | var(38904):[G:0.01]
TGCCCCATTG CACTCCAGCC TGGAGGACAA GAGTGAAGCT CCATTCCCCCT 39000
CTGCAAAAGAA AAGGAATATT ATCAGATTCC TAAGCTTTTT GGCTCCCCCT 39050 | var(39002):[C:0.33]
TTAGTTTGGG GGCTGGGGTG GTGAGTGTC T GACTGGCCCT CACTGTCCCTC 39100
CCTGGATGTG ATGAGACCCA GGTGTGGGTC AGGATGTGAT TCGTTTGTCC 39150
ACCAGAGGGC GCCCAAACTG CTTTGAGCTG CTGGGAAATG GTGCTCCTAG 39200
ACTTTTAGCA AACAAACAAA AAAAATGGC ACATCGGCAA ATTCAGACC 39250 | var(39203):[C:0.08]
ATTCTTTTTT TTTTTTTTTT TGGTTCCAGA GTAGCTGAAA TCTTTGTTC 39300
GTTACAAAGCA GGATAAAATG GAAACTGCCT GGGAGAGGCT GAGAAACCTT 39350
CTTGCTTGGG GGAGGTGGGG CACTGCTAGA ATTAATCGCT TCACAGACCA 39400
GCCCATCCAG GACTCCCTCAA ATTTGGCAA AAAGCCATTC ATTCATTCAT 39450
TCATTTATGT AGAGACGAGG GGGATCTGGC TATATTGCC T AATTGGTCT 39500 | REPEAT | var(39467):[A:0.21] | var(39494):[C:0.35]
CAAATTCCTG GCCTCAAGTG ATCCTCCTGC CTTGGTCTAC TAATGTGCTG 39550 | var(39522):[A:0.14]
CGATTACAGG CATGAGCCAC CGTGCCTAGC TCTAGTGGAC TTGAAATGTT 39600
GCCTTGGCCA GGGCCCTTAT GTTGAATGGC CCAGGTCCAC TTGTATGGTT 39650
CTGTACCAAG GTTAACCCCA TCCATAATG CCTGGGACAG TTGATGCAGG 39700 | var(39655):[G:0.01]
ACAATCAGCT TCTGTGCCAT TCAACCTCAG GACTGAGCAT GCTGGGCATT 39750
GTGGGTCCG AAGGTGGCTC CCCTGTCCCC TTCAAAATAC CTCTTTTTTC 39800
TTTTCTCTTT TTTTTTTTTT TTTTTTTTTT GAGACGAAGT CTGCTCTGT 39850 | REPEAT
TGCCCCAGCT AGAGTGCAGT GGTGGGATCT CAGCTCCCGG CAACCTCTGC 39900
TTCCCGGGTT CAGCGCATTC TCCTGCCTCA GCCTCCTGAG TAGCTGGGAT 39950
TACAGGTGCC CACCGCCACG GCTGGCTAAT TTTTGTATTT TTAGTAGAGA 40000 | var(39970):[A:0.30]
CAGGGTTTCA CCGTGTGGC CAGGCTGGTC TTGAACCTCT GACTGAGGC 40050
AACCTGCCCA CCTCAGCCTC CCAAAGTGTG GGGATTACAG GTTTGAGCCA 40100 | var(40062):[G:0.11]
CTGGGCCTAG GCGGTTTTTT TTTTTTTTTT AGAGGGAGTC TCACCTCTGT 40150 | REPEAT
GCCACGGCTG GAGTGCATG GCGCGATCTT GACTCACTGC AACTCCATT 40200 | var(40174):[T:0.01]
CCCGGGTTCA AGTGATTCTC CTCCCTCAGC CTCCCAAGTA GCTGGGATTA 40250

CAGGTGCATG CCACCACGGC CAGCTAATTT TGTATTTTTA GTAGAGACAG 40300
GGTTTCACTA TGTTGATCAT GCTGGTCTCA AACTCCTGAC CTTAGGTGAT 40350
CTGCCCGCCT TAGCCTCCCA AAGTGTGGG ATTACAGGTG TGAGCCACCG 40400
CGCCAGAGCC AAAATATGCT CATTTTAATA AAAATGCACAA GTAGGTTGAC 40450 | var(40438):[C:0.40]
AAGAAATTTCA CCTGCAACCT TGTCACCCAC CTAGAAATAA AGCCTCTGCA 40500
GCCTCCCTCT AAAGACTCAT CAATGTGAGG CTCAAAGAAC TTCTTAGGCT 40550 | var(40527):[A:0.05] | REPEAT
GGCTCGGGTG GCTCATTCTC GTAATCCCTG CACTTTGGAA GGCTGAGGCA 40600 | var(40598):[A:0.21]
GGAGGATCTC TTGAGGCCAG GAGTTCAAGA CAAGCCTGGG CAACATAGCC 40650
AGACCTCTGT TTCTATCCCC CACAAAAGA ACCTTCTTAA ACCGGAAATTG 40700 | var(40672):[A:0.49] | var(40691):[G:0.29]
AGTCCTACAA CCTCGATAAC TCACAAAATA GCCCGTGTGG CCTCTGCAG 40750 | var(40747):[A:0.12]
ACTTGGGAAG TTCTCCAAAT GTCCAGGGAG ATGTGCCAGG CGCTTTCCTG 40800
CCGTGACCAC GCTCCTCTGC CTGCTCCATT TCTTGGTGGC CTTCCCTTAG 40850 | var(40812):[A:0.01]
ACCTGGGCCT CACTCTTGCT TCTCTCTGCG AGCTCTGGGC GAGCTTGCTG 40900 | Exon 16
A L G D V A 776

GCAGAGGAAA TGAGAAGAAG CCCAGTAGCG TGAGGGCTCT GTCCATTGTC 40950
G R G N E K K P S S V R A L S I V 793
CTCCCCATCG GTAAGCGCGG GCCGGTCCCC CAGCGTCCCC CAGGTCACAG 41000
L P I 796
CCTCCCGCTA TGTGACCTCG TGCTGGCTG GTTGGGCTG TTCACTTTTT 41050
CTCCTGGACA GGGAAACAGC CCACTGGTGT CCTTTATCAC CCCCACGGCC 41100
TCTCCTGGCT TGGGGCTGAC AGTGACAAGA TCAGACAGCT AAGGGGTGAC 41150
ATGGAGGATG TGGAGCTGGG TCCCGTGGCT TGGAAATAGC TCACCGAGAT 41200
TTGAGTGCCT TCTGGGGAAC TGGTTCCCTT GCAGGGGGCT GTGTGGAGAG 41250
GGCGCTCTC CCTGCCTCAC CCATGCTCAT CCTAACTCGG TTACCATCAC 41300
ATCTCTTTTT TCTTTTTTTC TTAATTTTTA AGAAAAAGA AATTTAATTT 41350 | REPEAT
TTTTGAGAGA CAGAGCTCTG CTCTGTCAAC CAGGCTGGAG TGCAGTGGCA 41400 | var(41381):[-:0.16]
CCATCATGCC TCGCTGCAGC CTCATGTCT GGGCTCAAGC GATCCTCCCA 41450
CCTCAGCCTC CTGAGTAGCT GGTGCAAGCC ACTATACCCC ACTTCCATTT 41500
TCTTAAAAAG TCACAGCCCT GTGTGTGGCT AATCCTGGAC AGAAATCTAG 41550
AAGAAGTCAG CTACTCTCGG GGCGTGGCTC ACCCAGTGGG CTTGAGGTTA 41600
GATATTTCTT ATACTTATGA GGCTGGGTGT GGTGGCTTAT GCCTGTAATC 41650 | REPEAT
CCAGCACTTT GGGAGGCTGA AGTGGGTGGA TTGCTTGGGC TCAGGAGTTC 41700
GAGACCAACC TGGCAACAT GCGGAAACCC TGTCTTAGA AAAGGTACAA 41750
AAATTAGCTG GGCAGGTGGC ACGTGCCTGT GGTACCACT ACTTGAGGGC 41800
CTGAGGCAGG AGGATCGCTT GAACCTGGGA GGTGAGGTT GCAGTGAAGT 41850 | var(41817):[A:0.14]
GAGATCATGT CACTGCACCT CAGCCTGGTG ACAGAGCAAG ACCCCGTCTC 41900
AAAAAAAAAA AAGAAGAAAG AAAAATTCCT ATGCATAGAT TTGCCTCTTT 41950 | REPEAT

```

TCTGTTTGT TGTTTGAGA TGGAGTCTCG CTCTGTCGCC CAGGCTGGAG 42000  
TACAGTGGCT CAACCTCGGC TCACCTGCAAC CTCTGCCTCC CGGTTTCAAG 42050  
CAATTCTCCT GCCTCAGCCT CCTGAGTAGC TGGGACTACA GGCGCCCGCC 42100  
ACCATGCCCA GCTAATTTTT GTATTTTTAG TAGAGACTGA CTGGGTTTCA 42150  
TCATGTTGCC CAGGCTGGTC TCGAACTCTT GACCTCATGA TCCGCCCGCC 42200  
TCAGCCTCCC AAAATGCTGG GATTACAGGC GTGAGCCACC AGGCCCCAGGC 42250  
CGCAAGGCGA TCTCTAAAACA AACATAAAAAG ACCAGGAGTC AAGGTTATGG 42300 | var (42252) : [A:0.21]  
TACGATGCCG GTGTTTTAC TCCAGCCACG GAGCTGGGTC TCTGGTCTCG 42350  
GGGGCAGCTG TGTGACAGAG CGTGCCTCTC CCTACAGTGC TCCTCGTCTT 42400 | Exon 17  
V L L V F 801  
CCTTTGCTG GGGTCTTCC TTCTATGGAA GAACTGGCGG CTTAAGAACA 42450  
L C L G V F L L W K N W R L K N 817  
TCAAACAGCAT CAACTTTGAC AACCCCGTCT ATCAGAAGAC CACAGAGGAT 42500  
I N S I N F D N P V Y Q K T T E D 834  
GAGGTCCACA TTTGCCACAA CCAGGACGGC TACAGCTACC CCTCGGTGAG 42550  
E V H I C H N Q D G Y S Y P S 849  
TGACCCTCTC TAGAAAAGCCA GAGCCCATGG CGGCCCCCTC CCAGCTGGAG 42600  
GCATATGATC CTCAAAGGAC CAGGCCGAGG CTTCCCCAGC CCTCCAGATC 42650  
GAGGACAGCA TTAGTGAAT GCTTCTGTGC GCTCATTGAG AATGTCAGCG 42700  
GACAAATGCC TTGGTGGTGT AGAGGAATGT TGGATAAGCA AATAGAGAGC 42750  
TCCATCAGAT GGTGACAGGG CAAAAGAAAGT CAAAAGGAGT TCAGAGGCCG 42800 | REPEAT  
GGCGCGGTGG CTCATGCCCTG TAATCCCAGG ACTTTGGGAG GCCGAGGCTG 42850  
GCGGATCACC TGAAGTCAGG AGTTTGGAGC CAGCTTGGCC ATCATGACAA 42900  
AACCCCGTCT CATTAAAAA TACAAAAAAT TAGCCAGGCG TGGGAGTGGG 42950  
CGCCTGTAAT CCTAGTACT CGGGAGGCCG AGGTAGAAAA ATCGCTTGA 43000  
CCTAGGAGGC AGAGGTTGCA GTGAGCCGAG ATCGGCCAC TGCAATCCAG 43050  
CCCAGGAGCC AAGAGCAAAA CTCCATCTCA AAAAAAATA AAAAAAGGAGT 43100  
TCAGAGGCCG GGCATGGTGG TTCACACATG TGATCCCAAG ACTTGGGGAG 43150 | REPEAT | NOT SCANNED  
GTTGAGGCAG GAGAAATCAC TGAGCTCAGA GTTCAAGACC AGCCTGGGCA 43200  
GCACAGCAAG ACCCCATCTC TGCAAAAAAT AAAAAATTAG CCCAGTGTGG 43250  
TGATGAGCCG CTAGTTCCAG CTACTAGGGA GGCTAAGGCA GGAGGATTGC 43300  
TTGAGGCTAA GGTAGGAGAT TGAGACTGCA GTGACTTGTG ATTGGCTCAG 43350  
TGCGCTCCAG CCTGGGTGAC AGAGCAAGCC CTTGTCTCTT AAAAAAATA 43400  
AAAAATTCAA AGAAGGGTTT CCAGAGGCCG AGGAGGGAGG AAGGGAGAGG 43450  
AGGTGTTTTA TTTTTTGCT TTTATTTTTT ATTTTGAGAC AGAGTCTCTC 43500 | REPEAT  
TCTGTCACCC GACGTGGAGT GCAGTGCTGT GATCTTGGCT CACTGCAACT 43550  
TCTGCCCTCT GGGTTCAAGC AATTCCTATG CCTCAGCCTC AGCCTCCTGA 43600  
GTAGCTGGGA TTACAACACT ATGCCCGGGT AATTTTTGTA TTTTATAGTAG 43650 | var (43627) : [A:0.08]  
AGACGAGGTT TCGCCATGTT GCCCAGACTG GTCTGGAACT CCTGACCTCA 43700  
AGTATCCAC CCGCCTTGGC CTCGCCACGT GCTGGGATTG CAGGCCGTGAG 43750  
CCACTGGCCG CGCCTTGATC TTTACACAAG GGGTTTAGGG TAGGTAGCCT 43800 | REPEAT  
TCTCTGAACC GGCAGAACAG CCTGTGCCAA GGCCCTGAGG CTGGACCCGTG 43850  
CCTGTTGGGT TTGAGCCCGT TGTAGCTGGA GCAAACAGAG AGAGGGGTAA 43900  
AAAGGCAGGA GGCTACCAGG CAGGTTGTGC AGAGCCTTGT GGGCCACTGG 43950  
GGCAGACTTT GGCCTTTGCC CTGAGAGCGG TGGGAAGTGA CTGAAATCCGG 44000  
TACTCACCGT CTCCTCTGCG CGGCTCCTGG GGGAAATGTC TTGGGGATCA 44050 | var (44009) : [A:0.20]  
GGCTGGGGGA GGCCTGCCAG CCCAGGAGGT GAGAAAGTAG TGGCCTCCAG 44100 | var (44076) : [A:0.20]  
CCGTGTTTCC TGAATGCTGG ACTGATAGTT TCCGCTGTTT ACCATTTGTT 44150 | var (44103) : [A:0.12] | var (44114) : [G:0.34]  
GGCAGAGACA GATGGTCACT CTGGAGGATG ACCTGGCCGTG AACATCTGCC 44200 | Exon 18 | UTR  
R Q M V S L E D D V A 860  
TGGAGTCCCG TCCTTGCCCA GAACCCCTCC TGAGACCTCG CCGCCTTGT 44250 | var (44240) : [A:0.02] | var (44243) : [A:0.21]  
TTTATTTAAA GACAGAGAAG ACCAAAGCAT TGCCTGCCAG AGCTTTGTTT 44300  
TATATATTTA TTCATCTGGG AGGCAGAACA GGCTTCGGAC AGTGCCCATG 44350 | var (44332) : [A:0.07]  
CAATGGCTTG GGTGGGATT TTGGTTTCTT CCTTCCCTCG TGAAGGATAA 44400  
GAGAAACAGG CCCGGGGGGA CCAGGATGAC ACCTCCATTT CTCTCCAGGA 44450 | var (44414) : [A:0.02]  
AGTTTTGAGT TTCTCTCCAC CGTGACACAA TCCTCAAAACA TGGAAAGATGA 44500  
AAGGGCAGGG GATGTCAGGC CCAGAGAAAG AAGTGGCTTT CAACACACAA 44550 | var (44506) : [G:0.20] | var (44529) : [A:0.01]  
CAGCAGATGG CACCAACGGG ACCCCCTGGC CCTGCCTCAT CCACCAATCT 44600  
CTAAGCCAAA CCCTAAACT CAGGAGTCAA CGTGTTTACC TCTTCTATGC 44650  
AAGCCTTGCT AGACAGCCAG GTTAGCCCTT GCCCTGTAC CCCCAGATCA 44700 | var (44695) : [A:0.26]  
TGACCCACCC AGTGTCTTTC GAGGTGGGTT TGTACCTTCC TTAAGCCAGG 44750  
AAAGGGATTC ATGGCGTCGG AAATGATCTG GCTGAATCCG TGGTGGCAC 44800  
GAGACCAAAC TCATTCACCA AATGATGCCA CTTCCAGAG GCAGAGCCTG 44850  
AGTCACCGGT CACCCTTAAT ATTTATTAAG TGCCTGAGAC ACCCGGTTAC 44900 | var (44857) : [T:0.36]  
CTTGGCCGTG AGGACACGTG GCCTGCACCC AGGTGTGGCT GTCAGGACAC 44950 | var (44908) : [A:0.03]  
CAGCCTGGTG CCCATCTCC CGACCCCTAC CCACCTCCAT TCCCGTGGTC 45000 | var (44964) : [G:0.21] | var (44994) : [T:0.01]  
TCCTTGCAC TTTCAAGTTC AGAGTTGTAC ACTGTGTACA TTTGGCATT 45050  
GTGTTATTAT TTTGCACTGT TTTCTGTCTG GTGTGTTGGG ATGGGATCCC 45100 | var (45098) : [G:0.02]  
AGGCCAGGGA AAGCCCGTGT CAATGAAATGC CGGGGACAGA GAGGGGCAGG 45150  
TTGACCGGGA CTTCAAAGCC GTGATCGTGA ATATCGAGAA CTGCCATTGT 45200 | var (45173) : [C:0.08]  
CGTCTTTATG TCCGCCACCC TAGTGCTTCC ACTTCTATGC AAATGCCTCC 45250

```

AAGCCATTCA CTTCCCAAT CTTGTCGTTG ATGGGTATGT GTTAAAAACA 45300
TGCACGGTGA GGGCGGGGCG AGTGGCTCAC GCCTGTAATC CCAGCACTTT 45350 | REPEAT
GGGAGGCGGA GGGGGGTGGA TCATGAGGTC AGGAGATCGA GACCATCCTG 45400 | var (45359) : [A:0.20] | var (45364) : [C:0.01]
GCTAACAACG TGAACCCCGG TCTCTACTAA AAATACAAAA AATTAGCCGG 45450
GCGTGGTGGC GGGCACCTGT AGTCCCAGCT ACTCGGGAGG CTGAGGCAGG 45500
AGAATGGTGT GAACCCGGGA AGCGGAGCTT GCAGTGAGCC GAGATTGGCC 45550
CACTGCAGTC CGCAGTCTGG CCTGGGCGAC AGAGCGAGAC TCCGTCTCAA 45600 | var (45577) : [T:0.07]
AAAAAAAAA CAAAAAAAAA CCATGCATGG TGCATCAGCA GCCCATGGCC 45650 | var (45622) : [T:0.12] | var (45645) : [G:0.23]
TCTGGCCAGG CATGGCCAGG CTGAGGTGGG AGGATGGTTT GAGCTCAGCC 45700 | REPEAT
ATTGAGGCT GTCGTGAGCT ATGATTATGC CACTGCTTTC CAGCCTGGGC 45750 | var (45702) : [C:0.17]
AACATAGTAA GACCCCATCT CTTAAAAAAT GAATTTGGCC AGACACAGGT 45800 | REPEAT | var (45792) : [T:0.19]
GCCTCACGCC TGTAAATCCCA GCATTTGGG AGGCTGAGCT GGATCAGCTG 45850
AGTTCAGGAG TTGGAGACCA GGCCTGAGCA ACAAAGCGAG ATCCCATCTC 45900
TACAAAACC AAAAAGTTAA AAATCAGCTG GGTACGGTGG CACGTGCGCTG 45950 | var (45935) : [T:0.28]
TGATCCCAGC TACTTGGGAG GCTGAGGCAG GAGGATCGCC TGAGCCCGAG 46000
AGGTGGAGGT TGCAGTGAGC CATGATCGAG CCACTGCACCT CCAGCCTGGG 46050
CAACAGATGA AGACCCATAT TCAGAAATAC AACTATAAAA AAATAAATAA 46100
ATCCTCCAGT CTGGATCGTT TGACGGGACT TCAGGTTCTT TCTGAAATCG 46150
CCGTGTTACT GTTGCACTGA TGTCCGGAGA GACAGTGACA GCCTCCGCTA 46200
GACTCCCGCG TGAAGATGTC ACAAGGGATT GGCATTTGTC CCCAGGGACA 46250
AAACACTGTG TCCCCCCAG TGCAGGGAAC CGTGATAAGC CTTTCTGGTT 46300
TCGGAGCACG TAAATGCGTC CCTGTACAGA TAGTGGGGAT TTTTGTATT 46350
GTTTGCACTT TGTATATTGG TTGAAACTGT TATCACTTAT ATATATATAT 46400
ATACACACAT ATATATAAAA TCTATTTTAT TTTGCAAACC CTGGTTGCTG 46450 | var (46402) : [-:0.67] | var (46410) : [C:0.01]
TATTTGTICA GTGACTATTC TCGGGGCCCT GTGTAGGGGG TTATTGCCTC 46500
TGAAATGGCT CTCTTTTATG TACAAAAGATT ATTTGCACGA ACTGGACTGT 46550
GTGCAACGCT TTTTGGGAGA ATGATGTCCC CGTTGTATGT ATGAGTGGCT 46600
TCTGGGAGAT GGGTGTCACT TTTTAAACCA CTGTATAGAA GGTTTTGTGA 46650
GCCTGAATGT CTTACTGTGA TCAATTAAT TTCTAAATG AACCAATTTG 46700
TCTAAACTCG ATGCACGTTT TTCTGTTCG CGGCTTCTTT TGTTTTTTTT 46750 | var (46728) : [T:0.02] | var (46731) : [T:0.01] | REPEAT
TTTTTTCGTG AGATGGAGGC TGGCTCTGTC ACCCTGGCCT GGAGTGCAGT 46800
GGCATGATCT CGGCTTACTG CAAGCTCCGC CTCACAGGTT CAAGCAATTC 46850
TCTCGCCTCA GCCTCCCTAG TAGCTAGGAT TACAGGTGAG TGCCACCACG 46900
CCTGGCCAAAT TTTTTTTTTT TTTTTTTTTT TGAGACAGAG TCTCGCTCTG 46950 | REPEAT | NOT SCANNED
TCACCCAGGC TGGAGTGCAG TGGTGTGATC TCGGCTCACT GCAAGCTCTG 47000
CCTCCAGGT TAAATGCCAT CTCCTGTCTC AGCCTCCTGA GTAGCTGGGG 47050
CCACAGGCGC CTGCCACCAC GCCCGGCTAA TTTTTTTTTT TACTTCTTTT 47100
AGTACAGACG GGGTTTCACC ATGTTAGCCA GGATGGTCTC GATCTCCTGA 47150
CCTTGTGATC CACCTGCTTC GGCCTCCCAA AGTCTGAGA TTACAGGCGT 47200
GAGCCACCGC GGGTGGCCAA CGCTAATTTT TTTGTTTTTT TAGATGGAGT 47250 | REPEAT | REPEAT
CTTGTCTGTG CGCCACGGCT GGAGTGCATC GCGCTGATCT CTGCCTACTG 47300
CAAGCTCCGC CTCCCGGTTT CATGCCATTC TCCTGGCTCA GCCTCCTGAG 47350
TAACTGGGAC TACAGGCACC CGCCACCACG CCCGGCTAAT TTTTTGTATT 47400
TTTAAATAGG ACAGGGTTTC ACCGTGTTAG CCAGGATGGT CTTGATCTCC 47450
TGACCTGTG ATCCACCCGT CTCGGCCTCC CAAAGTGCCT GGATTAGAGG 47500
TGTGAGCCAC CACACCTGGC CTAGCCTGGC TAATTTTTGT ATTTTTGGTA 47550 | REPEAT
GAGACGGGGT TTCAACATGT TGGTCAAGCT GGTCTTGAAC TTCTGACCTC 47600
AGGTAATCTG CCTGCCTCAG TCTCCCAAAG TGCTGGGATT ACAGGTGTGA 47650
GCCACCGCGC CTGGCCTCAC TTCTTCTGT CATCTGTTG TGGATTGGAC 47700 | var (47669) : [G:0.25]
TCCCCAGGAG AAGGACCCAG AAGGGGAAGA CTCCCAGAAC TCCGGGCAAG 47750
ATGCAATCTC CGTGGGCTGC CACAGTGCCT GGCAGGTGCT GTGATGGCTG 47800 | var (47774) : [C:0.05]
AGCTGGTGAT TGTGTTCTCT GCTGTGCTT CTCTGAGTTG GAGATTTTGT 47850 | var (47804) : [A:0.19]
CAAGTCCCTC GCTCATCCAT TCATACACTC GACAAAATAT TGTGTAGTGC 47900 | REPEAT
TAAGTGCGAA CCATGCTCTG CCGTAGGCTT GTGGGACACT ACAGGGGATA 47950 | var (47908) : [A:0.20] | var (47911) : [T:0.09]
TAAAGAAATGA AAGCCGGGTG TGGTGGCTCA CACCTGTAAT CCTAGCAGTT 48000 | REPEAT | var (47971) : [C:0.22]
TGGGAGGCGC AGCGGGCGAG ATCATGAGGT CAGGAGATCG AGACCATCCT 48050 | var (48014) : [A:0.24] | var (48039) : [G:0.21]
AGCTAACACA GTGAAACCCC ATCTCTACTA AAAATACAAA AAATTAGCCA 48100
GCGTGGTGG TGGGCGCCTG TAGTCCCAGC TGCTTGGGAG GCTGAGGCAG 48150
GAGAATAGCG TGAACCTGGG AGTTGGAGCT TGCAGTGAGC CGAGATCGCA 48200
CCACTGCAC TTAGCCTGGG CAACAGAGCA AGACTCCATC TACAAAAAAA 48250
AAAAAAAAA ATGAAGTCTT GATACGGTGG CTCATGCCCT TAATCCCAGC 48300 | REPEAT
ACTTTGGGAG GCCAAGGCAG GCGGATCAGC AGCTCAGGAG ATCGAGACCA 48350
TCTGGGCCAA CGTGGCGAAA CCCAGTCTCT ACTAAGATA CAAAAAATTA 48400
GCCAGGCATG GTGGCGGGCG CCTGTAGTCC CAGCTACTTG GGAGGCTGAG 48450
GCAGGAAAT GGCATGAACC CAGGAGGCAG AGCTTGCAGT GAGCTGAGAT 48500 | NOT SCANNED
CGCGCCACTG CACTCCAGCC TGGGCGACAG AGCGAGACTC TGTCTCAAAA 48550
AAAAAACAAA AAAGAAATGA AAATCTCCCT GTCTGTCTTT AAGGACCTGA 48600

```

## BIOGRAPHY

<b>NAME</b>	Miss. Patthamawadee Charoensuk
<b>DATE OF BIRTH</b>	11 January 1979
<b>PLACE OF BIRTH</b>	Yala, Thailand
<b>INSTITUTIONS ATTENDED</b>	Prince of Songkla University, 1997-2001: Bachelor of Science (Biotechnology) Mahidol University, 2002-2005: Master of Science (Biochemistry)
<b>RESEARCH GRANT</b>	- Siriraj Graduate Thesis Scholarship - This thesis was supported by grants from Mahidol University.
<b>POSITION&amp;OFFICE</b>	-
<b>HOME ADDRESS</b>	53/160 Sukkayang Road Muang, Yala 95000 Tel. 06-2881102